AdaptHealth (AHCO) 10-Q 9 Nov 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 05, 2021
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Entity File Number	001-38399
Entity Registrant Name	AdaptHealth Corp.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-3677704
Entity Address, Address Line One	220 West Germantown Pike
Entity Address, Address Line Two	Suite 250
Entity Address, City or Town	Plymouth Meeting
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19462
City Area Code	610
Local Phone Number	630-6357
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	AHCO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		132,215,165
Entity Central Index Key	0001725255
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 336,654	$ 99,962
Accounts receivable	347,515	171,065
Inventory	99,881	58,783
Prepaid and other current assets	39,388	33,441
Total current assets	823,438	363,251
Equipment and other fixed assets, net	341,357	110,468
Operating lease right-of-use assets	148,891
Goodwill	3,362,268	998,810
Identifiable intangible assets, net	209,909	116,061
Other assets	12,051	16,483
Deferred tax assets	293,801	208,399
Total Assets	5,191,715	1,813,472
Current liabilities:
Accounts payable and accrued expenses	312,355	254,212
Current portion of capital lease obligations (pre-adoption)		22,282
Current portion of finance lease obligations	21,672
Current portion of operating lease obligations	31,015
Current portion of long-term debt	20,000	8,146
Contract liabilities	22,252	11,043
Other liabilities	73,369	89,524
Current portion of contingent consideration common shares liability	21,402	36,846
Total current liabilities	502,065	422,053
Long-term debt, less current portion	2,187,373	776,568
Operating lease obligations, less current portion	121,411
Other long-term liabilities	314,932	186,470
Contingent consideration common shares liability, less current portion	15,025	33,631
Warrant liability	56,546	113,905
Total Liabilities	3,197,352	1,532,627
Commitments and contingencies (note 14)
Stockholders' Equity
Preferred Stock, par value of $0.0001 per share, 5,000,000 shares authorized; 124,060 and 163,560 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	1	1
Additional paid-in capital	2,057,289	558,486
Accumulated deficit	(65,963)	(199,196)
Accumulated other comprehensive loss	(1,231)	(4,411)
Total stockholders' equity attributable to AdaptHealth Corp.	1,990,109	354,889
Noncontrolling interest in subsidiaries	4,254	(74,044)
Total Stockholders' Equity	1,994,363	280,845
Total Liabilities and Stockholders' Equity	5,191,715	1,813,472
Stock, common
Stockholders' Equity
Common stock	$ 13	8
Class B Common Stock
Stockholders' Equity
Common stock		$ 1

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	124,060	163,560
Preferred stock, shares outstanding (in shares)	124,060	163,560
Stock, common
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	300,000,000	210,000,000
Common stock, shares issued (in shares)	132,154,358	76,457,439
Common stock, shares outstanding (in shares)	132,154,358	76,457,439
Class B Common Stock
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	0	35,000,000
Common stock, shares issued (in shares)	0	13,218,758
Common stock, shares outstanding (in shares)	0	13,218,758

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue:
Net revenue	$ 653,293	$ 284,405	$ 1,752,429	$ 707,960
Revenue, Product and Service [Extensible List]	us-gaap:HealthCarePatientServiceMember	us-gaap:HealthCarePatientServiceMember	us-gaap:HealthCarePatientServiceMember	us-gaap:HealthCarePatientServiceMember
Costs and expenses:
Cost of net revenue	$ 529,887	$ 240,720	$ 1,417,305	$ 606,768
Cost, Product and Service [Extensible List]	us-gaap:HealthCarePatientServiceMember	us-gaap:HealthCarePatientServiceMember	us-gaap:HealthCarePatientServiceMember	us-gaap:HealthCarePatientServiceMember
General and administrative expenses	$ 33,006	$ 26,306	$ 132,584	$ 57,745
Depreciation and amortization, excluding patient equipment depreciation	14,690	4,120	46,014	6,398
Total costs and expenses	577,583	271,146	1,595,903	670,911
Operating income	75,710	13,259	156,526	37,049
Interest expense, net	24,252	12,406	69,584	27,826
Loss on extinguishment of debt	8,240	5,316	20,189	5,316
Change in fair value of contingent consideration - common shares liability (note 10)	(10,006)	25,525	(34,050)	41,850
Change in fair value of warrant liability (note 10)	(16,737)	36,912	(57,359)	72,358
Other (income) loss, net	(452)		698	(1,991)
Income (loss) before income taxes	70,413	(66,900)	157,464	(108,310)
Income tax expense (benefit)	12,147	(4,921)	22,782	(4,736)
Net income (loss)	58,266	(61,979)	134,682	(103,574)
Income (loss) attributable to noncontrolling interest	174	(10,944)	1,449	(22,458)
Net income (loss) attributable to AdaptHealth Corp.	$ 58,092	$ (51,035)	$ 133,233	$ (81,116)
Weighted average shares outstanding
Basic	131,684	57,372	124,228	47,986
Diluted	140,322	57,372	133,638	47,986
Net income (loss) per common share:
Earnings Per Share, Basic	$ 0.40	$ (0.89)	$ 0.97	$ (1.69)
Basic	0.40	(0.89)	0.97	(1.69)
Diluted	$ 0.20	$ (0.89)	$ 0.27	$ (1.69)

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Consolidated Statements of Comprehensive Income (Loss)
Net income (loss)	$ 58,266	$ (61,979)	$ 134,682	$ (103,574)
Other comprehensive income (loss):
Interest rate swap agreements, inclusive of reclassification adjustment	640	925	3,180	(11,558)
Comprehensive income (loss)	58,906	(61,054)	137,862	(115,132)
Income (loss) attributable to noncontrolling interests	174	(10,944)	1,449	(22,458)
Comprehensive income (loss) attributable to AdaptHealth Corp.	$ 58,732	$ (50,110)	$ 136,413	$ (92,674)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Stock, commonCommon StockPrivate Placement [Member]	Stock, commonCommon StockPublic Offering [Member]	Stock, commonCommon Stock	Stock, commonAdditional paid-in capital	Stock, common	Class B Common StockCommon Stock	Preferred StockPreferred Stock	Preferred StockAdditional paid-in capital	Preferred Stock	Preferred StockPrivate Placement [Member]	Preferred Stock	Additional paid-in capitalPrivate Placement [Member]	Additional paid-in capitalPublic Offering [Member]	Additional paid-in capital	Accumulated Deficit	Accumulated other comprehensive income	Noncontrolling interests in subsidiaries	Private Placement [Member]	Public Offering [Member]	Total
Balance at beginning of period at Dec. 31, 2019			$ 4			$ 3									$ (40,258)	$ 1,431	$ (26,963)			$ (65,783)
Shares, Outstanding, Beginning Balance at Dec. 31, 2019			40,816,000			31,564,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Issuance of stock for acquisitions														$ 6,248						6,248
Issuance of stock for acquisitions (in shares)			387,000
Exchange of Class B Common Stock for Class A Common Stock														(361)			361
Exchange of Class B Common Stock for Class A Common Stock (in shares)			1,000,000			(1,000,000)
Exercise of warrants														15,273						15,273
Exercise of warrants (in shares)			1,092,000
Equity-based compensation														2,223						2,223
Equity-based compensation (in shares)			59,000
Net income (loss)															(34,551)		(14,902)			(49,453)
Equity activity resulting from Tax Receivable Agreement														2,483						2,483
Change in fair value of interest rate swaps, inclusive of reclassification adjustment																(6,570)	(4,847)			(11,417)
Balance at end of period at Mar. 31, 2020			$ 4			$ 3								25,866	(74,809)	(5,139)	(46,351)			(100,426)
Shares, Outstanding, Ending Balance at Mar. 31, 2020			43,354,000			30,564,000
Balance at beginning of period at Dec. 31, 2019			$ 4			$ 3									(40,258)	1,431	(26,963)			$ (65,783)
Shares, Outstanding, Beginning Balance at Dec. 31, 2019			40,816,000			31,564,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Exercise of warrants (in shares)																				881,239
Net income (loss)																				$ (103,574)
Equity activity resulting from the Put/Call Agreement															2,700					(29,900)
Warrant liability adjustment																				49,098
Balance at end of period at Sep. 30, 2020			$ 6			$ 3					$ 1			484,780	(118,680)	(5,111)	(45,829)			315,170
Shares, Outstanding, Ending Balance at Sep. 30, 2020			62,681,000			25,875,000					184,000
Balance at beginning of period at Dec. 31, 2019			$ 4			$ 3									(40,258)	1,431	(26,963)			$ (65,783)
Shares, Outstanding, Beginning Balance at Dec. 31, 2019			40,816,000			31,564,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Issuance of Class A Common Stock in connection with Contingent Consideration Shares (in shares)																				1,000,000
Equity impact resulting from the Put/Call Agreement (in shares)																				(1,898,967)
Balance at end of period at Dec. 31, 2020			$ 8			$ 1					$ 1			558,486	(199,196)	(4,411)	(74,044)			$ 280,845
Shares, Outstanding, Ending Balance at Dec. 31, 2020			76,458,000			13,219,000					164,000
Balance at beginning of period at Mar. 31, 2020			$ 4			$ 3								25,866	(74,809)	(5,139)	(46,351)			(100,426)
Shares, Outstanding, Beginning Balance at Mar. 31, 2020			43,354,000			30,564,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Exchange of Class B Common Stock for Class A Common Stock														(1,580)			1,580
Exchange of Class B Common Stock for Class A Common Stock (in shares)			2,055,000			(2,055,000)
Exchange of Class A Common Stock for Series B-1 Preferred Stock			$ (2)								$ 1			1
Exchange of Class A Common Stock for Series B-1 Preferred Stock (in shares)			(15,810,000)								158,000
Distributions to noncontrolling interest																	(800)			(800)
Exercise of warrants			$ 1											17,627						17,628
Exercise of warrants (in shares)			1,034,000
Equity-based compensation														3,244						3,244
Equity-based compensation (in shares)			32,000
Net income (loss)															4,470		3,388			7,858
Equity activity resulting from Tax Receivable Agreement														2,223						2,223
Equity activity resulting from the Put/Call Agreement														(29,927)						(29,927)
Change in fair value of interest rate swaps, inclusive of reclassification adjustment																(656)	(410)			(1,066)
Balance at end of period at Jun. 30, 2020			$ 3			$ 3					$ 1			17,454	(70,339)	(5,795)	(42,593)			(101,266)
Shares, Outstanding, Ending Balance at Jun. 30, 2020			30,665,000			28,509,000					158,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Issuance of stock for acquisitions			$ 1											83,280						83,281
Issuance of stock for acquisitions (in shares)			4,344,000
Sale of stock, net of offering costs	$ 1	$ 1										$ 223,360	$ 133,041					$ 223,361	$ 133,042
Sale of stock (in shares)	10,930,000	9,200,000								75,000
Exchange of Class B Common Stock for Class A Common Stock														(7,467)			7,467
Exchange of Class B Common Stock for Class A Common Stock (in shares)			2,634,000			(2,634,000)
Exercise of warrants														40,691						$ 40,691
Exercise of warrants (in shares)			1,979,000																	881,239
Equity-based compensation														5,502						$ 5,502
Equity-based compensation (in shares)			35,000
Conversion of Series B-2 Preferred Stock to Series B-1 Preferred Stock (in shares)											(9,000)
Conversion of Series A Preferred Stock to Class A Common Stock (in shares)			2,888,000								(40,000)
Common Stock issued in connection with employee stock purchase plan (in shares)			6,000
Net income (loss)															(51,035)		(10,944)			(61,979)
Equity activity resulting from Tax Receivable Agreement														2,236						2,236
Other														(10,623)						(10,623)
Equity activity resulting from the Put/Call Agreement														(2,694)	2,694
Change in fair value of interest rate swaps, inclusive of reclassification adjustment																684	241			925
Balance at end of period at Sep. 30, 2020			$ 6			$ 3					$ 1			484,780	(118,680)	(5,111)	(45,829)			315,170
Shares, Outstanding, Ending Balance at Sep. 30, 2020			62,681,000			25,875,000					184,000
Balance at beginning of period at Dec. 31, 2020			$ 8			$ 1					$ 1			558,486	(199,196)	(4,411)	(74,044)			280,845
Shares, Outstanding, Beginning Balance at Dec. 31, 2020			76,458,000			13,219,000					164,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Issuance of stock for acquisitions			$ 2	$ 564,986	$ 564,988			$ 523,856	$ 523,856
Issuance of stock for acquisitions (in shares)			14,092,000				130,000
Issuance of stock options for acquisition														134,683						134,683
Sale of stock, net of offering costs		$ 1											$ 265,017						$ 265,018
Sale of stock (in shares)		8,450,000
Exchange of Class B Common Stock for Class A Common Stock			$ 1			$ (1)								(77,919)			77,919
Exchange of Class B Common Stock for Class A Common Stock (in shares)			13,219,000			(13,219,000)
Cashless exercise of options (in shares)			9,000
Equity-based compensation														8,582						8,582
Equity-based compensation (in shares)			172,000
Conversion of Series B-1 Preferred Stock to Class A Common Stock (in shares)			3,950,000								(40,000)
Conversion of Series C-1 Preferred Stock to Class A Common Stock			$ (1)											1
Conversion Of Series C-1 Preferred Stock to Class A Common Stock (in shares)			13,047,000								(130,000)
Common Stock issued in connection with employee stock purchase plan														314						314
Common Stock issued in connection with employee stock purchase plan (in shares)			8,000
Net income (loss)															(3,966)		324			(3,642)
Equity activity resulting from Tax Receivable Agreement														16,768						16,768
Other														(810)						(810)
Other (in shares)			(19,000)
Change in fair value of interest rate swaps, inclusive of reclassification adjustment																1,876				1,876
Balance at end of period at Mar. 31, 2021			$ 13								$ 1			1,993,962	(203,162)	(2,535)	4,199			1,792,478
Shares, Outstanding, Ending Balance at Mar. 31, 2021			129,386,000								124,000
Balance at beginning of period at Dec. 31, 2020			$ 8			$ 1					$ 1			558,486	(199,196)	(4,411)	(74,044)			280,845
Shares, Outstanding, Beginning Balance at Dec. 31, 2020			76,458,000			13,219,000					164,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Exchange of Class B Common Stock for Class A Common Stock																				77,900
Exchange of Class A Common Stock for Series B-1 Preferred Stock (in shares)					3,950,000
Exercise of stock options																				$ 12,100
Exercise of stock options (in shares)																				1,114,000
Net income (loss)																				$ 134,682
Balance at end of period at Sep. 30, 2021			$ 13								$ 1			2,057,289	(65,963)	(1,231)	4,254			1,994,363
Shares, Outstanding, Ending Balance at Sep. 30, 2021			132,154,000								124,000
Balance at beginning of period at Mar. 31, 2021			$ 13								$ 1			1,993,962	(203,162)	(2,535)	4,199			1,792,478
Shares, Outstanding, Beginning Balance at Mar. 31, 2021			129,386,000								124,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Issuance of stock for acquisitions														12,166						12,166
Issuance of stock for acquisitions (in shares)			441,000
Exercise of stock options														2,300						2,300
Exercise of stock options (in shares)			200,000
Distributions to noncontrolling interest																	(1,070)			(1,070)
Equity-based compensation														7,447						7,447
Equity-based compensation (in shares)			37,000
Net income (loss)															79,107		951			80,058
Change in fair value of interest rate swaps, inclusive of reclassification adjustment																664				664
Balance at end of period at Jun. 30, 2021			$ 13								$ 1			2,015,875	(124,055)	(1,871)	4,080			1,894,043
Shares, Outstanding, Ending Balance at Jun. 30, 2021			130,064,000								124,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Issuance of stock for acquisitions														25,507						25,507
Issuance of stock for acquisitions (in shares)			977,000
Exercise of stock options														9,840						9,840
Exercise of stock options (in shares)			898,000
Equity-based compensation														5,365						5,365
Equity-based compensation (in shares)			189,000
Common Stock issued in connection with employee stock purchase plan														702						702
Common Stock issued in connection with employee stock purchase plan (in shares)			26,000
Net income (loss)															58,092		174			58,266
Change in fair value of interest rate swaps, inclusive of reclassification adjustment																640				640
Balance at end of period at Sep. 30, 2021			$ 13								$ 1			$ 2,057,289	$ (65,963)	$ (1,231)	$ 4,254			$ 1,994,363
Shares, Outstanding, Ending Balance at Sep. 30, 2021			132,154,000								124,000

Consolidated Statements Of Ch_2

Consolidated Statements Of Changes in Stockholders' Equity (Deficit) (Parenthetical) - USD ($) $ in Thousands	Jan. 08, 2021	Jul. 31, 2020	Mar. 31, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Offering costs					$ 13,832	$ 11,197
Private Placement [Member]
Offering costs		$ 1,600		$ 1,639
Public Offering [Member]
Offering costs	$ 13,800	$ 9,600	$ 13,832	$ 9,558

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net income (loss)	$ 134,682	$ (103,574)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization, including patient equipment depreciation	146,476	55,186
Equity-based compensation	21,394	10,969
Change in fair value of contingent consideration - common shares liability (note 10)	(34,050)	41,850
Change in fair value of warrant liability (note 10)	(57,359)	72,358
Reduction in the carrying amount of operating lease right of use assets	23,832
Deferred income tax expense (benefit)	11,666	(7,590)
Change in fair value of interest rate swaps, net of reclassification adjustment	(2,185)	(2,130)
Change in fair value of contingent consideration	1,135	(2,900)
Payment of contingent consideration in connection with acquisition - operating	(1,000)	(1,000)
Amortization of intangible assets	34,351	2,675
Amortization of deferred financing costs	4,069	1,189
Imputed interest expense	173	128
Write-off of deferred financing costs	4,054	46
Loss on extinguishment of debt from prepayment penalty	16,135	5,316
Gain on equity method investment	(1,922)
Gain on sale of investment		(591)
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(25,046)	(19,251)
Inventory	3,626	(10,166)
Prepaid and other assets	(137)	(1,459)
Operating lease obligations	(23,292)
Operating liabilities	(81,852)	104,231
Net cash provided by operating activities	174,750	145,287
Cash flows from investing activities:
Payments for business acquisitions, net of cash acquired	(1,417,946)	(605,309)
Purchases of equipment and other fixed assets	(139,686)	(22,834)
Payments for investments	(875)	(1,000)
Proceeds from sale of investment		2,046
Net cash used in investing activities	(1,558,507)	(627,097)
Cash flows from financing activities:
Proceeds from borrowings on long-term debt and lines of credit	1,165,000	536,275
Repayments on long-term debt and lines of credit	(822,271)	(545,584)
Proceeds from the sale of Class A Common Stock and Series A Preferred Stock		225,000
Proceed from issuance/sale of Class A Common Stock	278,850	142,600
Proceeds from the issuance of senior unsecured notes	1,100,000	350,000
Proceeds from the exercise of warrants		24,495
Proceeds from the exercise of stock options	12,140
Repayments of finance lease obligations	(31,043)
Payments on capital leases (preadoption)		(29,710)
Payments for equity issuance costs	(13,832)	(11,197)
Payments of deferred financing costs	(29,185)	(12,879)
Proceeds received in connection with employee stock purchase plan	1,016
Payments for tax withholdings from equity-based compensation activity, net	(810)
Distributions to noncontrolling interest	(1,070)	(800)
Payment of contingent consideration in connection with acquisition- financing	(17,200)	(200)
Payment of deferred purchase price in connection with an acquisition	(5,011)	(750)
Payments for debt prepayment penalties	(16,135)
Net cash provided by financing activities	1,620,449	677,250
Net increase in cash and cash equivalents	236,692	195,440
Cash and cash equivalents - beginning of the period	99,962	76,878
Cash and cash equivalents - end of the period	336,654	272,318
Supplemental disclosures:
Cash paid for interest	67,409	22,788
Cash paid for income taxes	13,799	3,062
Noncash investing and financing activities:
Equipment acquired under finance lease obligations	22,902	28,888
Unpaid equipment and other fixed asset purchases at end of year	12,688	8,452
Assets subject to operating lease obligations	11,340
Operating lease obligations	(11,340)
Equity consideration issued in connection with acquisitions	1,261,200	89,529
Contingent purchase price in connection with acquisitions	2,000	6,464
Deferred purchase price in connection with acquisitions	$ 1,162	$ 33

General Information

General Information	9 Months Ended
	Sep. 30, 2021
General Information
General Information	(1) General Information AdaptHealth Corp. and subsidiaries (AdaptHealth or the Company), f/k/a DFB Healthcare Acquisitions Corp. (DFB), is a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services. AdaptHealth focuses primarily on providing (i) sleep therapy equipment, supplies and related services (including CPAP and bi PAP services) to individuals suffering from obstructive sleep apnea (OSA), (ii) medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors (CGM) and insulin pumps), (iii) home medical equipment (HME) to patients discharged from acute care and other facilities, (iv) oxygen and related chronic therapy services in the home, and (v) other HME medical devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs. AdaptHealth services beneficiaries of Medicare, Medicaid and commercial payors. ​ On July 8, 2019, AdaptHealth Holdings LLC (AdaptHealth Holdings) entered into an Agreement and Plan of Merger (the Merger Agreement), as amended on October 15, 2019, with DFB, pursuant to which AdaptHealth Holdings combined with DFB (the Business Combination). The Business Combination closed on November 8, 2019. ​ Unless the context otherwise requires, “the Company”, “we,” “us,” and “our” refer, for periods prior to the closing of the Business Combination, to AdaptHealth Holdings and its subsidiaries and, for periods upon or after the closing of the Business Combination, to AdaptHealth Corp. and its subsidiaries, including AdaptHealth Holdings and its subsidiaries. ​ The consolidated interim financial statements are unaudited, but reflect all normal recurring adjustments that are, in the opinion of management, necessary to fairly present the information set forth herein. The interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K/A for the year ended December 31, 2020. Interim results are not necessarily indicative of the results for a full year. ​ There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K/A for the year ended December 31, 2020, other than the adoption of Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2016-02, Leases ​ (a) Basis of Presentation The consolidated interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). In the opinion of management, the consolidated interim financial statements include all necessary adjustments for a fair presentation of the financial position and results of operations for the periods presented. The Business Combination was accounted for as a reverse recapitalization, with DFB treated as the acquired company and AdaptHealth Holdings as the acquirer, for financial reporting purposes. Therefore, the equity structure was restated to that of the Company. Prior to the quarter ended September 30, 2021, the Company was an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the Securities Act), as modified by the Jumpstart our Business Startups Act of 2012, (the JOBS Act), and took advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and other exemptions. As of September 30, 2021, the Company no longer qualifies as an emerging growth company due to issuing more than $1.0 billion in non-convertible debt in the prior three-year period, and as a result will no longer be exempt from the reporting requirements discussed above. (b) Basis of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. (c) Concentration of Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and trade accounts receivable. The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents. (d) Accounting Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition and the valuation of accounts receivable (implicit price concession), income taxes, contingent consideration, equity-based compensation, interest rate swaps, warrant liability and long-lived assets, including goodwill and identifiable intangible assets. Actual results could differ from those estimates. (e) Valuation of Goodwill The Company has a significant amount of goodwill on its balance sheet that resulted from the business acquisitions the Company has made in recent years. Goodwill is not amortized and is tested for impairment annually and upon the occurrence of a triggering event or change in circumstances indicating a possible impairment. Such changes in circumstance can include, among others, changes in the legal environment, reimbursement environment, operating performance, and/or future prospects. The Company performs its annual impairment review of goodwill during the fourth quarter of each year. The impairment testing can be performed on either a quantitative or qualitative basis. The Company first assesses qualitative factors to determine whether it is necessary to perform quantitative goodwill impairment testing. If determined necessary, the Company applies the quantitative impairment test to identify and measure the amount of impairment, if any. (f) Impairment of Long-Lived Assets The Company’s long-lived assets, such as equipment and other fixed assets and definite-lived identifiable intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Definite-lived identifiable intangible assets consist of tradenames, payor contracts, contractual rental agreements and developed technology. These assets are amortized using the straight-line method over their estimated useful lives, which reflects the pattern in which the economic benefits of the assets are expected to be consumed. These assets are tested for impairment consistent with the Company’s long-lived assets. The following table summarizes the useful lives of the identifiable intangible assets acquired: ​ ​ ​ ​ ​ Tradenames 5 10 ​ years Payor contracts 10 ​ years Contractual rental agreements 2 ​ years Developed technology 5 ​ years ​ The Company did not incur any impairment charges on long-lived assets for the three and nine months ended September 30, 2021 and 2020. In addition to consideration of impairment upon the events or changes in circumstances described above, management regularly evaluates the remaining useful lives of its long-lived assets. (g) Business Segment The Company’s chief operating decision-makers are its Chief Executive Officer and President, who make resource allocation decisions and assess performance based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating decision-makers, or anyone else, for any planning, strategy and key decision-making regarding operations. The corporate office is responsible for contract negotiation with vendors and payors, corporate compliance with healthcare laws and regulations, and revenue cycle management, among other corporate supporting functions. Accordingly, the Company has a single reportable segment and operating segment structure. (h) Accounting for Leases During the quarter ended September 30, 2021, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842) expedients Whenever the Company enters into a new arrangement, it must determine, at the inception date, whether the arrangement is or contains a lease. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and obtain substantially all the economic benefits from the use of the underlying asset. If a lease exists, the Company must then determine the separate lease and nonlease components of the arrangement. Each right to use an underlying asset conveyed by a lease arrangement should generally be considered a separate lease component if it both: (i) can benefit the Company without depending on other resources not readily available to the Company and (ii) does not significantly affect and is not significantly affected by other rights of use conveyed by the lease. Aspects of a lease arrangement that transfer other goods or services to the Company but do not meet the definition of lease components are considered nonlease components. The consideration owed by the Company pursuant to a lease arrangement is generally allocated to each lease and nonlease component for accounting purposes. However, the Company has elected, for all of its leases, to not separate lease and nonlease components. Each lease component is accounted for separately from other lease components, but together with the associated nonlease components. For each lease, the Company must then determine the lease term, the present value of lease payments and the classification of the lease as either an operating or finance lease. The lease term is the period of the lease not cancellable by the Company, together with periods covered by: (i) renewal options the Company is reasonably certain to exercise, (ii) termination options the Company is reasonably certain not to exercise, and (iii) renewal or termination options that are controlled by the lessor. The present value of lease payments is calculated based on: ● Lease payments – lease payments include fixed and certain variable payments, less lease incentives, together with amounts probable of being owed by the Company under residual value guarantees and, if reasonably certain of being paid, the cost of certain renewal options and early termination penalties set forth in the lease arrangement. Lease payments exclude consideration that is not related to the transfer of goods and services of the Company. ● Discount rate – the discount rate must be determined based on information available to the Company upon the commencement of the lease. Lessees are required to use the rate implicit in the lease whenever such rate is readily available; however, as the implicit rate in the Company’s leases is generally not readily determinable, the Company generally uses the hypothetical incremental borrowing rate it would have to pay to borrow an amount equal to the lease payments, on a collateralized basis, over a timeframe similar to the lease term. In making the determination of whether a lease is an operating lease or a finance lease, the Company considers the lease term in relation to the economic life of the leased asset, the present value of lease payments in relation to the fair value of the leased asset and certain other factors, including the lessee’s and lessor’s rights, obligations, and economic incentives over the term of the lease. Generally, upon the commencement of a lease, the Company will record a lease liability and a ROU asset. However, the Company has elected, for all underlying assets with initial terms of twelve months or less (known as short-term leases), to not recognize a lease liability or ROU asset. Lease liabilities are initially recorded at lease commencement as the present value of future lease payments. ROU assets are initially recorded at lease commencement as the initial amount of the lease liability, together with the following, if applicable: (i) initial direct costs incurred by the lessee and (ii) lease payments made by the lessor net of lease incentives received, prior to lease commencement. Over the lease term, the Company generally increases its lease liabilities using the effective interest method and decreases its lease liabilities for lease payments made. For finance leases, amortization and interest expense are recognized separately in the consolidated statements of operations, with amortization expense generally recorded on a straight-line basis over the lease term and interest expense recorded using the effective interest method. For operating leases, a single lease cost is generally recognized in the consolidated statements of operations on a straight-line basis over the lease term unless an impairment has been recorded with respect to a leased asset. Lease costs for short-term leases not recognized in the consolidated balance sheets are recognized in the consolidated statements of operations on a straight-line basis over the lease term. Variable lease costs not initially included in the lease liability and ROU asset impairment charges are expensed as incurred. ROU assets are assessed for impairment, similar to other long-lived assets. Prior to the adoption of ASC 842, the Company accounted for leases under FASB ASC Topic 840, Leases (i) Recently Issued Accounting Pronouncements In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848) ​ (j) Recently Adopted Accounting Pronouncements In February 2016, the FASB issued ASC 842, which requires lessees to recognize leases on its balance sheet and disclose key information about leasing arrangements. Refer to the discussion above regarding the Company’s adoption of ASC 842 during the quarter ended September 30, 2021, which had an effective adoption date of January 1, 2021. In connection with such adoption, the Company recognized a cumulative-effect adjustment as of the January 1, 2021 adoption date by recording $91.5 million of operating lease obligations on its consolidated balance sheet, with a corresponding ROU asset , based on the present value of the remaining minimum rental payments for existing operating leases as of such date. The adoption did not have an impact on the Company’s accounting for existing finance leases. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments ​ (k) Reclassifications ​ Certain prior year amounts have been reclassified to conform to the current year presentation. ​

Revenue Recognition and Account

Revenue Recognition and Accounts Receivable	9 Months Ended
	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Revenue Recognition and Accounts Receivable	(2) Revenue Recognition and Accounts Receivable Revenue Recognition The Company generates revenues for services and related products that the Company provides to patients for home medical equipment, related supplies, and other items. The Company’s revenues are recognized in the period in which services and related products are provided to customers and are recorded either at a point in time for the sale of supplies and disposables, or over the fixed monthly service period for equipment. Revenues are recognized when control of the promised good or service is transferred to customers, in an amount that reflects the consideration to which the Company expects to receive from patients or under reimbursement arrangements with Medicare, Medicaid and third-party payors, in exchange for those goods and services. The Company determines the transaction price based on contractually agreed-upon amounts or rates, adjusted for estimates of variable consideration, such as implicit price concessions. The Company utilizes the expected value method to determine the amount of variable consideration that should be included to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The Company applies constraint to the transaction price, such that net revenue is recorded only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such adjustments become known. Sales revenue is recognized upon transfer of control of products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. Revenues for the sale of durable medical equipment and related supplies, including oxygen equipment, ventilators, wheelchairs, hospital beds and infusion pumps, are recognized when control of the promised good or service is transferred to customers, which is generally upon shipment for direct to consumer supplies and upon delivery to the home for durable medical equipment. ​ The Company provides certain equipment to patients which is reimbursed periodically in fixed monthly payments for as long as the patient is using the equipment and medical necessity continues (in certain cases, the fixed monthly payments are capped at a certain amount). The equipment provided to the patient is based upon medical necessity as documented by prescriptions and other documentation received from the patient’s physician. The patient generally does not negotiate or have input with respect to the manufacturer or model of the equipment prescribed by their physician and delivered by the Company. Once initial delivery of this equipment is made to the patient for initial setup, a monthly billing process is established based on the initial setup service date. The Company recognizes the fixed monthly revenue ratably over the service period as earned, less estimated adjustments, and defers revenue for the portion of the monthly bill that is unearned. No separate revenue is earned from the initial setup process. Included in fixed monthly revenue are unbilled amounts for which the revenue recognition criteria had been met as of period-end but were not yet billed to the payor. The estimate of net unbilled fixed monthly revenue recognized is based on historical trends and estimates of future collectability. ​ The Company’s billing system contains payor-specific price tables that reflect the fee schedule amounts in effect or contractually agreed upon by various government and commercial payors for each item of equipment or supply provided to a customer. Revenues are recorded based on the applicable fee schedule. The Company has established a contractual allowance to account for adjustments that result from differences between the payment amount received and the expected realizable amount. If the payment amount received differs from the net realizable amount, an adjustment is recorded to revenues in the period that these payment differences are determined. The Company reports revenues in its consolidated financial statements net of such adjustments. ​ The Company’s business experiences some seasonality. Its patients are generally responsible for a greater percentage of the cost of their treatment or therapy during the early months of the calendar year due to co-insurance, co-payments and deductibles, and therefore may defer treatment and services of certain therapies until meeting their annual deductibles. In addition, changes to employer insurance coverage often go into effect at the beginning of each calendar year which may impact eligibility requirements and delay or defer treatment. These factors may lead to lower net revenue and cash flow in the early part of the year versus the latter half of the year. Additionally, the increased incidence of respiratory infections during the winter season may result in initiation of additional respiratory services such as oxygen therapy for certain patient populations. The Company’s net revenue and quarterly operating results may fluctuate significantly in the future depending on these and other factors. ​ The Company recognizes revenue in the consolidated statements of operations and contract assets on the consolidated balance sheets only when services have been provided. Since the Company has performed its obligation under the contract, it has unconditional rights to the consideration recorded as contract assets and therefore classifies those billed and unbilled contract assets as accounts receivable. ​ Fixed monthly payments that the Company receives from customers in advance of providing services represent contract liabilities. Such payments primarily relate to patients who are billed monthly in advance and are recognized over the period as earned. ​ The Company disaggregates net revenue from contracts with customers by payor type and by core service lines. The Company believes that disaggregation of net revenue into these categories depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. The payment terms and conditions within the Company’s revenue-generating contracts vary by payor type and payor source. The composition of net revenue by payor type for the three and nine months ended September 30, 2021 and 2020 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2021 ​ 2020 2021 ​ 2020 Insurance ​ $ 399,748 ​ $ 175,418 ​ $ 1,061,627 ​ $ 438,034 Government ​ ​ 180,511 ​ ​ 81,967 ​ ​ 491,564 ​ ​ 193,725 Patient pay ​ 73,034 ​ 27,020 ​ 199,238 ​ 76,201 Net revenue ​ $ 653,293 ​ $ 284,405 ​ $ 1,752,429 ​ $ 707,960 ​ The composition of net revenue by core service lines for the three and nine months ended September 30, 2021 and 2020 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2021 ​ 2020 2021 ​ 2020 Net sales revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Sleep ​ $ 173,359 ​ $ 74,655 ​ $ 465,372 ​ $ 227,970 Diabetes ​ ​ 134,228 ​ ​ 52,887 ​ ​ 352,559 ​ ​ 64,566 Supplies to the home ​ ​ 42,441 ​ ​ 44,579 ​ ​ 126,479 ​ ​ 100,479 Respiratory ​ 6,228 ​ 5,152 ​ 25,003 ​ 26,034 HME ​ ​ 30,989 ​ ​ 14,998 ​ ​ 85,505 ​ ​ 39,304 Other ​ ​ 44,926 ​ ​ 14,869 ​ ​ 95,115 ​ ​ 38,725 Total net sales revenue ​ $ 432,171 ​ $ 207,140 ​ $ 1,150,033 ​ $ 497,078 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net revenue from fixed monthly equipment reimbursements: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Sleep ​ $ 62,755 ​ $ 24,971 ​ $ 177,199 ​ $ 70,284 Diabetes ​ ​ 3,722 ​ ​ 946 ​ ​ 9,791 ​ ​ 946 Respiratory ​ 117,918 ​ 32,269 ​ 312,900 ​ 88,132 HME ​ ​ 26,043 ​ ​ 14,256 ​ ​ 70,854 ​ ​ 39,695 Other ​ ​ 10,684 ​ ​ 4,823 ​ ​ 31,652 ​ ​ 11,825 Total net revenue from fixed monthly equipment reimbursements ​ $ 221,122 ​ $ 77,265 ​ $ 602,396 ​ $ 210,882 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total net revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Sleep ​ $ 236,114 ​ $ 99,626 ​ $ 642,571 ​ $ 298,254 Diabetes ​ ​ 137,950 ​ ​ 53,833 ​ ​ 362,350 ​ ​ 65,512 Supplies to the home ​ ​ 42,441 ​ ​ 44,579 ​ ​ 126,479 ​ ​ 100,479 Respiratory ​ 124,146 ​ 37,421 ​ 337,903 ​ 114,166 HME ​ ​ 57,032 ​ ​ 29,254 ​ ​ 156,359 ​ ​ 78,999 Other ​ ​ 55,610 ​ ​ 19,692 ​ ​ 126,767 ​ ​ 50,550 Total net revenue ​ $ 653,293 ​ $ 284,405 ​ $ 1,752,429 ​ $ 707,960 ​ In response to the COVID-19 pandemic and the National Emergency Declaration, dated March 13, 2020, the Company increased its cash liquidity by, among other things, seeking recoupable advance payments of $45.8 million made available by CMS under the CARES Act legislation, which was received in April 2020. In addition, in connection with an acquisition completed in July 2020, the Company assumed a liability of $3.7 million relating to CMS recoupable advance payments received by the acquired company prior to the date of acquisition. The recoupment of the advance payments by CMS began in April 2021 and is being applied to services provided and revenue recognized during the period in which the recoupment occurs, and will impact the Company’s cash receipts for services provided until such time all amounts have been recouped. During the three and nine months ended September 30, 2021, CMS has recouped $11.1 million and $27.0 million, respectively. At September 30, 2021, the Company has deferred a total of $22.5 million related to CMS recoupable advance payments, which is included in other current liabilities in the consolidated balance sheet. Accounts Receivable Due to the continuing changes in the healthcare industry and third-party reimbursement environment, certain estimates are required to record accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. The complexity of third-party billing arrangements and laws and regulations governing Medicare and Medicaid may result in adjustments to amounts originally recorded. The Company performs a periodic analysis to review the valuation of accounts receivable and collectability of outstanding balances. Management’s evaluation takes into consideration such factors as historical cash collections experience, business and economic conditions, trends in healthcare coverage, other collection indicators and information about specific receivables. The Company’s evaluation also considers the age and composition of the outstanding amounts in determining their estimated net realizable value. Receivables are considered past due when not collected by established due dates. Specific patient balances are written off after collection efforts have been followed and the account has been determined to be uncollectible. Revisions in reserve estimates are recorded as an adjustment to net revenue in the period of revision. Included in accounts receivable are earned but unbilled accounts receivables. Billing delays, ranging from several days to several weeks, can occur due to the Company’s policy of compiling required payor specific documentation prior to billing for its services rendered. At September 30, 2021 and December 31, 2020, the Company recorded unbilled accounts receivables of $17.9 million and $20.2 million, respectively.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2021
Business Combinations [Abstract]
Acquisitions	(3) Acquisitions During the nine months ended September 30, 2021 and 2020, the Company completed several acquisitions to strengthen its current market share in existing markets or to expand into new markets. Each of the Company’s acquisitions was accounted for using the acquisition method pursuant to the requirements of FASB ASC Topic 805, Business Combinations Nine Months Ended September 30, 2021 On February 1, 2021, the Company acquired 100% of the equity interests of AeroCare Holdings, Inc. (AeroCare). AeroCare is a leading national technology-enabled respiratory and home medical equipment distribution platform in the United States and offers a comprehensive suite of direct-to-patient equipment and services including CPAP and BiPAP machines, oxygen concentrators, home ventilators, and other durable medical equipment products. The total consideration consisted of (i) a cash payment of approximately $1.1 billion at closing, (ii) the issuance of 13,992,615 shares of the Company’s Class A Common Stock at closing, (iii) the issuance of 130,474.73 shares of the Company’s Series C Convertible Preferred Stock at closing, and (iv) the issuance of 3,959,892 options to purchase shares of the Company’s Class A Common Stock in the future, which had a weighted-average exercise price of $6.24 per share and a weighted-average remaining exercise period of approximately 7 years from the date of closing. Refer to Note 10, Stockholders’ Equity – Preferred Stock rental agreements and $68.6 million of tradenames), $2.1 billion to goodwill, $82.7 million to accounts payable and accrued expenses, $55.1 million to operating lease obligations, $64.9 million to deferred tax liabilities, and $20.9 million of net liabilities to other working capital accounts. On April 30, 2021, the Company acquired 100% of the equity interests of Spiro Health Services, LLC (Spiro). Spiro is a provider of home medical equipment and supplies. The total consideration consisted of a cash payment of $66.1 million at closing, the issuance of 244,641 shares of the Company’s Class A Common Stock at closing, and a potential contingent consideration payment of up to $1.0 million, which was determined to be the fair value at the acquisition date and such amount was recorded as a contingent consideration liability in connection with the Company’s preliminary acquisition accounting. The $1.0 million was paid to the Spiro sellers in August 2021. The Company allocated the consideration paid to the estimated fair values of the net assets acquired on a provisional basis, including $2.1 million to cash, $8.5 million to accounts receivable, $4.9 million to inventory, $2.2 million to equipment and other fixed assets, $2.7 million to operating lease ROU assets, $1.0 million to identifiable intangible assets (consisting of tradenames), $62.6 million to goodwill, $5.1 million to accounts payable and accrued expenses, $2.7 million to operating lease obligations, $2.2 million to finance lease obligations, and $0.2 million of net assets to other working capital accounts. On June 1, 2021, the Company acquired 100% of the equity interests of Healthy Living Medical Supply, LLC (Healthy Living). Healthy Living is a provider of continuous glucose monitors and insulin pumps. The total consideration consisted of a cash payment of $47.0 million at closing and the issuance of 196,779 shares of the Company’s Class A Common Stock at closing. The Company allocated the consideration paid to the estimated fair values of the net assets acquired on a provisional basis, including $0.6 million to cash, $7.5 million to accounts receivable, $2.9 million to inventory, $1.2 million to equipment and other fixed assets, $1.4 million to operating lease ROU assets, $1.3 million to identifiable intangible assets (consisting of tradenames), $42.0 million to goodwill, $3.6 million to accounts payable and accrued expenses, $1.4 million to operating lease obligations, and $0.2 million of net assets to other working capital accounts. On July 1, 2021, the Company acquired 100% of the equity interests of Agilis Med Holdings, LLC (Agilis). Agilis is an e-commerce retailer of sleep apnea and respiratory equipment in the United States. The total consideration consisted of a cash payment of $30.8 million at closing, the issuance of 538,079 shares of the Company’s Class A Common Stock at closing, and a potential contingent consideration payment of up to $1.0 million, which was determined to be the fair value at the acquisition date and such amount was recorded as a contingent consideration liability in connection with the Company’s preliminary acquisition accounting. Such amount is included in other long-term liabilities in the accompanying consolidated balance sheets at September 30, 2021 based on the expected payment date. In October 2020, the Company acquired a minority interest in Agilis, which was being accounted for under the equity method of accounting prior to the July 2021 transaction. The carrying value of such investment was $8.1 million at the July 2021 transaction date. The fair value of the equity method investment was $10.0 million at the July 2021 transaction date. In connection with the accounting for the July 2021 transaction, the Company recorded goodwill of $10.0 million and eliminated the carrying value of the equity method investment of $8.1 million and recorded a gain on equity method of investment of $1.9 million, which is included in other (income) loss, net in the accompanying consolidated statements of operations during the three and nine months ended September 30, 2021. The Company allocated the consideration paid to the estimated fair values of the net assets acquired on a provisional basis, including $1.2 million to cash, $2.5 million to inventory, $0.5 million to operating lease ROU assets, $0.5 million to identifiable intangible assets (consisting of tradenames), $52.9 million to goodwill, $0.6 million to accounts payable and accrued expenses, and $0.5 million to operating lease obligations. On July 1, 2021, the Company acquired 100% of the equity interests of WeCare Medical, LLC (WeCare). WeCare is a distributor of durable medical equipment and supplies in the United States. The total consideration consisted of a cash payment of $34.8 million at closing and the issuance of 231,866 shares of the Company’s Class A Common Stock at closing. The Company allocated the consideration paid to the estimated fair values of the net assets acquired on a provisional basis, including $0.5 million to cash, $6.3 million to accounts receivable, $1.5 million to inventory, $8.2 million to equipment and other fixed assets, $1.0 million to operating lease ROU assets, $0.4 million to identifiable intangible assets (consisting of tradenames), $29.1 million to goodwill, $3.4 million to deferred tax liabilities, $1.4 million to accounts payable and accrued expenses, and $1.0 million to operating lease obligations. In addition, during the nine months ended September 30, 2021, the Company acquired 100% of the equity interests of five providers of home medical equipment and acquired certain assets of the durable medical equipment business of a provider of home medical equipment. The total consideration paid for these six acquisitions consisted of cash payments of $113.7 million at closing, cash payments of $1.5 million during the nine months ended September 30, 2021 for post-closing net working capital adjustments, and the issuance of 306,569 shares of the Company’s Common Stock at closing. The Company allocated the consideration paid for these six acquisitions to the estimated fair values of the net assets acquired on a provisional basis, including $2.7 million to cash, $20.3 million to accounts receivable, $5.8 million to inventory, $12.0 million to equipment and other fixed assets, $12.2 million to operating lease ROU assets, $2.4 million to identifiable intangible assets (consisting of tradenames), $96.6 million to goodwill, $13.6 million to accounts payable and accrued expenses, $12.2 to operating lease obligations, $4.7 million to finance lease obligations and $1.4 million of net assets to other working capital accounts. One of the acquisitions also includes potential contingent payments of up to $4.0 million based on certain conditions after closing, which was determined to have a nominal acquisition date fair value, and thus no contingent consideration liability was recorded in connection with the Company’s preliminary acquisition accounting for the acquisition. In addition, during the nine months ended September 30, 2021, the Company completed certain other acquisitions. In the aggregate the consideration paid consisted of cash payments of $6.5 million at closing and deferred payment liabilities of $1.2 million. The Company allocated the consideration paid to the estimated fair values of the net assets acquired on a provisional basis, including $0.6 million to accounts receivable, $0.4 million to inventory, $1.0 million to equipment and other fixed assets, $6.1 million to goodwill, $0.3 million to accounts payable and accrued expenses, and $0.1 million of net liabilities to other working capital accounts. The following table summarizes the consideration paid for all acquisitions during the nine months ended September 30, 2021 (in thousands): ​ ​ ​ ​ ​ Cash consideration ​ $ 1,453,302 Equity consideration ​ 1,261,200 Contingent consideration ​ ​ 2,000 Deferred payments ​ 1,162 Total ​ $ 2,717,664 ​ The Company allocated the consideration paid to the net assets acquired based on their estimated acquisition date fair values. The Company is still evaluating the fair value of certain assets and liabilities for which provisional amounts were recorded and expects to finalize such valuations during the remainder of 2021 or early 2022. Based upon management’s evaluation, which is preliminary and subject to completion of working capital and other adjustments, the consideration paid for all acquisitions during the nine months ended September 30, 2021 was allocated as follows during such period (in thousands): ​ ​ ​ ​ ​ Cash ​ $ 34,699 Accounts receivable ​ 119,168 Inventory ​ 45,684 Prepaid and other current assets ​ 6,394 Equipment and other fixed assets ​ 215,350 Operating lease right-of-use assets ​ ​ 72,872 Goodwill ​ 2,386,151 Identifiable intangible assets ​ ​ 128,400 Other assets ​ ​ 1,194 Deferred tax liabilities ​ ​ (67,849) Accounts payable and accrued expenses ​ (107,410) Contract liabilities ​ ​ (14,619) Other current liabilities ​ ​ (11,576) Other long-term liabilities ​ ​ (1,055) Operating lease obligations ​ ​ (72,872) Finance lease obligations ​ (6,867) Net assets acquired ​ $ 2,727,664 ​ During the nine months ended September 30, 2021, the Company received net cash receipts of $0.7 million relating to working capital adjustments associated with businesses that were acquired during 2020 which was recorded as a decrease to goodwill during the period. ​ Nine Months Ended September 30, 2020 ​ On January 2, 2020, the Company purchased 100% of the equity interests of the Patient Care Solutions business (PCS), which was a subsidiary of McKesson Corporation. PCS is a home medical equipment supplies business. The total consideration consisted of a cash payment of $15.0 million at closing. Subsequent to the closing, during the three months ended September 30, 2020, the Company received $1.0 million in connection with a working capital adjustment related to the acquisition. During the nine months ended September 30, 2020, the Company allocated the consideration paid to the estimated fair values of the net assets acquired on a provisional basis, including $17.4 million to accounts receivable, $0.5 million to equipment and other fixed assets, $0.1 million to goodwill, $3.6 million to accounts payable and other accrued expenses, and $0.4 million of net liabilities to other working capital accounts. ​ On March 2, 2020, the Company purchased certain assets of the durable medical equipment business of Advanced Home Care, Inc. (Advanced). The total consideration consisted of a cash payment of $58.5 million at closing. During the nine months ended September 30, 2020, the Company allocated the consideration paid to the estimated fair values of the net assets acquired on a provisional basis, including $21.0 million to equipment and other fixed assets, $2.7 million to inventory, $0.6 million to identifiable intangible assets (consisting of tradenames) $35.8 million to goodwill, and $1.6 million of net liabilities to other working capital accounts. The acquisition of Advanced also includes a potential contingent payment of up to $9.0 million based on certain conditions after closing. As of September 30, 2020, the Company had not yet determined the fair value of such contingent payment, as such an estimated fair value was not included in the consideration paid as part of the Company’s preliminary acquisition accounting during the nine months ended September 30, 2020. In the fourth quarter of 2020, the Company determined that the potential contingent payment had an acquisition date fair value of $5.0 million which was recorded as a contingent liability. The fair value of the estimated contingent liability of $5.0 million at September 30, 2021 is included in other current liabilities in the accompanying consolidated balance sheets based on the expected payment date. ​ On July 1, 2020, the Company acquired 100% of the equity interests in Solara Medical Supplies, LLC (Solara). Solara is an independent distributor of continuous glucose monitors (“CGM”) in the United States and offers a comprehensive suite of direct-to-patient diabetes management supplies to patients throughout the country, including CGMs, insulin pumps and other diabetic supplies. The total consideration consisted of a cash payment of $380.7 million at closing and the issuance of 3,906,250 shares of the Company’s Class A Common Stock at closing. The Company allocated the consideration paid to the estimated fair values of the net assets acquired on a provisional basis, including $12.1 million to cash, $15.1 million to accounts receivable, $15.0 million to inventory, $4.4 million to equipment and other fixed assets, $85.7 million to identifiable intangible assets (consisting of $60.0 million of payor contracts and $25.7 million of tradenames), $347.1 million to goodwill, $22.4 million to accounts payable and accrued expenses, and $3.0 million of net liabilities to other working capital accounts. ​ On July 1, 2020, the Company acquired 100% of the equity interests of ActivStyle, Inc. (ActivStyle). ActivStyle is a leading direct-to-consumer supply company that provides incontinence and urology products to patients throughout the United States. The total consideration consisted of a cash payment of $65.5 million at closing. The Company allocated the consideration paid to the estimated fair values of the net assets acquired on a provisional basis, including $5.0 million to cash, $4.1 million to accounts receivable, $0.5 million to inventory, $1.0 million to equipment and other fixed assets, $10.1 million to identifiable intangible assets (consisting of $7.0 million of developed technology and $3.1 million of tradenames), $51.2 million to goodwill, $7.3 million to accounts payable and accrued expenses, and $0.9 million of assets to other working capital accounts. ​ In addition, during the nine months ended September 30, 2020, the Company acquired 100% of the equity interests of two providers of home medical equipment and a distributor of diabetes management products and supplies. The total consideration for these acquisitions consisted of cash payments of $88.1 million at closing and the issuance of 824,693 shares of the Company’s Class A Common Stock at closing. The Company allocated the consideration paid for these acquisitions to the estimated fair values of the net assets acquired on a provisional basis, including $0.3 million to cash, $12.1 million to accounts receivable, $4.1 million to inventory, $14.7 million to equipment and other fixed assets, $0.9 million to identifiable intangible assets (consisting of tradenames), $91.2 million to goodwill, $13.4 million to accounts payable and accrued expenses, $1.6 million to finance lease obligations, and $1.3 million of net liabilities to other working capital accounts. One of these acquisitions included potential contingent payments of up to $3.0 million, based on certain conditions after closing, which were determined to have an acquisition date fair value of $2.8 million, which was recorded as a contingent consideration liability in connection with the Company’s acquisition accounting. The fair value of the potential contingent payments of $3.0 million as of September 30, 2021 is included in other current liabilities in the accompanying consolidated balance sheets based on the expected payment date. ​ In addition, during the nine months ended September 30, 2020, the Company completed certain other acquisitions. In the aggregate the consideration paid consisted of cash payments of $16.3 million at closing and deferred payment liabilities of less than $0.1 million. The Company allocated the consideration paid to the estimated fair values of the net assets acquired on a provisional basis, including $0.4 million to cash, $0.7 million to accounts receivable, $0.7 million to inventory, $1.3 million to equipment and other fixed assets. $0.1 million to identifiable intangible assets (consisting of tradenames), $18.3 million to goodwill, $1.2 million to accounts payable and accrued expenses, and $0.3 million of net liabilities to other working capital accounts. Certain of these acquisitions included potential contingent payments of up to $5.0 million, based on certain conditions after closing, which were determined to have an acquisition date fair value of $3.7 million, which was recorded as a contingent consideration liability in connection with the Company’s acquisition accounting. The fair value of the potential contingent payments of $4.4 million as of September 30, 2021 is included in other current liabilities ($2.1 million) and other long-term liabilities ($2.3 million) in the accompanying consolidated balance sheets based on the expected payment dates. ​ The following table summarizes the consideration paid for all acquisitions during the nine months ended September 30, 2020 (in thousands): ​ ​ ​ ​ ​ Cash consideration ​ $ 623,107 Equity consideration ​ 89,529 Contingent consideration ​ 6,464 Deferred payments ​ ​ 33 Total ​ $ 719,133 ​ The Company allocated the consideration paid to the net assets acquired based on their estimated acquisition date fair values. Based upon management’s evaluation, which was preliminary and subject to completion of working capital and other adjustments, the consideration paid for all acquisitions during the nine months ended September 30, 2020 was allocated as follows during such period (in thousands): ​ ​ ​ ​ ​ Cash ​ $ 17,798 Accounts receivable ​ 49,464 Inventory ​ 23,073 Prepaid and other current assets ​ 4,254 Equipment and other fixed assets ​ 42,852 Goodwill ​ 543,689 Intangible assets ​ ​ 97,400 Accounts payable and accrued expenses ​ (47,759) Contract liabilities ​ ​ (3,675) Other liabilities ​ ​ (5,069) Other long-term liabilities ​ ​ (1,186) Finance lease obligations ​ ​ (1,708) Net assets acquired ​ $ 719,133 ​ The Company finalized the valuations of the fair values of the net assets acquired for these acquisitions during the remainder of 2020 and the first half of 2021. Pro-Forma Information The unaudited pro-forma financial information presented below has been prepared by adjusting the historical results of the Company to include the historical results of the acquisitions described above. The unaudited pro-forma financial information is presented for illustrative purposes only and may not be indicative of the results of operations that would have actually occurred. In addition, future results may vary significantly from the results reflected in the pro-forma information. The unaudited pro-forma financial information does not reflect the impact of future events that may occur after the acquisitions, such as the impact of cost savings or other synergies that may result from these acquisitions, and does not include interest expense associated with debt incurred to fund the acquisitions. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2021 2020 2021 2020 Net revenue ​ $ 657,611 ​ $ 600,794 ​ $ 1,953,706 ​ $ 1,770,675 Operating income ​ $ 77,046 ​ $ 58,973 ​ $ 181,039 ​ $ 167,279 ​ Results of Businesses Acquired The following table presents the amount of net revenue and operating income (loss) in the period of acquisition since the respective acquisition dates for the acquisitions described above that is included in the Company’s consolidated statements of operations for the three and nine months ended September 30, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2021 2020 2021 2020 Net revenue ​ $ 289,604 ​ $ 115,077 ​ $ 680,460 ​ $ 208,803 Operating income (loss) ​ $ 37,454 ​ $ 4,637 ​ $ 95,143 ​ $ (2,984) ​

Equipment and Other Fixed Asset

Equipment and Other Fixed Assets	9 Months Ended
	Sep. 30, 2021
Equipment and Other Fixed Assets
Equipment and Other Fixed Assets	(4) Equipment and Other Fixed Assets Equipment and other fixed assets as of September 30, 2021 and December 31, 2020 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2021 2020 Patient medical equipment ​ $ 436,725 $ 158,108 Delivery vehicles ​ 27,012 8,211 Other ​ 53,697 26,098 ​ ​ 517,434 ​ 192,417 Less accumulated depreciation ​ (176,077) ​ (81,949) ​ ​ $ 341,357 ​ $ 110,468 ​

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Identifiable Intangible Assets	(5) Goodwill and Identifiable Intangible Assets Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. The change in the carrying amount of goodwill for the nine months ended September 30, 2021 was as follows (in thousands): ​ ​ ​ ​ ​ Balance at December 31, 2020 ​ $ 998,810 Goodwill from acquisitions ​ ​ 2,386,151 Net cash receipts relating to prior acquisitions ​ ​ (657) Reductions ​ ​ (22,036) Balance at September 30, 2021 ​ $ 3,362,268 ​ Annually, and upon the identification of a triggering event, management is required to perform an evaluation of the recoverability of goodwill. Triggering events potentially warranting an interim goodwill impairment test include, among other factors, declines in historical or projected revenue, operating income or cash flows, and declines in the Company’s stock price or market capitalization. While management cannot predict if or when future goodwill impairments may occur, a goodwill impairment could have a material adverse effect on the Company’s operating income, net assets and the Company’s cost of, or access to, capital. The Company did not record any goodwill impairment charges during the three and nine months ended September 30, 2021 and 2020. ​ As discussed in Note 3, Acquisitions Solara. Based on available information obtained by the Company during the nine months ended September 30, 2021, the Company recorded certain measurement period adjustments to the acquisition accounting for Solara, resulting in an increase to accounts receivable of $28.9 million and an increase to accounts payable and accrued expenses of $6.3 million, with a corresponding decrease to goodwill of $22.6 million during the period. ​ Identifiable intangible assets that are separable and have determinable useful lives are valued separately and amortized over the period which reflects the pattern in which the economic benefits of the assets are expected to be consumed. Identifiable intangible assets consisted of the following at September 30, 2021 and December 31, 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2021 ​ ​ ​ ​ ​ Weighted-Average ​ ​ ​ ​ ​ Remaining Life (Years) Tradenames, net of accumulated amortization of $9,666 ​ $ 98,133 ​ 8.8 Payor contracts, net of accumulated amortization of $9,766 ​ ​ 72,234 ​ 8.8 Contractual rental agreements, net of accumulated amortization of $19,383 ​ ​ 34,817 ​ 1.5 Developed technology, net of accumulated amortization of $1,575 ​ ​ 4,725 ​ 3.8 Identifiable intangible assets, net ​ $ 209,909 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 ​ ​ ​ ​ ​ Weighted-Average ​ ​ ​ ​ ​ Remaining Life (Years) Tradenames, net of accumulated amortization of $1,793 ​ $ 32,007 ​ 8.8 Payor contracts, net of accumulated amortization of $3,616 ​ ​ 78,384 ​ 9.6 Developed technology, net of accumulated amortization of $630 ​ ​ 5,670 ​ 4.5 Identifiable intangible assets, net ​ $ 116,061 ​ ​ ​ Amortization expense related to identifiable intangible assets, which is included in depreciation and amortization, excluding patient equipment depreciation, in the accompanying statements of operations, was $10.1 million and $34.4 million for the three and nine months ended September 30, 2021, respectively. Amortization expense related to identifiable intangible assets, which is included in depreciation and amortization, excluding patient equipment depreciation, in the accompanying statements of operations, was $2.7 million for the three and nine months ended September 30, 2020. ​ Future amortization expense related to identifiable intangible assets is estimated to be as follows (in thousands): ​ ​ ​ ​ ​ Twelve months ending September 30, ​ ​ 2022 ​ $ 48,376 2023 ​ 28,993 2024 ​ 21,276 2025 ​ 20,828 2026 ​ 18,682 Thereafter ​ 71,754 Total ​ $ 209,909 ​ The Company recorded no impairment charges related to identifiable intangible assets during the three and nine months ended September 30, 2021 and 2020.

Fair Value of Assets and Liabil

Fair Value of Assets and Liabilities	9 Months Ended
	Sep. 30, 2021
Fair Value of Assets and Liabilities
Fair Value of Assets and Liabilities	(6) Fair Value of Assets and Liabilities FASB ASC Topic 820, Fair Value Measurements and Disclosures ​ ​ ​ Level input ​ Input Definition Level 1 ​ Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date. Level 2 ​ Inputs, other than quoted prices included in Level 1 that are observable for the asset or liability through corroboration with market data at the measurement date. Level 3 ​ Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. ​ The following table presents the valuation of the Company’s financial assets and liabilities as of September 30, 2021 and December 31, 2020 measured at fair value on a recurring basis. The fair value estimates presented herein are based on information available to management as of September 30, 2021 and December 31, 2020. These estimates are not necessarily indicative of the amounts the Company could ultimately realize. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Level 1 Level 2 Level 3 September 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ Money market accounts ​ $ 200,059 ​ $ — ​ $ — Total assets measured at fair value ​ $ 200,059 ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ Acquisition-related contingent consideration-short term ​ $ — ​ $ — ​ $ 15,398 Acquisition-related contingent consideration-long term ​ — ​ — ​ 3,250 Interest rate swap agreements-short term ​ ​ — ​ ​ 5,957 ​ ​ — Interest rate swap agreements-long term ​ — ​ 4,838 ​ — Contingent consideration common shares liability-short term ​ ​ — ​ ​ — ​ ​ 21,402 Contingent consideration common shares liability-long term ​ ​ — ​ ​ — ​ ​ 15,025 Warrant liability ​ ​ — ​ ​ — ​ ​ 56,546 Total liabilities measured at fair value ​ $ — ​ $ 10,795 ​ $ 111,621 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Level 1 Level 2 Level 3 December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ Money market accounts ​ $ 5,602 ​ $ — ​ $ — Total assets measured at fair value ​ $ 5,602 ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ Acquisition-related contingent consideration-short term ​ $ — ​ $ — ​ $ 23,941 Acquisition-related contingent consideration-long term ​ — ​ — ​ 9,599 Interest rate swap agreements-short term ​ ​ — ​ ​ 5,941 ​ ​ — Interest rate swap agreements-long term ​ — ​ 10,220 ​ — Contingent consideration common shares liability-short term ​ ​ — ​ ​ — ​ ​ 36,846 Contingent consideration common shares liability-long term ​ ​ — ​ ​ — ​ ​ 33,631 Warrant liability ​ ​ — ​ ​ — ​ ​ 113,905 Total liabilities measured at fair value ​ $ — ​ $ 16,161 ​ $ 217,922 ​ Interest Rate Swaps The Company recognizes its interest rate swaps as either assets or liabilities in the accompanying consolidated balance sheets at fair value. The valuation of these derivative instruments is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The Company’s interest rate swaps held as of September 30, 2021 and December 31, 2020 were classified as Level 2 of the fair value hierarchy. Refer to Note 7, Derivative Instruments and Hedging Activities Contingent Consideration The Company estimates the fair value of acquisition-related contingent consideration liabilities by applying the income approach using a probability-weighted discounted cash flow model. This fair value measurement is based on significant inputs not observed in the market and thus represents a Level 3 measurement. Level 3 instruments are valued based on unobservable inputs that are supported by little or no market activity and reflect the Company’s own assumptions in measuring fair value. Each period, the Company evaluates the fair value of acquisition-related contingent consideration obligations and records any changes in the fair value of such liabilities in other income in the Company’s consolidated statements of operations. At September 30, 2021, contingent consideration liabilities of $15.4 million and $3.3 million were included in other current liabilities and other long-term liabilities, respectively, in the accompanying consolidated balance sheets. At December 31, 2020, contingent consideration liabilities of $23.9 million and $9.6 million were included in other current liabilities and other long-term liabilities, respectively, in the accompanying consolidated balance sheets. A reconciliation of the Company’s contingent consideration liabilities related to acquisitions for the nine months ended September 30, 2021 and 2020 is as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, 2021 ​ Beginning Balance Additions Payments Change in Fair Value Other activity Ending Balance Contingent consideration - Level 3 liabilities ​ $ 33,540 ​ $ 2,000 ​ $ (18,200) ​ $ 1,135 ​ $ 173 ​ $ 18,648 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, 2020 ​ Beginning Balance Additions Payments Change in Fair Value Other activity Ending Balance Contingent consideration - Level 3 liabilities ​ $ 14,725 ​ $ 6,464 ​ $ (1,200) ​ $ (2,900) $ 46 ​ $ 17,135 ​ Contingent Consideration Common Shares Liability ​ The Company estimates the fair value of the contingent consideration common shares liability using a Monte-Carlo simulation analysis. A Monte-Carlo simulation is a tool used to project asset prices based on a widely accepted drift calculation, the volatility of the asset, incremental time-steps and a random component known as a Weiner process that introduces the dynamic behavior in the asset price. In this framework, asset prices follow a log-normal distribution as they fluctuate through time, which the simulation process captures. A specific model can be developed around the projected stock price to capture the effects of any market performance conditions on value. Price path specific conditions can be captured in this type of open form model. The Monte-Carlo process expresses potential future scenarios that when simulated thousands of times can be viewed statistically to ascertain fair value. The contingent consideration common shares contain market conditions to determine whether the shares are earned based on the Company’s common stock price during specified measurement periods. Given the path-dependent nature of the requirement in which the shares are earned, a Monte-Carlo simulation was used to estimate the fair value of the liability. The Company’s common stock price was simulated to each measurement period based on the above described methodology. In each iteration, the simulated stock price was compared to the conditions under which the shares are earned. In iterations where the stock price corresponded to shares being earned, the future value of the earned shares was discounted back to present value. The fair value of the liability was estimated based on the average of all iterations of the simulation. Refer to Note 10, Stockholders’ Equity ​ Warrant Liability ​ The warrant liability represents the estimated fair value of the Company’s outstanding private warrants. The fair value of the private warrants was estimated using the Black-Scholes option pricing model. As an input to the Black-Scholes option pricing model, the volatility implied by trades in the public warrants was considered. In order to estimate this implied volatility, a Monte-Carlo simulation was employed. Refer to the discussion above for a description of the Monte-Carlo simulation analysis. Refer to Note 10, Stockholders’ Equity ​ Non-Financial Assets Measured at Fair Value on a Non-Recurring Basis ​ The following table presents the Company’s hierarchy for non-financial assets measured at fair value on a non-recurring basis (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2021 2020 Assets: ​ ​ ​ Goodwill (Level 3) ​ $ 3,362,268 ​ $ 998,810 Identifiable intangible assets, net (Level 3) ​ $ 209,909 ​ $ 116,061 ​ The fair value allocation related to the Company’s acquisitions are determined using a discounted cash flow approach, or a replacement cost approach, which are based on significant unobservable inputs (Level 3). The Company estimates the fair value using the income approach (which is a discounted cash flow technique) or the cost approach. These valuation methods required management to make various assumptions, including, but not limited to, future profitability, cash flows, replacement costs, and discount rates. The Company’s estimates are based upon historical trends, management’s knowledge and experience and overall economic factors, including projections of future earnings potential. ​ Developing discounted future cash flows in applying the income approach requires the Company to evaluate its intermediate to longer-term strategies, including, but not limited to, estimates of revenue growth, operating margins, capital requirements, inflation and working capital management. The development of appropriate rates to discount the estimated future cash flows requires the selection of risk premiums, which can materially impact the present value of future cash flows. ​ The Company estimated the fair value of acquired identifiable intangible assets using discounted cash flow techniques that included an estimate of future cash flows, consistent with overall cash flow projections used to determine the purchase price paid to acquire the business, discounted at a rate of return that reflects the relative risk of the cash flows. The Company estimated the fair value of certain acquired identifiable intangible assets based on the cost approach using estimated costs consistent with historical experience. The Company believes the estimates and assumptions used in the valuation methods are reasonable.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	9 Months Ended
	Sep. 30, 2021
Derivative Instruments and Hedging Activities
Derivative Instruments and Hedging Activities	(7) Derivative Instruments and Hedging Activities The Company records all derivatives on its consolidated balance sheet at fair value. As of September 30, 2021 and December 31, 2020, the Company had outstanding interest rate derivatives with third parties in which the Company pays a fixed interest rate and receives a rate equal to the one-month LIBOR. The notional amount associated with the swap agreements was $250 million as of September 30, 2021 and December 31, 2020 and have maturity dates at certain dates through March 2024. The Company has designated its swaps as effective cash flow hedges of interest rate risk. Accordingly, changes in the fair value of the interest rate swaps are recorded as a component of accumulated other comprehensive income (loss) within stockholders’ equity and subsequently reclassified into interest expense in the same period during which the hedged transaction affects earnings. The table below presents the fair value of the Company’s derivatives designated as hedging instruments as well as their classification in the consolidated balance sheets at September 30, 2021 and December 31, 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2021 ​ December 31, 2020 ​ ​ Balance Sheet Location ​ Asset (Liability) Interest rate swap agreements ​ Other current liabilities ​ $ (5,957) ​ $ (5,941) Interest rate swap agreements ​ Other long-term liabilities ​ (4,838) ​ (10,220) Total ​ ​ ​ $ (10,795) ​ $ (16,161) ​ During the three months ended September 30, 2021, as a result of the effect of cash flow hedge accounting, the Company recognized a gain of $1.4 million in other comprehensive income (loss). In addition, during the three months ended September 30, 2021, $0.8 million was reclassified from other comprehensive income (loss) and recognized as a reduction to interest expense, net, in the accompanying consolidated statements of operations. During the nine months ended September 30, 2021, as a result of the effect of cash flow hedge accounting, the Company recognized a gain of $5.4 million in other comprehensive income (loss). In addition, during the nine months ended September 30, 2021, $2.2 million was reclassified from other comprehensive income (loss) and recognized as a reduction to interest expense, net, in the accompanying consolidated statements of operations. During the three months ended September 30, 2020, as a result of the effect of cash flow hedge accounting, the Company recognized income of $1.6 million in other comprehensive income (loss). In addition, during the three months ended September 30, 2020, $0.7 million was reclassified from other comprehensive income (loss) and recognized as a reduction to interest expense, net, in the accompanying consolidated statements of operations. During the nine months ended September 30, 2020, as a result of the effect of cash flow hedge accounting, the Company recognized a loss of $9.4 million in other comprehensive income (loss). In addition, during the nine months ended September 30, 2020, $2.1 million was reclassified from other comprehensive income (loss) and recognized as a reduction to interest expense, net, in the accompanying consolidated statements of operations.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	9 Months Ended
	Sep. 30, 2021
Accounts Payable and Accrued Expenses
Accounts Payable and Accrued Expenses	(8) Accounts Payable and Accrued Expenses Accounts payable and accrued expenses as of September 30, 2021 and December 31, 2020 consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2021 ​ 2020 Accounts payable ​ $ 211,373 $ 191,038 Employee-related accruals ​ 40,483 ​ 26,705 Accrued interest ​ 11,178 ​ 11,062 Other ​ 49,321 ​ 25,407 Total ​ $ 312,355 ​ $ 254,212 ​

Debt

Debt	9 Months Ended
	Sep. 30, 2021
Debt
Debt	(9) Debt The following is a summary of long term-debt as of September 30, 2021 and December 31, 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2021 ​ 2020 Secured term loans ​ $ 790,000 $ 248,438 Revolving credit facility ​ ​ — ​ ​ 55,000 Senior unsecured notes ​ ​ 1,450,000 ​ ​ 350,000 Note payable ​ — ​ 143,500 Other ​ — ​ 333 Unamortized deferred financing fees ​ (32,627) ​ (12,557) ​ ​ 2,207,373 ​ 784,714 Current portion ​ (20,000) ​ (8,146) Long-term portion ​ $ 2,187,373 ​ $ 776,568 ​ ​ On January 20, 2021, the Company refinanced its then existing debt borrowings and entered into a new credit agreement with its existing bank group, which was amended in April 2021 (the 2021 Credit Agreement). The 2021 Credit Agreement included borrowings of $800 million under a term loan (the 2021 Term Loan), and $450 million in commitments for revolving credit loans (the 2021 Revolver). The 2021 Revolver has a $55 million letter of credit sublimit. The 2021 Term Loan and the 2021 Revolver both have maturities in January 2026. Borrowings under the 2021 Term Loan were used in part to partially finance the cash portion of the purchase price for the acquisition of AeroCare, to repay existing amounts outstanding under the 2020 Credit Agreement (see discussion below), to repay amounts outstanding under revolving credit loans under the 2021 Credit Agreement which were borrowed prior to the April 2021 amendment, and to pay related fees and expenses. Amounts borrowed under the 2021 Credit Agreement bear interest quarterly at variable rates based upon the sum of (a) the Adjusted LIBOR Rate (subject to a floor) equal to the LIBOR (as defined) for the applicable interest period multiplied by the statutory reserve rate, plus (b) an applicable margin (as defined) ranging from 1.50% to 3.25% per annum based on the Consolidated Senior Secured Leverage Ratio (as defined). The 2021 Revolver carries a commitment fee during the term of the 2021 Credit Agreement ranging from 0.25% to 0.50% per annum of the average daily undrawn portion of the 2021 Revolver based on the Consolidated Senior Secured Leverage Ratio. On August 16, 2021, the Company amended the 2021 Credit Agreement to expressly permit the issuance of the 5.125% Senior Notes (as defined below) and the prepayment of the outstanding principal amount under the New Promissory Note (as defined below) with the proceeds of the 5.125% Senior Notes. In addition, the amendment increased the amount of unencumbered cash that may be used to reduce total indebtedness in the calculation of certain financial covenants for the fiscal quarters ending September 30, 2021 and December 31, 2021. In connection with the 2021 Credit Agreement, the Company paid financing costs of $7.6 million during the nine months ended September 30, 2021. Further, in connection with the transactions completed pursuant to the 2021 Credit Agreement, the Company wrote off unamortized deferred financing costs of $2.1 million, which is included in loss on extinguishment of debt in the accompanying consolidated statements of operations for the nine months ended September 30, 2021. ​ Under the 2021 Credit Agreement, the Company is subject to a number of restrictive covenants that, among other things, impose operating and financial restrictions on the Company. Financial covenants include a Consolidated Total Leverage Ratio and a Consolidated Interest Coverage Ratio, both as defined in the 2021 Credit Agreement. The 2021 Credit Agreement also contains certain customary events of default, including, among other things, failure to make payments when due thereunder, failure to observe or perform certain covenants, cross-defaults, bankruptcy and insolvency-related events, and non-compliance with healthcare laws. Any borrowing under the 2021 Credit Agreement may be repaid, in whole or in part, at any time and from time to time without premium or penalty, other than customary breakage costs, and any amounts repaid under the 2021 Revolver may be reborrowed. Mandatory prepayments are required under the 2021 Revolver when borrowings and letter of credit usage exceed the total commitments for revolving credit loans. Mandatory prepayments are also required in connection with the disposition of assets to the extent not reinvested, unpermitted debt transactions, and excess cash flow, as defined, if certain leverage tests are not met. The Company was in compliance with all debt covenants as of September 30, 2021. ​ In July 2020, the Company refinanced its then existing debt borrowings and entered into a new credit agreement with a new bank group (the 2020 Credit Agreement). The 2020 Credit Agreement consisted of a $250 million term loan (the 2020 Term Loan) and $200 million in commitments for revolving credit loans (the 2020 Revolver). The borrowings under the 2020 Term Loan bore interest quarterly at variable rates based upon the sum of (a) the Adjusted LIBOR Rate (subject to a floor) equal to the LIBOR (as defined in the 2020 Credit Agreement) for the applicable interest period, plus (b) an applicable margin ranging from 2.50% to 3.75% per annum based on the Consolidated Total Leverage Ratio (as defined in the 2020 Credit Agreement). The 2020 Revolver carried a commitment fee during the term of the 2020 Credit Agreement ranging from 0.25% to 0.50% per annum of the average daily undrawn portion of the 2020 Revolver based on the Consolidated Total Leverage Ratio. ​ In March 2019, the Company entered into several agreements, amendments and new credit facilities (herein after referred to as the March 2019 Recapitalization Transactions). The March 2019 Recapitalization Transactions included $425 million in new credit facilities, which consisted of a $300 million Initial Term Loan, $50 million Delayed Draw Term Loan, and $75 million Revolving Credit Facility, collectively referred to herein as the 2019 Credit Facility. Amounts borrowed under the 2019 Credit Facility bore interest quarterly at variable rates based upon the sum of (a) the LIBOR Rate for such interest period, plus (b) an applicable margin based upon the Company’s Consolidated Total Leverage Ratio (as defined in the 2019 Credit Facility). In November 2019, the Company repaid $50 million under the Initial Term Loan. In July 2020, the Company amended the 2019 Credit Facility and borrowed $216.3 million under an incremental term loan; such proceeds were used to partially fund an acquisition. The Company used a portion of the net proceeds from the borrowings under the 2020 Term Loan and the issuance of the 6.125% Senior Notes (see discussion below) to fully repay the outstanding principal balances under the 2019 Credit Facility totaling $523.9 million, and to pay the related accrued interest, fees and expenses. ​ Secured Term Loans ​ The borrowings under the 2021 Term Loan require quarterly principal repayments of $5.0 million beginning June 30, 2021 through March 31, 2023, increasing to $10.0 million beginning June 30, 2023 through December 31, 2025, and the unpaid principal balance is due at maturity in January 2026. At September 30, 2021, there was $790 million outstanding under the 2021 Term Loan. The interest rate under the term loan was 2.63% at September 30, 2021. ​ Revolving Credit Facility ​ During the nine months ended September 30, 2021, the Company borrowed $365 million under revolving credit loans pursuant to the 2021 Credit Agreement, which were all repaid during the period. As such, there was $0 outstanding under the 2021 Revolver at September 30, 2021. Borrowings under the 2021 Revolver may be used for working capital and other general corporate purposes, including for capital expenditures and acquisitions permitted under the 2021 Credit Agreement. At September 30, 2021, after consideration of stand-by letters of credit outstanding of $14.9 million, the remaining maximum borrowings available pursuant to the Company’s revolving credit loans were $435.1 million. ​ Senior Unsecured Notes ​ On August 19, 2021, the Company issued $600.0 million aggregate principal amount of 5.125% senior unsecured notes due 2030 (the 5.125% Senior Notes). The 5.125% Senior Notes will mature on March 1, 2030. Interest on the 5.125% Senior Notes is payable on March 1st and September 1st of each year, beginning on March 1, 2022. The 5.125% Senior Notes will be redeemable at the Company’s option, in whole or in part, at any time on or after March 1, 2025, and the redemption price for the 5.125% Senior Notes if redeemed during the 12 months beginning (i) March 1, 2025 is 102.563%, (ii) March 1, 2026 is 101.281%, (iii) March 1, 2027 and thereafter is 100.000%, in each case together with accrued and unpaid interest. The Company may also redeem some or all of the 5.125% Senior Notes before March 1, 2025 at a redemption price of 100% of the principal amount of the 5.125% Senior Notes, plus a “make-whole” premium, together with accrued and unpaid interest. In addition, the Company may redeem up to 40% of the original aggregate principal amount of the 5.125% Senior Notes before March 1, 2025 with the proceeds from certain equity offerings at a redemption price equal to 105.125% of the principal amount of the 5.125% Senior Notes, together with accrued and unpaid interest. Furthermore, the Company may be required to make an offer to purchase the 5.125% Senior Notes upon the sale of certain assets or upon specific kinds of changes of control. Borrowings under the 5.125% Senior Notes were used to repay existing amounts outstanding under the 2021 Revolver, to repay the outstanding balance under the New Promissory Note (see discussion below), and to pay related fees and expenses. In connection with the issuance of the 5.125% Senior Notes, the Company paid financing costs of $11.1 million. ​ On January 4, 2021, the Company issued $500.0 million aggregate principal amount of 4.625% senior unsecured notes due 2029 (the 4.625% Senior Notes). The 4.625% Senior Notes will mature on August 1, 2029. Interest on the 4.625% Senior Notes is payable on February 1st and August 1st of each year, beginning on August 1, 2021. The 4.625% Senior Notes will be redeemable at the Company’s option, in whole or in part, at any time on or after February 1, 2024, and the redemption price for the 4.625% Senior Notes if redeemed during the 12 months beginning (i) February 1, 2024 is 102.313%, (ii) February 1, 2025 is 101.156%, (iii) February 1, 2026 and thereafter is 100.000%, in each case together with accrued and unpaid interest. The Company may also redeem some or all of the 4.625% Senior Notes before February 1, 2024 at a redemption price of 100% of the principal amount of the 4.625% Senior Notes, plus a “make-whole” premium, together with accrued and unpaid interest. In addition, the Company may redeem up to 40% of the original aggregate principal amount of the 4.625% Senior Notes before February 1, 2024 with the proceeds from certain equity offerings at a redemption price equal to 104.625% of the principal amount of the 4.625% Senior Notes, together with accrued and unpaid interest. Furthermore, the Company may be required to make an offer to purchase the 4.625% Senior Notes upon the sale of certain assets or upon specific kinds of changes of control. Borrowings under the 4.625% Senior Notes were used to partially finance the cash portion of the purchase price for the acquisition of AeroCare, and to pay related fees and expenses. In connection with the issuance of the 4.625% Senior Notes, the Company paid financing costs of $10.4 million. ​ In July 2020, the Company issued $350.0 million aggregate principal amount of 6.125% senior unsecured notes due 2028 (the 6.125% Senior Notes). The 6.125% Senior Notes will mature on August 1, 2028. Interest on the 6.125% Senior Notes is payable on February 1st and August 1st of each year, beginning on February 1, 2021. The 6.125 % Senior Notes will be redeemable at the Company’s option, in whole or in part, at any time on or after August 1, 2023, and the redemption price for the 6.125 % Senior Notes if redeemed during the 12 months beginning (i) August 1, 2023 is 103.063%, (ii) August 1, 2024 is 102.042%, (iii) August 1, 2025 is 101.021% and (iv) August 1, 2026 and thereafter is 100.000%, in each case together with accrued and unpaid interest. The Company may also redeem some or all of the 6.125 % Senior Notes before August 1, 2023 at a redemption price of 100% of the principal amount of the 6.125% Senior Notes , plus a “make-whole” premium, together with accrued and unpaid interest. In addition, the Company may redeem up to 40% of the original aggregate principal amount of the 6.125 % Senior Notes before August 1, 2023 with the proceeds from certain equity offerings at a redemption price equal to 106.125% of the principal amount of the 6.125% Senior Notes , together with accrued and unpaid interest. Furthermore, the Company may be required to make an offer to purchase the 6.125% Senior Notes upon the sale of certain assets or upon specific kinds of changes of control. ​ Note Payable ​ In connection with the March 2019 Recapitalization Transactions, the Company signed a Note and Unit Purchase Agreement with an investor. Pursuant to the agreement, the Company issued a promissory note with a principal amount of $100 million (the Promissory Note). In connection with the transactions completed as part of the Business Combination, the Promissory Note was replaced with a new amended and restated promissory note with a principal amount of $100 million, and the investor converted certain of its members’ interests to a $43.5 million promissory note. The new $100 million promissory note, together with the $43.5 million promissory note, are collectively referred to herein as the New Promissory Note. In June 2021, the Company repaid $71.8 million of the outstanding principal balance under the New Promissory Note. In connection with such repayment, the Company paid a debt prepayment penalty of $8.5 million, reflecting the previously disclosed 10% prepayment penalty plus an incremental amount negotiated as part of the June 2021 repayment, and wrote off $1.4 million of unamortized deferred financing costs; both amounts are included in loss on extinguishment of debt in the accompanying consolidated statements of operations during the nine months ended September 30, 2021. In August 2021, the Company repaid the remaining outstanding principal balance of $71.7 million under the New Promissory Note. In connection with such repayment, the Company paid a debt prepayment penalty of $7.7 million, reflecting the previously disclosed 10% prepayment penalty plus an incremental amount negotiated as part of the August 2021 repayment, and wrote off $0.6 million of unamortized deferred financing costs; both amounts are included in loss on extinguishment of debt in the accompanying consolidated statements of operations during the three and nine months ended September 30, 2021. ​ In May 2020, the Company and the investor entered into a Put/Call Option and Consent Agreement (the Put/Call Agreement), pursuant to which certain put and call rights were granted to the parties with respect to shares of Class A Common Stock, shares of Class B Common Stock, and common units of AdaptHealth Holdings (each such common unit, together with one share of Class B Common Stock, a Consideration Unit) held by the investor at the time. Pursuant to the Put/Call Agreement, which was amended in October 2020, during the period from July 1, 2020 to December 31, 2020 (the Option Period), the investor could require the Company to purchase up to 1,898,967 shares of Class A Common Stock and/or Consideration Units held by the investor (such shares of Class A Common Stock and Consideration Units, collectively, Interests) at a price per share of Class A Common Stock or per Consideration Unit equal to the greater of (x) $14.50 and (y) 85% of the 30-day volume-weighted average price per share of the Company’s Class A Common Stock on the date the exercise notice is delivered. During the Option Period, the Company could also require the investor to sell up to 1,898,967 of the Interests held by the investor to the Company at a price per share of Class A Common Stock or per Consideration Unit of $15.76. In addition, under the Put/Call Agreement, the investor waived certain consent rights under the New Promissory Note. In connection with the accounting for the Put/Call Agreement, during the nine months ended September 30, 2020, the Company recorded a decrease to additional paid-in capital of $29.9 million, representing the settlement amount of the related call option, and classified such amount as mezzanine equity. In addition, during the nine months ended September 30, 2020, the Company recorded a decrease to additional paid-in capital and accumulated deficit of $2.7 million, representing the estimated net fair value of the related call and put option.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2021
Stockholders' Equity
Stockholders' Equity	(10) Stockholders’ Equity On January 8, 2021, the Company issued 8,450,000 shares of Class A Common Stock at a price of $33.00 per share pursuant to an underwritten public offering (the 2021 Stock Offering) for gross proceeds of $278.9 million. In connection with this transaction, the Company received proceeds of $265.6 million which is net of the underwriting discount. A portion of the proceeds from the 2021 Stock Offering were used to partially finance the cash portion of the purchase price for the acquisition of AeroCare, and to pay related fees and expenses. In connection with the 2021 Stock Offering, the Company paid offering costs, inclusive of the underwriting discount, of $13.8 million. In July 2020, the Company received gross proceeds of $190.0 million in connection with the sale of 10,930,471 shares of Class A Common Stock and 39,706 shares of Series A Preferred Stock pursuant to a private placement transaction. In addition, in July 2020, the Company received gross proceeds of $35.0 million in connection with the sale of 35,000 shares of Series B-2 Preferred Stock pursuant to a private placement transaction. The proceeds from these transactions were used to partially fund an acquisition. In connection with these transactions, the Company paid offering costs of $1.6 million. In September 2020, the 39,706 shares of Series A Preferred Stock were converted into 2,887,709 shares of Class A Common Stock. In addition, in September 2020, the 35,000 shares of Series B-2 Preferred Stock were converted into 25,454.55 shares of Series B-1 Preferred Stock (see below for a discussion of the Company’s outstanding Series B-1 Preferred Stock). ​ In July 2020, the Company issued 9,200,000 shares of Class A Common Stock at a price of $15.50 per share pursuant to an underwritten public offering and received gross proceeds of $142.6 million. In connection with this transaction, the Company paid offering costs, inclusive of the underwriting discount, of $9.6 million. ​ Upon the Closing of the Business Combination, the former owners of AdaptHealth Holdings held approximately 49% of the economic interest in AdaptHealth Corp. and the former stockholders of DFB held the remaining approximate 51% of the economic interests in AdaptHealth Corp., both in the form of shares of the Company’s Class A Common Stock. In addition, AdaptHealth Corp. owned approximately 56% of the combined company with the remaining 44% owned by the former owners of AdaptHealth Holdings in the form of common units representing limited liability company interests in AdaptHealth Holdings from and after the Closing of the Business Combination (New AdaptHealth Units). ​ Following the Closing of the Business Combination, the combined results of DFB and AdaptHealth Holdings are consolidated, and the holders of Class A Common Stock owned an approximate 56% direct controlling interest and the holders of New AdaptHealth Units owned an approximate 44% direct noncontrolling economic interest shown as noncontrolling interest in the consolidated financial statements of the combined entity. The direct noncontrolling economic interest in AdaptHealth Holdings held by the owners of AdaptHealth Holdings was in the form of New AdaptHealth Units (and a corresponding number of non-economic shares of Class B Common Stock) and were exchangeable on a one-to-one basis for shares of Class A Common Stock. Following the Closing of the Business Combination, all of the New AdaptHealth Units and a corresponding number of shares of Class B Common Stock were exchanged for shares of Class A Common Stock, of which the final 13,218,758 of the exchanges occurred on January 1, 2021. As a result, there are no New AdaptHealth Units and shares of Class B Common Stock outstanding, and therefore the prior holders of New AdaptHealth Units no longer own a direct noncontrolling economic interest in AdaptHealth Holdings. Accordingly, the Company recorded a decrease to the noncontrolling interest of $77.9 million during the nine months ended September 30, 2021 in the accompanying consolidated statements of stockholders’ equity (deficit). ​ Following the filing of the Charter with the Secretary of State of the State of Delaware on July 28, 2021, the Company’s Class A Common Stock was renamed to Common Stock, and the Common Stock is the sole class of common stock of the Company. ​ Preferred Stock In June 2020, the Company entered into an exchange agreement (the Exchange Agreement) with an investor pursuant to which the investor exchanged 15,810,547 shares of the Company’s Class A Common Stock for 158,105.47 shares of Series B-1 Preferred Stock, par value $0.0001 per share. The Series B-1 Preferred Stock liquidation preference is limited to its par value of $0.0001 per share. The Series B-1 Preferred Stock will participate equally and ratably on an as-converted basis with the holders of Common Stock in all cash dividends paid on the Common Stock. The Series B-1 Preferred Stock is non-voting. The holder may convert each share of Series B-1 Preferred Stock into 100 shares of Common Stock (subject to certain anti-dilution adjustments) at its election, except to the extent that following such conversion, the number of shares of Common Stock held by such holder and its affiliates exceed 4.9% of the outstanding Common Stock of the Company. During the nine months ended September 30, 2021, 39,500 shares of Series B-1 Preferred Stock were converted into 3,950,000 shares of Class A Common Stock. As discussed in Note 3, Acquisitions voting power of the Company issuable upon conversion of the Series C Convertible Preferred Stock issued to the former equity holders of AeroCare, by removal of the conversion restriction that prohibits such conversion of Series C Convertible Preferred Stock. Following the receipt of the approval of the Company’s stockholders, the holders were able to elect to convert, and the Company was able to elect to effect a mandatory conversion of, each share of Series C Convertible Preferred Stock into 100 shares of Class A Common Stock (subject to certain anti-dilution adjustments). The Company elected to effect a mandatory conversion of the Series C Convertible Preferred Stock, and the conversion of 130,474.73 shares of Series C Convertible Preferred Stock to 13,047,473 shares of Class A Common Stock occurred on March 18, 2021. Warrants At the Closing of the Business Combination, the Company had 12,666,666 warrants outstanding. Each warrant is exercisable into one share of Common Stock at a price of $11.50 per share. The exercise price and number of shares of Common Stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for the issuance of common stock at a price below its exercise price. There were no warrants exercised during the nine months ended September 30, 2021. During the nine months ended September 30, 2020, 6,254,803 warrants were exercised in cashless transactions resulting in the issuance of 1,973,707 shares of Class A Common Stock, which included the redemption of Public Warrants (see below). In addition, during the nine months ended September 30, 2020, 2,131,315 warrants were exercised for cash proceeds of $24.5 million, resulting in the issuance of 2,131,315 shares of Class A Common Stock. As of September 30, 2021, the Company had 4,280,548 warrants outstanding, which have an expiration date of November 20, 2024. The Company classifies its warrants as a liability in its consolidated balance sheets because of certain terms included in the corresponding warrant agreement. The estimated fair value of the warrants is recorded as a liability, with such fair value reclassified to stockholders’ equity upon the exercise of such warrants. Prior to exercise, the change in the estimated fair value of such warrants each period is recognized as a non-cash charge or gain in the Company’s consolidated statements of operations. A reconciliation of the changes in the warrant liability during the nine months ended September 30, 2021 and 2020 was as follows (in thousands): ​ ​ ​ ​ ​ Estimated fair value of warrant liability at December 31, 2020 ​ $ 113,905 Change in estimated fair value of the warrant liability ​ ​ (57,359) Estimated fair value of warrant liability at September 30, 2021 ​ $ 56,546 ​ ​ ​ ​ Estimated fair value of warrant liability at December 31, 2019 ​ $ 27,635 Change in estimated fair value of the warrant liability ​ ​ 72,358 Reclassification of warrant liability to equity for exercised warrants ​ (49,098) Estimated fair value of warrant liability at September 30, 2020 ​ $ 50,895 ​ The decrease in the estimated fair value of the warrant liability of $57.4 million during the nine months ended September 30, 2021 was recorded as a non-cash gain in the Company’s consolidated statements of operations during such period. The increase in the estimated fair value of the warrant liability of $72.4 million during the nine months ended September 30, 2020 was recorded as a non-cash charge in the Company’s consolidated statements of operations during such period. As discussed above, the fair value of the warrants at the date of exercise is reclassed to stockholders’ equity upon the exercise of such warrants. During the nine months ended September 30, 2020, $49.1 million was reclassified to stockholders’ equity in connection with the exercise of warrants, which was recorded as an increase to additional paid-in capital. There were no warrant exercises during the nine months ended September 30, 2021. ​ Redemption of Public Warrants On August 4, 2020, the Company announced its intention to redeem all of its outstanding public warrants (the Public Warrants) to purchase shares of the Company’s Class A Common Stock, that were issued under the Warrant Agreement, dated February 15, 2018 (the Warrant Agreement), by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent (the Warrant Agent), as part of the units sold in the Company’s initial public offering (the IPO), for a redemption price of $0.01 per Public Warrant (the Redemption Price), that remained outstanding on September 2, 2020 (the Redemption Date). Warrants to purchase common stock that were issued under the Warrant Agreement in a private placement simultaneously with the IPO and still held by the initial holders thereof or their permitted transferees were not subject to this redemption. Under the terms of the Warrant Agreement, the Company was entitled to redeem all of the outstanding Public Warrants if the last sales price of the Company’s Class A Common Stock was at least $18.00 per share on each of twenty trading days within any thirty-day trading period ending on the third trading day prior to the date on which a notice of redemption is given. At the direction of the Company, the Warrant Agent delivered a notice of redemption to each of the registered holders of the outstanding Public Warrants. In addition, in accordance with the Warrant Agreement, the Company elected to require that, upon delivery of the notice of redemption, all Public Warrants were to be exercised only on a “cashless basis.” Accordingly, holders were no longer able to exercise Public Warrants and receive common stock in exchange for payment in cash of the $11.50 per warrant exercise price. Instead, a holder exercising a Public Warrant was deemed to pay the $11.50 per warrant exercise price by the surrender of 0.6144 of a share of common stock (such fraction determined as described below) that such holder would have been entitled to receive upon a cash exercise of a Public Warrant. Accordingly, by virtue of the cashless exercise of the Public Warrants, exercising warrant holders received 0.3856 of a share of common Stock for each Public Warrant surrendered for exercise. Any Public Warrants that remained unexercised on the Redemption Date were voided and no longer exercisable, and the holders will have no rights with respect to those Public Warrants, except to receive the Redemption Price. The number of shares of Class A Common Stock that each exercising warrant holder received by virtue of the cashless exercise (instead of paying the $11.50 per Public Warrant cash exercise price) was calculated in accordance with the terms of the Warrant Agreement and was equal to the quotient obtained by dividing (x) the product of the number of shares underlying the Public Warrants held by such warrant holder, multiplied by the difference between $18.7175, the average last sale price of the Company’s Class A Common Stock for the ten trading days ending on July 29, 2020, the third trading day prior to the date of the redemption notice (the Fair Market Value) and $11.50, by (y) the Fair Market Value. If any holder of Public Warrants would, after taking into account all of such holder’s Public Warrants exercised at one time, be entitled to receive a fractional interest in a share of common stock, the number of shares the holder was entitled to receive was rounded down to the nearest whole number of shares. During the three and nine months ended September 30, 2020, 2,285,410 Public Warrants were redeemed resulting in the issuance of 881,239 shares of Class A Common Stock. As a result of these transactions, there are no Public Warrants outstanding. Contingent Consideration Common Shares Pursuant to the Merger Agreement, the former owners of AdaptHealth Holdings who received Class A Common Stock and Class B Common Stock in connection with the Business Combination are entitled to receive earn-out consideration to be paid in the form of Class A Common Stock, if the average price of the Company’s Class A Common Stock for the month of December prior to each measurement date equals or exceeds certain hurdles set forth in the Merger Agreement (Contingent Consideration Common Shares). The former owners of AdaptHealth Holdings were entitled to receive 1,000,000 shares of Class A Common Stock on December 31, 2020 based on an average stock price hurdle of $15. The average stock price of the Company’s Class A Common Stock was greater than $15 per share for the applicable measurement period as of the December 31, 2020 measurement date, which triggered the issuance of 1,000,000 shares of Class A Common Stock at such date. In addition, the former owners of AdaptHealth Holdings are entitled to receive up to an additional 1,000,000 shares of Common Stock on each of December 31, 2021 and 2022 (each a measurement date) and such average stock price hurdles are $18 and $22 at each measurement date, respectively. The Contingent Consideration Common Shares would be issued immediately in the event of a change of control as defined in the Merger Agreement. The estimated fair value of the Contingent Consideration Common Shares is recorded as a liability in the Company’s consolidated balance sheets, with such fair value reclassified to stockholders’ equity upon the issuance of any shares that are earned. Prior to issuance, the change in the estimated fair value of such shares each period is recognized as a non-cash charge or gain in the Company’s consolidated statements of operations. A reconciliation of the changes in the contingent consideration common shares liability during the nine months ended September 30, 2021 and 2020 was as follows (in thousands): ​ ​ ​ ​ ​ Estimated fair value of contingent consideration common shares liability at December 31, 2020 ​ $ 70,477 Change in estimated fair value of the contingent consideration common shares liability ​ ​ (34,050) Estimated fair value of contingent consideration common shares liability at September 30, 2021 ​ $ 36,427 ​ ​ ​ ​ Estimated fair value of contingent consideration common shares liability at December 31, 2019 ​ $ 9,316 Change in estimated fair value of the contingent consideration common shares liability ​ 41,850 Estimated fair value of contingent consideration common shares liability at September 30, 2020 ​ $ 51,166 ​ A portion of the estimated fair value of the contingent consideration common shares is classified as a current liability and a long-term liability in the Company’s consolidated balance sheets based on the estimated issuance dates of such shares at the corresponding balance sheet date. The decrease in the estimated fair value of the contingent consideration common shares liability of $34.1 million during the nine months ended September 30, 2021 was recorded as a non-cash gain in the Company’s consolidated statements of operations during such period. The increase in the estimated fair value of the contingent consideration common shares liability of $41.9 million during the nine months ended September 30, 2020 was recorded as a non-cash charge in the Company’s consolidated statements of operations during such period. Equity-based Compensation In connection with the Company’s 2019 Stock Incentive Plan (the 2019 Plan), the Company provides equity-based compensation to attract and retain employees while also aligning employees’ interest with the interests of its stockholders. The 2019 Plan permits the grant of various equity-based awards to selected employees and non-employee directors. At September 30, 2021, the 2019 Plan permits the grant of up to 10,000,000 shares of Common Stock, subject to certain adjustments and limitations. At September 30, 2021, 3,418,548 shares of the Company’s Common Stock were available for issuance under the 2019 Plan. The following awards were granted in connection with the 2019 Plan during the nine months ended September 30, 2021. Stock Options In January 2021, the Company granted 703,170 options to purchase shares of the Company’s Class A Common Stock to certain senior executives of the Company. The options vest ratably over a three-year period from the date of grant based on only a service condition and have a contractual exercise period of five years from the date of grant. The total grant-date fair value of the options granted, using a Black-Scholes option pricing model, was $6.9 million. During the nine months ended September 30, 2021, 234,390 of the options from this grant were forfeited as a result of the resignation of the Company’s former Co-CEO (see discussion below). In addition, in connection with the resignation, the Company accelerated the vesting of 184,932 options that were granted to the Company’s former Co-CEO in November 2019, and the remaining 648,401 unvested options from the November 2019 grant were forfeited. In connection with the accelerated vesting of the 184,932 options, the Company recorded $1.9 million of equity-based compensation expense, which is included in general and administrative expenses during the nine months ended September 30, 2021 in the accompanying consolidated statements of operations. As previously announced, on April 13, 2021, the Company placed its then Co-Chief Executive Officer, Luke McGee, on unpaid leave while a matter relating to his past private activity was pending. On June 14, 2021, the Company and Mr. McGee agreed that Mr. McGee would resign from his positions as Co-CEO of the Company and a Director of the Company effective as of June 11, 2021. In connection with Mr. McGee’s resignation, the Company accelerated the vesting of certain unvested stock options as discussed above, and also accelerated the vesting of certain unvested shares of restricted stock as discussed below. Other than the accelerated vesting of the stock options and shares of restricted stock, and back pay paid to Mr. McGee relating to his unpaid base wages from April 13, 2021 to June 11, 2021, no other compensation was paid to Mr. McGee in connection with his resignation. The weighted-average assumptions used to determine the grant-date fair value of the stock options granted during the nine months ended September 30, 2021 were as follows: ​ ​ ​ ​ ​ Expected volatility 44.5 % Risk-free interest rate 0.18 % Expected term 4.0 years Dividend yield ​ N/A ​ ​ The following table provides the activity regarding the Company’s outstanding stock options during the nine months ended September 30, 2021 that were granted in connection with the 2019 Plan (in thousands, except per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Grant Date ​ ​ Weighted-Average ​ Weighted-Average ​ ​ Number of ​ ​ Fair Value ​ ​ Exercise Price ​ Remaining ​ ​ Options ​ ​ per Share ​ ​ per Share ​ Contractual Term Outstanding, December 31, 2020 ​ 3,464 ​ $ 2.18 ​ $ 11.56 ​ ​ Granted ​ 703 ​ $ 9.81 ​ $ 48.72 ​ ​ Exercised ​ (1,034) ​ $ 2.19 ​ $ 11.57 ​ ​ Forfeited ​ (914) ​ $ 2.27 ​ $ 11.66 ​ ​ Outstanding, September 30, 2021 ​ 2,219 $ 3.75 $ 19.36 7.3 Years ​ The following table provides the activity for all outstanding stock options during the nine months ended September 30, 2021 (in thousands, except per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ Weighted-Average ​ ​ Number of ​ ​ Exercise Price ​ ​ Remaining ​ ​ Options ​ ​ per Share ​ ​ Contractual Term Outstanding, December 31, 2020 ​ 3,464 ​ $ 11.56 ​ ​ ​ Granted under the 2019 Plan ​ 703 ​ $ 48.72 ​ ​ ​ Issued in connection with the AeroCare acquisition ​ 3,960 ​ $ 6.24 ​ ​ ​ Exercised ​ (1,114) ​ $ 11.13 ​ ​ ​ Forfeited ​ (914) ​ $ 11.66 ​ ​ ​ Outstanding, September 30, 2021 ​ 6,099 $ 11.03 ​ 6.7 Years ​ During the three and nine months ended September 30, 2021, 897,984 and 1,097,984 stock options were exercised resulting in $9.8 million and $12.1 million of cash proceeds received by the Company, respectively, during such periods. There were no stock option exercises during the nine months ended September 30, 2020. Restricted Stock During the nine months ended September 30, 2021, the Company granted 969,152 shares of restricted stock to various employees which vest ratably over the three or four-year periods following the grant dates, subject to the employees’ continuous employment through the applicable vesting date. The grant-date fair value of these awards was $30.0 million. During the nine months ended September 30, 2021, the Company granted 45,938 shares of restricted stock, primarily to non-employee directors, which vest over one year following the grant dates. The grant-date fair value of these awards was $1.1 million. During the nine months ended September 30, 2021, in connection with the resignation of the Company’s former Co-CEO, the Company accelerated the vesting of 22,192 shares of restricted stock that were granted in November 2019, and the remaining 77,808 unvested shares from the November 2019 grant were forfeited. In connection with the accelerated vesting of the 22,192 shares, the Company recorded $0.5 million of equity-based compensation expense, which is included in general and administrative expenses during the nine months ended September 30, 2021 in the accompanying consolidated statements of operations. Activity related to the Company’s non-vested restricted stock grants for the nine months ended September 30, 2021 is presented below (in thousands, except per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of Shares of ​ ​ Weighted-Average Grant Date ​ ​ Restricted Stock ​ Fair Value per Share Non-vested balance, December 31, 2020 ​ 2,248 $ 15.60 Granted ​ 1,015 ​ $ 30.62 Vested ​ (335) ​ $ 17.39 Forfeited ​ (616) ​ $ 16.77 Non-vested balance, September 30, 2021 ​ 2,312 ​ $ 21.32 ​ Incentive Units AdaptHealth Holdings granted Incentive Units in June 2019 (the 2019 Incentive Units) and in April 2018 (the 2018 Incentive Units) to certain members of management. The Incentive Units were intended to constitute profits interests and were granted for purposes of enabling such individuals to participate in the long-term growth and financial success of the Company and were issued in exchange for services to be performed. With respect to the 2019 Incentive Units, 50% of the awards were scheduled to vest in equal annual installments on each of the first four one-year Other Activity During the nine months ended September 30, 2021, the Company granted 63,249 fully vested shares of Class A Common Stock to various employees of the Company, primarily newly hired employees. These shares had a grant-date fair value of $2.3 million, which was recognized as equity-based compensation expense during the nine months ended September 30, 2021, which is included in cost of net revenue in the accompanying consolidated statements of operations during such period. Equity-Based Compensation Expense The Company recorded equity-based compensation expense of $5.4 million during the three months ended September 30, 2021, of which $3.4 million and $2.0 million is included in general and administrative expenses and cost of net revenue, respectively, in the accompanying consolidated statements of operations. The Company recorded equity-based compensation expense of $5.5 million during the three months ended September 30, 2020, of which $3.7 million and $1.8 million is included in general and administrative expenses and cost of net revenue, respectively, in the accompanying consolidated statements of operations. The Company recorded equity-based compensation expense of $21.4 million during the nine months ended September 30, 2021, of which $14.5 million and $6.9 million is included in general and administrative expenses and cost of net revenue, respectively, in the accompanying consolidated statements of operations. The Company recorded equity-based compensation expense of $11.0 million during the nine months ended September 30, 2020, of which $7.0 million and $4.0 million is included in general and administrative expenses and cost of net revenue, respectively, in the accompanying consolidated statements of operations. At September 30, 2021, there was $38.3 million of unrecognized compensation expense related to equity-based compensation awards, which is expected to be recognized over a weighted-average period of 2.7 years.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	9 Months Ended
	Sep. 30, 2021
Earnings per share
Earnings (Loss) Per Share	(11) Earnings Per Share Earnings Per Share (EPS) is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period on a basic and diluted basis. The Company calculates diluted earnings per share using the more dilutive of the treasury stock method and the two-class method after giving effect to all potential dilutive common stock. The Company’s potentially dilutive securities include potential common shares related to outstanding warrants, contingent consideration common shares, unvested restricted stock, outstanding stock options and outstanding preferred stock. Refer to Note 10, Stockholders’ Equity Diluted EPS considers the impact of potentially dilutive securities except when the potential common shares have an antidilutive effect. The Company’s outstanding preferred stock are considered participating securities, thus requiring the two-class method of computing EPS. Calculation of EPS under the two-class method excludes from the numerator any dividends paid or owed on participating securities and any undistributed earnings considered to be attributable to participating securities. The related participating securities are similarly excluded from the denominator. Computations of basic and diluted net income (loss) per share were as follows (in thousands, except per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2021 ​ 2020 2021 ​ 2020 Numerator ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net income (loss) attributable to AdaptHealth Corp. ​ $ 58,092 ​ $ (51,035) ​ $ 133,233 ​ $ (81,116) Less: Earnings allocated to participating securities (1) ​ ​ 5,002 ​ ​ — ​ ​ 12,572 ​ ​ — Net income (loss) for basic EPS ​ $ 53,090 ​ $ (51,035) ​ $ 120,661 ​ $ (81,116) Change in fair value of warrant liability (2) ​ ​ (16,737) ​ ​ — ​ ​ (57,359) ​ ​ — Change in fair value of contingent consideration common shares liability (2) ​ ​ (8,145) ​ ​ — ​ ​ (27,718) ​ ​ — Net income (loss) for diluted EPS ​ $ 28,208 ​ $ (51,035) ​ $ 35,584 ​ $ (81,116) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Denominator (1) (2) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic weighted-average common shares outstanding ​ ​ 131,684 ​ ​ 57,372 ​ ​ 124,228 ​ ​ 47,986 Add: Warrants (2) ​ ​ 2,245 ​ ​ — ​ ​ 2,598 ​ ​ — Add: Contingent Consideration Common Shares (2) ​ ​ 2,000 ​ ​ — ​ ​ 2,000 ​ ​ — Add: Stock options ​ ​ 3,794 ​ ​ — ​ ​ 4,112 ​ ​ — Add: Unvested restricted stock ​ ​ 599 ​ ​ — ​ ​ 700 ​ ​ — Diluted weighted-average common shares outstanding ​ ​ 140,322 ​ ​ 57,372 ​ ​ 133,638 ​ ​ 47,986 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic net income (loss) per share ​ $ 0.40 ​ $ (0.89) ​ $ 0.97 ​ $ (1.69) Diluted net income (loss) per share ​ $ 0.20 ​ $ (0.89) ​ $ 0.27 ​ $ (1.69) ​ (1) The Company’s preferred stock are considered participating securities. Calculation of EPS under the two-class method excludes from the numerator any dividends paid or owed on participating securities and any undistributed earnings considered to be attributable to participating securities. The related participating securities are similarly excluded from the denominator. There were participating securities outstanding for all periods presented. There was no amount allocated to the participating securities during the three and nine months ended September 30, 2020 due to the net loss reported in those periods. (2) For the three and nine months ended September 30, 2021, in accordance with the requirements of ASC Topic 260, Earnings per Share , the impact to earnings from the change in fair value of the Company’s contingent consideration common shares liability and the Company’s warrant liability are reversed from the numerator, and the corresponding securities are included in the denominator, for purposes of calculating diluted net income per share as the effect of the numerator and denominator adjustments for these derivative instruments is dilutive as a result of the gains recorded for the changes in fair value of these instruments during those periods. For the three and nine months ended September 30, 2020, the numerator and denominator for the diluted net loss per share calculation is the same as used in the basic net loss per share calculation and therefore exclude the effect of potential dilutive securities as their inclusion would have been anti-dilutive. Due to the Company reporting a net loss attributable to common stockholders for the three and nine months ended September 30, 2020, all potentially dilutive securities related to outstanding warrants, contingent consideration common shares, unvested restricted stock, and outstanding stock options were excluded from the computation of diluted net loss per share as their inclusion would have been anti-dilutive. The table below provides the weighted-average number of potential common shares associated with outstanding securities not included in the Company’s calculation of diluted net income (loss) per share for the three and nine months ended September 30, 2021 and 2020 because to do so would be antidilutive (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ ​ Nine Months Ended September 30, ​ ​ 2021 ​ 2020 2021 ​ 2020 Preferred Stock ​ ​ 12,406 ​ ​ 18,356 ​ ​ 12,944 ​ ​ 6,567 Warrants ​ ​ — ​ ​ 1,936 ​ ​ — ​ ​ 1,438 Stock Options ​ ​ — ​ ​ 1,566 ​ ​ — ​ ​ 1,163 Unvested restricted stock ​ ​ — ​ ​ 383 ​ ​ — ​ ​ 724 Contingent Consideration Common Shares ​ ​ — ​ ​ 700 ​ ​ — ​ ​ 700 Total ​ ​ 12,406 ​ ​ 22,941 ​ ​ 12,944 ​ ​ 10,592 ​

Leases

Leases	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Leases	(12) Leases The Company leases its office facilities and office equipment under noncancelable lease agreements which expire at various dates through March 2033. Some of these lease agreements include an option to renew at the end of the term. The Company also leases certain patient medical equipment with such leases set to expire at various dates through May 2022. The Company also leases certain office facilities on a month-to-month basis. In some instances, the Company is also required to pay its pro rata share of real estate taxes and utility costs in connection with the premises. Some of the leases contain fixed annual increases of minimum rent. ​ The Company’s leases frequently allow for lease payments that could vary based on factors such as inflation and the incurrence of contractual charges such as those for common area maintenance or utilities. ​ Renewal and/or early termination options are common in the lease arrangements, particularly with respect to real estate leases. The Company’s right-of-use assets and lease liabilities generally include periods covered by renewal options and exclude periods covered by early termination options (based on the conclusion that it is reasonably certain that the Company will exercise such renewal options and not exercise such early termination options). ​ The Company is also party to certain sublease arrangements related to real estate leases, where the Company acts as the lessee and intermediate lessor. ​ The Company has acquired patient medical equipment and supplies, and office equipment through multiple finance leases. The finance lease obligations represent the present value of minimum lease payments under the respective agreement, payable monthly at various interest rates. ​ The following table presents information about the Company’s right-of-use assets and lease liabilities as of September 30, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Consolidated Balance Sheets Line Item ​ September 30, 2021 Right-of-use (ROU) assets: ​ ​ ​ ​ ​ Operating lease ROU assets ​ Operating lease right-of-use assets ​ $ 148,891 Finance lease ROU assets ​ Equipment and other fixed assets, net ​ 25,803 Total ROU assets ​ ​ ​ $ 174,694 Operating lease liabilities: ​ ​ ​ ​ ​ Current operating lease liabilities ​ Current portion of operating lease obligations ​ $ 31,015 Noncurrent operating lease liabilities ​ Operating lease obligations, less current portion ​ 121,411 Total operating lease liabilities ​ ​ ​ $ 152,426 Finance lease liabilities: ​ ​ ​ ​ ​ Current finance lease liabilities ​ Current portion of finance lease obligations ​ $ 21,672 Noncurrent finance lease liabilities ​ Other long-term liabilities ​ 203 Total finance lease liabilities ​ ​ ​ $ 21,875 ​ The following table presents information about lease costs and expenses and sublease income for the three and nine months ended September 30, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Consolidated Statements of ​ Three Months Ended ​ Nine Months Ended ​ ​ Operations Line Item ​ September 30, 2021 ​ September 30, 2021 Operating lease costs ​ Cost of net revenue ​ $ 9,837 ​ $ 27,695 Finance lease costs: ​ ​ ​ ​ ​ ​ ​ ​ Amortization of ROU assets ​ Cost of net revenue ​ $ 8,487 ​ $ 27,549 Other lease costs and income: ​ ​ ​ ​ ​ ​ ​ ​ Short-term lease costs ​ Cost of net revenue ​ $ 4,093 ​ $ 19,905 Variable leases costs (1) ​ Cost of net revenue ​ $ 3,784 ​ $ 10,061 Sublease income ​ Cost of net revenue ​ $ 405 ​ $ 911 ​ (1) Amounts represent variable costs incurred that were not included in the initial measurement of the lease liability such as common area maintenance and utilities costs associated with leased real estate. ​ The following table provides the undiscounted amount of future cash flows included in the Company’s lease liabilities as of September 30, 2021, for each of the five years subsequent to September 30, 2021, and thereafter, as well as a reconciliation of such undiscounted cash flows to the Company’s lease liabilities as of September 30, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Leases ​ Finance Leases 2021 (excluding the nine months ended September 30, 2021) ​ $ 9,540 ​ $ 10,788 2022 ​ 34,352 ​ 11,034 2023 ​ 29,396 ​ 149 2024 ​ 24,451 ​ — 2025 ​ 20,435 ​ — Thereafter ​ 56,793 ​ — Total future leases payments ​ $ 174,967 ​ $ 21,971 Less: amount representing interest ​ (22,541) ​ (96) Present value of future lease payments (lease liability) ​ $ 152,426 ​ $ 21,875 ​ The Company’s future minimum lease commitments for operating leases as of December 31, 2020, as determined in accordance with ASC 840, were as follows (in thousands): ​ ​ ​ ​ ​ Twelve months ending December 31, ​ ​ 2021 ​ $ 18,403 2022 ​ 14,893 2023 ​ 11,788 2024 ​ 9,055 2025 ​ 5,960 Thereafter ​ 15,646 Total minimum payments required (a) ​ $ 75,745 ​ (a) Minimum payments have not been reduced by minimum sublease rentals of $1.9 million due in the future under noncancelable subleases ​ The following table provides the weighted average remaining lease terms and weighted average discount rates for the Company’s leases as of September 31, 2021: ​ ​ ​ ​ ​ Weighted average remaining lease term, weighted based on lease liability balances: ​ ​ ​ Operating leases ​ ​ 6.8 years Finance leases ​ ​ 0.6 years Weighted average discount rate, weighted based on remaining balance of lease payments: ​ ​ ​ Operating leases ​ ​ 3.7% ​ The following table provides certain cash flows and supplemental noncash information related to our lease liabilities for the nine months ended September 30, 2021 (in thousands): ​ ​ ​ ​ ​ Cash paid for amounts included in the measurement of lease liabilities: ​ ​ ​ Operating cash payments for operating leases ​ $ 27,154 Financing cash payments for finance leases ​ $ 31,043 Lease liabilities arising from obtaining right-of-use assets: ​ ​ ​ Operating leases ​ $ 84,212 Finance leases ​ $ 22,902 ​

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Taxes
Income Taxes	(13) Income Taxes On January 2, 2021, the Company completed a corporate restructuring to simplify its tax structure (the Tax Restructuring). In connection with the Tax Restructuring, on January 1, 2021, all remaining outstanding shares of Class B Common Stock, together with a corresponding number of New AdaptHealth Units, were exchanged for shares of Class A Common Stock. After these exchanges, AdaptHealth Holdings filed an entity classification election with the Internal Revenue Service, electing to be treated as a taxable corporation for U.S. federal income tax purposes effective January 2, 2021. As a result of the Business Combination and prior to the Tax Restructuring, the Company was subject to U.S. federal, state, and local income taxes with respect to its allocable share of any taxable income or loss of AdaptHealth Holdings. AdaptHealth Holdings was treated as a partnership for U.S. income tax purposes and generally did not pay income taxes in most jurisdictions. Instead, AdaptHealth Holdings’ taxable income or loss was passed through to its members, including the Company. Additionally, the Company was subject to U.S. federal, state, and local income taxes on the taxable income or loss of the underlying C-corporations in the AdaptHealth group where taxes are paid at the entity level. As a result of the Tax Restructuring, the Company is subject to U.S. federal, state, and local income taxes on materially all of its earnings. For the three months ended September 30, 2021 and 2020, the Company recorded income tax expense of $12.1 million and income tax benefit of $4.9 million, respectively. For the nine months ended September 30, 2021 and 2020, the Company recorded income tax expense of $22.8 million and income tax benefit of $4.7 million, respectively. As of September 30, 2021 and December 31, 2020, the Company had an unrecognized tax benefit of $1.9 million. Tax Receivable Agreement ​ AdaptHealth Corp. is party to a Tax Receivable Agreement (TRA) with certain current and former members of AdaptHealth Holdings. The TRA provides for the payment by AdaptHealth Corp. of 85% of the tax savings, if any, that AdaptHealth Corp. realizes (or is deemed to realize in certain circumstances) as a result of (i) certain increases in tax basis resulting from exchanges of New AdaptHealth Units and shares of Class B Common Stock; (ii) certain tax attributes of the corresponding sellers existing prior to an exchange; (iii) imputed interest deemed to be paid by AdapthHealth Corp. as a result of payments it makes under the TRA; and (iv) certain increases in tax basis resulting from payments AdaptHealth Corp. makes under the TRA. ​ During the nine months ended September 30, 2021, the Company increased its TRA liability through an aggregate $146.5 million reduction in additional paid-in capital resulting from additional exchanges of New AdaptHealth Units and shares of Class B Common Stock. Correspondingly, during the nine months ended September 30, 2021, the Company increased its deferred tax asset by $163.3 million through an increase in additional paid-in-capital resulting from these exchanges and other increases of AdaptHealth Corp.’s ownership interest in AdaptHealth Holdings. ​ At September 30, 2021 and December 31, 2020, the Company had a liability recorded relating to the TRA of $300.1 million and $152.0 million, respectively, which is included in other long-term liabilities in the accompanying consolidated balance sheets.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies.
Commitments and Contingencies	(14) Commitments and Contingencies In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business that cover a wide range of matters. In accordance with FASB ASC Topic 450, Accounting for Contingencies ​ In connection with the Company’s acquisition of PPS HME Holdings LLC (PPS), in May 2018, the Company assumed a Corporate Integrity Agreement (CIA) at one of PPS’ subsidiaries, Braden Partners L.P. d/b/a Pacific Pulmonary Services (BP). The CIA was entered into with the Office of Inspector General of the U.S. Department of Health and Human Services (OIG). The CIA has a five-year term which expires in April 2022. In connection with the acquisition and integration of PPS by AdaptHealth, the OIG confirmed that the requirements of the CIA imposed upon BP would only apply to the operations of BP and therefore no operations of any other AdaptHealth affiliate are subject to the requirements of the CIA following the acquisition. On January 17, 2021, the OIG notified PPS that its report for the period ended March 31, 2020 had been accepted and PPS had satisfied its obligations under the CIA as of such date. The Company submitted its report for the period ended March 31, 2021 on a timely basis. ​ On June 28, 2019, Solara, which was acquired by AdaptHealth in July 2020, determined that an unauthorized third-party gained access to a limited number of employee Microsoft Office accounts beginning in April 2019, as a result of a phishing email campaign. Solara undertook a comprehensive review of the accounts to identify what personal information was stored within the accounts and to whom that information related. In connection with the incident, Solara notified potentially affected individuals and reported this incident to law enforcement and relevant state and federal regulators. Solara was a defendant in a class action regarding the incident in federal court. In October 2021, the parties tentatively agreed to a settlement for a payment of $5.1 million, which will be covered in full by insurance and an escrow established at the time of the Solara acquisition. As of September 30, 2021, the Company recorded a liability of $5.1 million and a corresponding indemnification asset, which are included in other current liabilities and other current assets, respectively, in the accompanying consolidated balance sheets. ​ The Company and certain of its current and former officers were named as defendants in a lawsuit, as described below. The Company cannot reasonably predict the outcome of this legal proceeding, nor can it estimate the amount of loss or range of loss, if any, that may result. An adverse outcome in this proceeding could have a material adverse effect on the Company’s results of operations, cash flows or financial condition. The results of legal proceedings are inherently uncertain, and material adverse outcomes are possible. ​ On July 29, 2021, Robert Charles Faille Jr., a purported shareholder of the Company, filed a purported class action complaint against the Company and certain of its current and former officers in the United States District Court for the Eastern District of Pennsylvania (the Complaint). The Complaint purports to be asserted on behalf of a class of persons who purchased the Company’s stock between November 11, 2019 and July 16, 2021. The Complaint generally alleges that the Company and certain of its current and former officers violated federal securities laws by making allegedly false and misleading statements and/or failing to disclose material information regarding the Company’s organic growth trajectory. The Complaint seeks unspecified damages. On October 14, 2021, the Delaware County Employees Retirement System and the Bucks County Employees Retirement System were named Lead Plaintiffs. Pursuant to the stipulated initial scheduling order, Lead Plaintiffs must file a consolidated complaint by no later than December 15, 2021. The Company intends to vigorously defend against the allegations contained in the Complaint, but there can be no assurance that the defense will be successful. ​

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2021
Related Party Transactions
Related Party Transactions	(15) Related Party Transaction The Company and one of its executive officers and shareholders own an equity interest in a vendor of the Company that provides automated order intake software. The individual’s equity ownership is less than 1%. The expense related to this vendor was $1.2 million and $0.6 million for the three months ended September 30, 2021 and 2020, respectively. The expense related to this vendor was $3.4 million and $1.7 million for the nine months ended September 30, 2021 and 2020, respectively. The Company accounts for this investment under the cost method of accounting based on its level of equity ownership. ​

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2021
Subsequent Events
Subsequent Events	(16) Subsequent Events Subsequent to September 30, 2021, the Company acquired certain home medical equipment and diabetes businesses. The total consideration included cash payments of $67.6 million at closing. Due to the timing of these acquisitions, as of the date the consolidated interim financial statements were available to be issued, the Company was in the process of determining the allocation of the fair value of the consideration paid to the fair value of the net assets acquired and a preliminary allocation has not yet been determined. ​

General Information (Policies)

General Information (Policies)	9 Months Ended
	Sep. 30, 2021
Summary of Significant Accounting Policies
Basis of Presentation	The consolidated interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). In the opinion of management, the consolidated interim financial statements include all necessary adjustments for a fair presentation of the financial position and results of operations for the periods presented. The Business Combination was accounted for as a reverse recapitalization, with DFB treated as the acquired company and AdaptHealth Holdings as the acquirer, for financial reporting purposes. Therefore, the equity structure was restated to that of the Company. Prior to the quarter ended September 30, 2021, the Company was an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the Securities Act), as modified by the Jumpstart our Business Startups Act of 2012, (the JOBS Act), and took advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and other exemptions. As of September 30, 2021, the Company no longer qualifies as an emerging growth company due to issuing more than $1.0 billion in non-convertible debt in the prior three-year period, and as a result will no longer be exempt from the reporting requirements discussed above.
Basis of Consolidation	(b) Basis of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Concentration of Credit Risk	(c) Concentration of Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and trade accounts receivable. The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents.
Accounting Estimates	(d) Accounting Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition and the valuation of accounts receivable (implicit price concession), income taxes, contingent consideration, equity-based compensation, interest rate swaps, warrant liability and long-lived assets, including goodwill and identifiable intangible assets. Actual results could differ from those estimates.
Valuation of Goodwill	(e) Valuation of Goodwill The Company has a significant amount of goodwill on its balance sheet that resulted from the business acquisitions the Company has made in recent years. Goodwill is not amortized and is tested for impairment annually and upon the occurrence of a triggering event or change in circumstances indicating a possible impairment. Such changes in circumstance can include, among others, changes in the legal environment, reimbursement environment, operating performance, and/or future prospects. The Company performs its annual impairment review of goodwill during the fourth quarter of each year. The impairment testing can be performed on either a quantitative or qualitative basis. The Company first assesses qualitative factors to determine whether it is necessary to perform quantitative goodwill impairment testing. If determined necessary, the Company applies the quantitative impairment test to identify and measure the amount of impairment, if any.
Impairment of Long Lived Assets	(f) Impairment of Long-Lived Assets The Company’s long-lived assets, such as equipment and other fixed assets and definite-lived identifiable intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Definite-lived identifiable intangible assets consist of tradenames, payor contracts, contractual rental agreements and developed technology. These assets are amortized using the straight-line method over their estimated useful lives, which reflects the pattern in which the economic benefits of the assets are expected to be consumed. These assets are tested for impairment consistent with the Company’s long-lived assets. The following table summarizes the useful lives of the identifiable intangible assets acquired: ​ ​ ​ ​ ​ Tradenames 5 10 ​ years Payor contracts 10 ​ years Contractual rental agreements 2 ​ years Developed technology 5 ​ years ​ The Company did not incur any impairment charges on long-lived assets for the three and nine months ended September 30, 2021 and 2020. In addition to consideration of impairment upon the events or changes in circumstances described above, management regularly evaluates the remaining useful lives of its long-lived assets.
Business segment	The Company’s chief operating decision-makers are its Chief Executive Officer and President, who make resource allocation decisions and assess performance based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating decision-makers, or anyone else, for any planning, strategy and key decision-making regarding operations. The corporate office is responsible for contract negotiation with vendors and payors, corporate compliance with healthcare laws and regulations, and revenue cycle management, among other corporate supporting functions. Accordingly, the Company has a single reportable segment and operating segment structure.
Accounting for Leases	During the quarter ended September 30, 2021, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842) expedients Whenever the Company enters into a new arrangement, it must determine, at the inception date, whether the arrangement is or contains a lease. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and obtain substantially all the economic benefits from the use of the underlying asset. If a lease exists, the Company must then determine the separate lease and nonlease components of the arrangement. Each right to use an underlying asset conveyed by a lease arrangement should generally be considered a separate lease component if it both: (i) can benefit the Company without depending on other resources not readily available to the Company and (ii) does not significantly affect and is not significantly affected by other rights of use conveyed by the lease. Aspects of a lease arrangement that transfer other goods or services to the Company but do not meet the definition of lease components are considered nonlease components. The consideration owed by the Company pursuant to a lease arrangement is generally allocated to each lease and nonlease component for accounting purposes. However, the Company has elected, for all of its leases, to not separate lease and nonlease components. Each lease component is accounted for separately from other lease components, but together with the associated nonlease components. For each lease, the Company must then determine the lease term, the present value of lease payments and the classification of the lease as either an operating or finance lease. The lease term is the period of the lease not cancellable by the Company, together with periods covered by: (i) renewal options the Company is reasonably certain to exercise, (ii) termination options the Company is reasonably certain not to exercise, and (iii) renewal or termination options that are controlled by the lessor. The present value of lease payments is calculated based on: ● Lease payments – lease payments include fixed and certain variable payments, less lease incentives, together with amounts probable of being owed by the Company under residual value guarantees and, if reasonably certain of being paid, the cost of certain renewal options and early termination penalties set forth in the lease arrangement. Lease payments exclude consideration that is not related to the transfer of goods and services of the Company. ● Discount rate – the discount rate must be determined based on information available to the Company upon the commencement of the lease. Lessees are required to use the rate implicit in the lease whenever such rate is readily available; however, as the implicit rate in the Company’s leases is generally not readily determinable, the Company generally uses the hypothetical incremental borrowing rate it would have to pay to borrow an amount equal to the lease payments, on a collateralized basis, over a timeframe similar to the lease term. In making the determination of whether a lease is an operating lease or a finance lease, the Company considers the lease term in relation to the economic life of the leased asset, the present value of lease payments in relation to the fair value of the leased asset and certain other factors, including the lessee’s and lessor’s rights, obligations, and economic incentives over the term of the lease. Generally, upon the commencement of a lease, the Company will record a lease liability and a ROU asset. However, the Company has elected, for all underlying assets with initial terms of twelve months or less (known as short-term leases), to not recognize a lease liability or ROU asset. Lease liabilities are initially recorded at lease commencement as the present value of future lease payments. ROU assets are initially recorded at lease commencement as the initial amount of the lease liability, together with the following, if applicable: (i) initial direct costs incurred by the lessee and (ii) lease payments made by the lessor net of lease incentives received, prior to lease commencement. Over the lease term, the Company generally increases its lease liabilities using the effective interest method and decreases its lease liabilities for lease payments made. For finance leases, amortization and interest expense are recognized separately in the consolidated statements of operations, with amortization expense generally recorded on a straight-line basis over the lease term and interest expense recorded using the effective interest method. For operating leases, a single lease cost is generally recognized in the consolidated statements of operations on a straight-line basis over the lease term unless an impairment has been recorded with respect to a leased asset. Lease costs for short-term leases not recognized in the consolidated balance sheets are recognized in the consolidated statements of operations on a straight-line basis over the lease term. Variable lease costs not initially included in the lease liability and ROU asset impairment charges are expensed as incurred. ROU assets are assessed for impairment, similar to other long-lived assets. Prior to the adoption of ASC 842, the Company accounted for leases under FASB ASC Topic 840, Leases
Recent Accounting Pronouncements	(i) Recently Issued Accounting Pronouncements In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848) ​ (j) Recently Adopted Accounting Pronouncements In February 2016, the FASB issued ASC 842, which requires lessees to recognize leases on its balance sheet and disclose key information about leasing arrangements. Refer to the discussion above regarding the Company’s adoption of ASC 842 during the quarter ended September 30, 2021, which had an effective adoption date of January 1, 2021. In connection with such adoption, the Company recognized a cumulative-effect adjustment as of the January 1, 2021 adoption date by recording $91.5 million of operating lease obligations on its consolidated balance sheet, with a corresponding ROU asset , based on the present value of the remaining minimum rental payments for existing operating leases as of such date. The adoption did not have an impact on the Company’s accounting for existing finance leases. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments
Reclassifications	(k) Reclassifications ​ Certain prior year amounts have been reclassified to conform to the current year presentation.

General Information (Tables)

General Information (Tables)	9 Months Ended
	Sep. 30, 2021
General Information
Schedule of useful lives of acquired intangible assets	​ ​ ​ ​ ​ Tradenames 5 10 ​ years Payor contracts 10 ​ years Contractual rental agreements 2 ​ years Developed technology 5 ​ years

Revenue Recognition and Accou_2

Revenue Recognition and Accounts Receivable (Tables)	9 Months Ended
	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Schedule of composition of net revenues by payor type and core service lines	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2021 ​ 2020 2021 ​ 2020 Insurance ​ $ 399,748 ​ $ 175,418 ​ $ 1,061,627 ​ $ 438,034 Government ​ ​ 180,511 ​ ​ 81,967 ​ ​ 491,564 ​ ​ 193,725 Patient pay ​ 73,034 ​ 27,020 ​ 199,238 ​ 76,201 Net revenue ​ $ 653,293 ​ $ 284,405 ​ $ 1,752,429 ​ $ 707,960 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2021 ​ 2020 2021 ​ 2020 Net sales revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Sleep ​ $ 173,359 ​ $ 74,655 ​ $ 465,372 ​ $ 227,970 Diabetes ​ ​ 134,228 ​ ​ 52,887 ​ ​ 352,559 ​ ​ 64,566 Supplies to the home ​ ​ 42,441 ​ ​ 44,579 ​ ​ 126,479 ​ ​ 100,479 Respiratory ​ 6,228 ​ 5,152 ​ 25,003 ​ 26,034 HME ​ ​ 30,989 ​ ​ 14,998 ​ ​ 85,505 ​ ​ 39,304 Other ​ ​ 44,926 ​ ​ 14,869 ​ ​ 95,115 ​ ​ 38,725 Total net sales revenue ​ $ 432,171 ​ $ 207,140 ​ $ 1,150,033 ​ $ 497,078 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net revenue from fixed monthly equipment reimbursements: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Sleep ​ $ 62,755 ​ $ 24,971 ​ $ 177,199 ​ $ 70,284 Diabetes ​ ​ 3,722 ​ ​ 946 ​ ​ 9,791 ​ ​ 946 Respiratory ​ 117,918 ​ 32,269 ​ 312,900 ​ 88,132 HME ​ ​ 26,043 ​ ​ 14,256 ​ ​ 70,854 ​ ​ 39,695 Other ​ ​ 10,684 ​ ​ 4,823 ​ ​ 31,652 ​ ​ 11,825 Total net revenue from fixed monthly equipment reimbursements ​ $ 221,122 ​ $ 77,265 ​ $ 602,396 ​ $ 210,882 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total net revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Sleep ​ $ 236,114 ​ $ 99,626 ​ $ 642,571 ​ $ 298,254 Diabetes ​ ​ 137,950 ​ ​ 53,833 ​ ​ 362,350 ​ ​ 65,512 Supplies to the home ​ ​ 42,441 ​ ​ 44,579 ​ ​ 126,479 ​ ​ 100,479 Respiratory ​ 124,146 ​ 37,421 ​ 337,903 ​ 114,166 HME ​ ​ 57,032 ​ ​ 29,254 ​ ​ 156,359 ​ ​ 78,999 Other ​ ​ 55,610 ​ ​ 19,692 ​ ​ 126,767 ​ ​ 50,550 Total net revenue ​ $ 653,293 ​ $ 284,405 ​ $ 1,752,429 ​ $ 707,960

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2021
Business Acquisition
Schedule of proforma net revenue and operating income	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2021 2020 2021 2020 Net revenue ​ $ 657,611 ​ $ 600,794 ​ $ 1,953,706 ​ $ 1,770,675 Operating income ​ $ 77,046 ​ $ 58,973 ​ $ 181,039 ​ $ 167,279
Summary of results of business acquired	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2021 2020 2021 2020 Net revenue ​ $ 289,604 ​ $ 115,077 ​ $ 680,460 ​ $ 208,803 Operating income (loss) ​ $ 37,454 ​ $ 4,637 ​ $ 95,143 ​ $ (2,984)
Significant Acquisitions In 2021 [Member]
Business Acquisition
Summary of consideration	​ ​ ​ ​ ​ Cash consideration ​ $ 1,453,302 Equity consideration ​ 1,261,200 Contingent consideration ​ ​ 2,000 Deferred payments ​ 1,162 Total ​ $ 2,717,664
Summary of estimated fair values of the net assets acquired	​ ​ ​ ​ ​ Cash ​ $ 34,699 Accounts receivable ​ 119,168 Inventory ​ 45,684 Prepaid and other current assets ​ 6,394 Equipment and other fixed assets ​ 215,350 Operating lease right-of-use assets ​ ​ 72,872 Goodwill ​ 2,386,151 Identifiable intangible assets ​ ​ 128,400 Other assets ​ ​ 1,194 Deferred tax liabilities ​ ​ (67,849) Accounts payable and accrued expenses ​ (107,410) Contract liabilities ​ ​ (14,619) Other current liabilities ​ ​ (11,576) Other long-term liabilities ​ ​ (1,055) Operating lease obligations ​ ​ (72,872) Finance lease obligations ​ (6,867) Net assets acquired ​ $ 2,727,664
Significant Acquisitions In 2020 [Member]
Business Acquisition
Summary of consideration	​ ​ ​ ​ ​ Cash consideration ​ $ 623,107 Equity consideration ​ 89,529 Contingent consideration ​ 6,464 Deferred payments ​ ​ 33 Total ​ $ 719,133
Summary of estimated fair values of the net assets acquired	​ ​ ​ ​ ​ Cash ​ $ 17,798 Accounts receivable ​ 49,464 Inventory ​ 23,073 Prepaid and other current assets ​ 4,254 Equipment and other fixed assets ​ 42,852 Goodwill ​ 543,689 Intangible assets ​ ​ 97,400 Accounts payable and accrued expenses ​ (47,759) Contract liabilities ​ ​ (3,675) Other liabilities ​ ​ (5,069) Other long-term liabilities ​ ​ (1,186) Finance lease obligations ​ ​ (1,708) Net assets acquired ​ $ 719,133

Equipment and Other Fixed Ass_2

Equipment and Other Fixed Assets (Tables)	9 Months Ended
	Sep. 30, 2021
Equipment and Other Fixed Assets
Schedule of equipment and other fixed assets	​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2021 2020 Patient medical equipment ​ $ 436,725 $ 158,108 Delivery vehicles ​ 27,012 8,211 Other ​ 53,697 26,098 ​ ​ 517,434 ​ 192,417 Less accumulated depreciation ​ (176,077) ​ (81,949) ​ ​ $ 341,357 ​ $ 110,468

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2021
Goodwill.
Schedule of change in the carrying amount of goodwill	​ ​ ​ ​ ​ Balance at December 31, 2020 ​ $ 998,810 Goodwill from acquisitions ​ ​ 2,386,151 Net cash receipts relating to prior acquisitions ​ ​ (657) Reductions ​ ​ (22,036) Balance at September 30, 2021 ​ $ 3,362,268
Schedule of identifiable intangible assets	​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2021 ​ ​ ​ ​ ​ Weighted-Average ​ ​ ​ ​ ​ Remaining Life (Years) Tradenames, net of accumulated amortization of $9,666 ​ $ 98,133 ​ 8.8 Payor contracts, net of accumulated amortization of $9,766 ​ ​ 72,234 ​ 8.8 Contractual rental agreements, net of accumulated amortization of $19,383 ​ ​ 34,817 ​ 1.5 Developed technology, net of accumulated amortization of $1,575 ​ ​ 4,725 ​ 3.8 Identifiable intangible assets, net ​ $ 209,909 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 ​ ​ ​ ​ ​ Weighted-Average ​ ​ ​ ​ ​ Remaining Life (Years) Tradenames, net of accumulated amortization of $1,793 ​ $ 32,007 ​ 8.8 Payor contracts, net of accumulated amortization of $3,616 ​ ​ 78,384 ​ 9.6 Developed technology, net of accumulated amortization of $630 ​ ​ 5,670 ​ 4.5 Identifiable intangible assets, net ​ $ 116,061 ​ ​
Schedule of future amortization expense related to identifiable intangible assets	​ ​ ​ ​ ​ Twelve months ending September 30, ​ ​ 2022 ​ $ 48,376 2023 ​ 28,993 2024 ​ 21,276 2025 ​ 20,828 2026 ​ 18,682 Thereafter ​ 71,754 Total ​ $ 209,909

Fair Value of Assets and Liab_2

Fair Value of Assets and Liabilities (Tables)	9 Months Ended
	Sep. 30, 2021
Business Acquisition, Contingent Consideration [Line Items]
Summary of financial assets and liabilities measured at fair value on a recurring basis	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Level 1 Level 2 Level 3 September 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ Money market accounts ​ $ 200,059 ​ $ — ​ $ — Total assets measured at fair value ​ $ 200,059 ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ Acquisition-related contingent consideration-short term ​ $ — ​ $ — ​ $ 15,398 Acquisition-related contingent consideration-long term ​ — ​ — ​ 3,250 Interest rate swap agreements-short term ​ ​ — ​ ​ 5,957 ​ ​ — Interest rate swap agreements-long term ​ — ​ 4,838 ​ — Contingent consideration common shares liability-short term ​ ​ — ​ ​ — ​ ​ 21,402 Contingent consideration common shares liability-long term ​ ​ — ​ ​ — ​ ​ 15,025 Warrant liability ​ ​ — ​ ​ — ​ ​ 56,546 Total liabilities measured at fair value ​ $ — ​ $ 10,795 ​ $ 111,621 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Level 1 Level 2 Level 3 December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ Money market accounts ​ $ 5,602 ​ $ — ​ $ — Total assets measured at fair value ​ $ 5,602 ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ Acquisition-related contingent consideration-short term ​ $ — ​ $ — ​ $ 23,941 Acquisition-related contingent consideration-long term ​ — ​ — ​ 9,599 Interest rate swap agreements-short term ​ ​ — ​ ​ 5,941 ​ ​ — Interest rate swap agreements-long term ​ — ​ 10,220 ​ — Contingent consideration common shares liability-short term ​ ​ — ​ ​ — ​ ​ 36,846 Contingent consideration common shares liability-long term ​ ​ — ​ ​ — ​ ​ 33,631 Warrant liability ​ ​ — ​ ​ — ​ ​ 113,905 Total liabilities measured at fair value ​ $ — ​ $ 16,161 ​ $ 217,922
Summary of non-financial assets measured on a non-recurring basis	​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2021 2020 Assets: ​ ​ ​ Goodwill (Level 3) ​ $ 3,362,268 ​ $ 998,810 Identifiable intangible assets, net (Level 3) ​ $ 209,909 ​ $ 116,061
Acquisition Related Contingent Consideration [Member]
Business Acquisition, Contingent Consideration [Line Items]
Reconciliation of contingent consideration liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, 2021 ​ Beginning Balance Additions Payments Change in Fair Value Other activity Ending Balance Contingent consideration - Level 3 liabilities ​ $ 33,540 ​ $ 2,000 ​ $ (18,200) ​ $ 1,135 ​ $ 173 ​ $ 18,648 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, 2020 ​ Beginning Balance Additions Payments Change in Fair Value Other activity Ending Balance Contingent consideration - Level 3 liabilities ​ $ 14,725 ​ $ 6,464 ​ $ (1,200) ​ $ (2,900) $ 46 ​ $ 17,135

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities (Tables)	9 Months Ended
	Sep. 30, 2021
Derivative Instruments and Hedging Activities
Summary of fair value of derivative financial instruments as well as their classification on the consolidated balance sheets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2021 ​ December 31, 2020 ​ ​ Balance Sheet Location ​ Asset (Liability) Interest rate swap agreements ​ Other current liabilities ​ $ (5,957) ​ $ (5,941) Interest rate swap agreements ​ Other long-term liabilities ​ (4,838) ​ (10,220) Total ​ ​ ​ $ (10,795) ​ $ (16,161) ​

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2021
Accounts Payable and Accrued Expenses
Schedule of components accounts payable and accrued expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2021 ​ 2020 Accounts payable ​ $ 211,373 $ 191,038 Employee-related accruals ​ 40,483 ​ 26,705 Accrued interest ​ 11,178 ​ 11,062 Other ​ 49,321 ​ 25,407 Total ​ $ 312,355 ​ $ 254,212

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2021
Debt
Schedule of summary of long term debt	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2021 ​ 2020 Secured term loans ​ $ 790,000 $ 248,438 Revolving credit facility ​ ​ — ​ ​ 55,000 Senior unsecured notes ​ ​ 1,450,000 ​ ​ 350,000 Note payable ​ — ​ 143,500 Other ​ — ​ 333 Unamortized deferred financing fees ​ (32,627) ​ (12,557) ​ ​ 2,207,373 ​ 784,714 Current portion ​ (20,000) ​ (8,146) Long-term portion ​ $ 2,187,373 ​ $ 776,568

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2021
Business Acquisition
Schedule of changes in warrant liability	​ ​ ​ ​ ​ Estimated fair value of warrant liability at December 31, 2020 ​ $ 113,905 Change in estimated fair value of the warrant liability ​ ​ (57,359) Estimated fair value of warrant liability at September 30, 2021 ​ $ 56,546 ​ ​ ​ ​ Estimated fair value of warrant liability at December 31, 2019 ​ $ 27,635 Change in estimated fair value of the warrant liability ​ ​ 72,358 Reclassification of warrant liability to equity for exercised warrants ​ (49,098) Estimated fair value of warrant liability at September 30, 2020 ​ $ 50,895
Schedule of stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ Weighted-Average ​ ​ Number of ​ ​ Exercise Price ​ ​ Remaining ​ ​ Options ​ ​ per Share ​ ​ Contractual Term Outstanding, December 31, 2020 ​ 3,464 ​ $ 11.56 ​ ​ ​ Granted under the 2019 Plan ​ 703 ​ $ 48.72 ​ ​ ​ Issued in connection with the AeroCare acquisition ​ 3,960 ​ $ 6.24 ​ ​ ​ Exercised ​ (1,114) ​ $ 11.13 ​ ​ ​ Forfeited ​ (914) ​ $ 11.66 ​ ​ ​ Outstanding, September 30, 2021 ​ 6,099 $ 11.03 ​ 6.7 Years
Schedule of restricted stock activity	​ ​ ​ ​ ​ ​ ​ ​ ​ Number of Shares of ​ ​ Weighted-Average Grant Date ​ ​ Restricted Stock ​ Fair Value per Share Non-vested balance, December 31, 2020 ​ 2,248 $ 15.60 Granted ​ 1,015 ​ $ 30.62 Vested ​ (335) ​ $ 17.39 Forfeited ​ (616) ​ $ 16.77 Non-vested balance, September 30, 2021 ​ 2,312 ​ $ 21.32
Common Shares Liability
Business Acquisition
Reconciliation of contingent consideration liabilities	​ ​ ​ ​ ​ Estimated fair value of contingent consideration common shares liability at December 31, 2020 ​ $ 70,477 Change in estimated fair value of the contingent consideration common shares liability ​ ​ (34,050) Estimated fair value of contingent consideration common shares liability at September 30, 2021 ​ $ 36,427 ​ ​ ​ ​ Estimated fair value of contingent consideration common shares liability at December 31, 2019 ​ $ 9,316 Change in estimated fair value of the contingent consideration common shares liability ​ 41,850 Estimated fair value of contingent consideration common shares liability at September 30, 2020 ​ $ 51,166
2019 Incentive Plan
Business Acquisition
Schedule of stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Grant Date ​ ​ Weighted-Average ​ Weighted-Average ​ ​ Number of ​ ​ Fair Value ​ ​ Exercise Price ​ Remaining ​ ​ Options ​ ​ per Share ​ ​ per Share ​ Contractual Term Outstanding, December 31, 2020 ​ 3,464 ​ $ 2.18 ​ $ 11.56 ​ ​ Granted ​ 703 ​ $ 9.81 ​ $ 48.72 ​ ​ Exercised ​ (1,034) ​ $ 2.19 ​ $ 11.57 ​ ​ Forfeited ​ (914) ​ $ 2.27 ​ $ 11.66 ​ ​ Outstanding, September 30, 2021 ​ 2,219 $ 3.75 $ 19.36 7.3 Years
Options
Business Acquisition
Schedule of assumptions used to determine the grant date fair value	​ ​ ​ ​ ​ Expected volatility 44.5 % Risk-free interest rate 0.18 % Expected term 4.0 years Dividend yield ​ N/A ​

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings per share
Schedule of calculation of basic and diluted earnings per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2021 ​ 2020 2021 ​ 2020 Numerator ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net income (loss) attributable to AdaptHealth Corp. ​ $ 58,092 ​ $ (51,035) ​ $ 133,233 ​ $ (81,116) Less: Earnings allocated to participating securities (1) ​ ​ 5,002 ​ ​ — ​ ​ 12,572 ​ ​ — Net income (loss) for basic EPS ​ $ 53,090 ​ $ (51,035) ​ $ 120,661 ​ $ (81,116) Change in fair value of warrant liability (2) ​ ​ (16,737) ​ ​ — ​ ​ (57,359) ​ ​ — Change in fair value of contingent consideration common shares liability (2) ​ ​ (8,145) ​ ​ — ​ ​ (27,718) ​ ​ — Net income (loss) for diluted EPS ​ $ 28,208 ​ $ (51,035) ​ $ 35,584 ​ $ (81,116) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Denominator (1) (2) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic weighted-average common shares outstanding ​ ​ 131,684 ​ ​ 57,372 ​ ​ 124,228 ​ ​ 47,986 Add: Warrants (2) ​ ​ 2,245 ​ ​ — ​ ​ 2,598 ​ ​ — Add: Contingent Consideration Common Shares (2) ​ ​ 2,000 ​ ​ — ​ ​ 2,000 ​ ​ — Add: Stock options ​ ​ 3,794 ​ ​ — ​ ​ 4,112 ​ ​ — Add: Unvested restricted stock ​ ​ 599 ​ ​ — ​ ​ 700 ​ ​ — Diluted weighted-average common shares outstanding ​ ​ 140,322 ​ ​ 57,372 ​ ​ 133,638 ​ ​ 47,986 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic net income (loss) per share ​ $ 0.40 ​ $ (0.89) ​ $ 0.97 ​ $ (1.69) Diluted net income (loss) per share ​ $ 0.20 ​ $ (0.89) ​ $ 0.27 ​ $ (1.69) ​ (1) The Company’s preferred stock are considered participating securities. Calculation of EPS under the two-class method excludes from the numerator any dividends paid or owed on participating securities and any undistributed earnings considered to be attributable to participating securities. The related participating securities are similarly excluded from the denominator. There were participating securities outstanding for all periods presented. There was no amount allocated to the participating securities during the three and nine months ended September 30, 2020 due to the net loss reported in those periods. (2) For the three and nine months ended September 30, 2021, in accordance with the requirements of ASC Topic 260, Earnings per Share , the impact to earnings from the change in fair value of the Company’s contingent consideration common shares liability and the Company’s warrant liability are reversed from the numerator, and the corresponding securities are included in the denominator, for purposes of calculating diluted net income per share as the effect of the numerator and denominator adjustments for these derivative instruments is dilutive as a result of the gains recorded for the changes in fair value of these instruments during those periods. For the three and nine months ended September 30, 2020, the numerator and denominator for the diluted net loss per share calculation is the same as used in the basic net loss per share calculation and therefore exclude the effect of potential dilutive securities as their inclusion would have been anti-dilutive.
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ ​ Nine Months Ended September 30, ​ ​ 2021 ​ 2020 2021 ​ 2020 Preferred Stock ​ ​ 12,406 ​ ​ 18,356 ​ ​ 12,944 ​ ​ 6,567 Warrants ​ ​ — ​ ​ 1,936 ​ ​ — ​ ​ 1,438 Stock Options ​ ​ — ​ ​ 1,566 ​ ​ — ​ ​ 1,163 Unvested restricted stock ​ ​ — ​ ​ 383 ​ ​ — ​ ​ 724 Contingent Consideration Common Shares ​ ​ — ​ ​ 700 ​ ​ — ​ ​ 700 Total ​ ​ 12,406 ​ ​ 22,941 ​ ​ 12,944 ​ ​ 10,592

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Lease, Cost [Table Text Block]	​ ​ ​ ​ ​ ​ ​ ​ ​ Consolidated Balance Sheets Line Item ​ September 30, 2021 Right-of-use (ROU) assets: ​ ​ ​ ​ ​ Operating lease ROU assets ​ Operating lease right-of-use assets ​ $ 148,891 Finance lease ROU assets ​ Equipment and other fixed assets, net ​ 25,803 Total ROU assets ​ ​ ​ $ 174,694 Operating lease liabilities: ​ ​ ​ ​ ​ Current operating lease liabilities ​ Current portion of operating lease obligations ​ $ 31,015 Noncurrent operating lease liabilities ​ Operating lease obligations, less current portion ​ 121,411 Total operating lease liabilities ​ ​ ​ $ 152,426 Finance lease liabilities: ​ ​ ​ ​ ​ Current finance lease liabilities ​ Current portion of finance lease obligations ​ $ 21,672 Noncurrent finance lease liabilities ​ Other long-term liabilities ​ 203 Total finance lease liabilities ​ ​ ​ $ 21,875 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Consolidated Statements of ​ Three Months Ended ​ Nine Months Ended ​ ​ Operations Line Item ​ September 30, 2021 ​ September 30, 2021 Operating lease costs ​ Cost of net revenue ​ $ 9,837 ​ $ 27,695 Finance lease costs: ​ ​ ​ ​ ​ ​ ​ ​ Amortization of ROU assets ​ Cost of net revenue ​ $ 8,487 ​ $ 27,549 Other lease costs and income: ​ ​ ​ ​ ​ ​ ​ ​ Short-term lease costs ​ Cost of net revenue ​ $ 4,093 ​ $ 19,905 Variable leases costs (1) ​ Cost of net revenue ​ $ 3,784 ​ $ 10,061 Sublease income ​ Cost of net revenue ​ $ 405 ​ $ 911 ​ (1) Amounts represent variable costs incurred that were not included in the initial measurement of the lease liability such as common area maintenance and utilities costs associated with leased real estate. ​
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Leases ​ Finance Leases 2021 (excluding the nine months ended September 30, 2021) ​ $ 9,540 ​ $ 10,788 2022 ​ 34,352 ​ 11,034 2023 ​ 29,396 ​ 149 2024 ​ 24,451 ​ — 2025 ​ 20,435 ​ — Thereafter ​ 56,793 ​ — Total future leases payments ​ $ 174,967 ​ $ 21,971 Less: amount representing interest ​ (22,541) ​ (96) Present value of future lease payments (lease liability) ​ $ 152,426 ​ $ 21,875
Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Leases ​ Finance Leases 2021 (excluding the nine months ended September 30, 2021) ​ $ 9,540 ​ $ 10,788 2022 ​ 34,352 ​ 11,034 2023 ​ 29,396 ​ 149 2024 ​ 24,451 ​ — 2025 ​ 20,435 ​ — Thereafter ​ 56,793 ​ — Total future leases payments ​ $ 174,967 ​ $ 21,971 Less: amount representing interest ​ (22,541) ​ (96) Present value of future lease payments (lease liability) ​ $ 152,426 ​ $ 21,875
Summary of minimum annual lease commitments under noncancelable operating leases (preadoption)	​ ​ ​ ​ ​ Twelve months ending December 31, ​ ​ 2021 ​ $ 18,403 2022 ​ 14,893 2023 ​ 11,788 2024 ​ 9,055 2025 ​ 5,960 Thereafter ​ 15,646 Total minimum payments required (a) ​ $ 75,745 ​ (a) Minimum payments have not been reduced by minimum sublease rentals of $1.9 million due in the future under noncancelable subleases
Schedule Of Lease Terms And Discount Rates [Table Text Block]	​ ​ ​ ​ ​ Weighted average remaining lease term, weighted based on lease liability balances: ​ ​ ​ Operating leases ​ ​ 6.8 years Finance leases ​ ​ 0.6 years Weighted average discount rate, weighted based on remaining balance of lease payments: ​ ​ ​ Operating leases ​ ​ 3.7%
Schedule Of Cash And NonCash Activity Related To Lease Liabilities [Table Text Block]	​ ​ ​ ​ ​ Cash paid for amounts included in the measurement of lease liabilities: ​ ​ ​ Operating cash payments for operating leases ​ $ 27,154 Financing cash payments for finance leases ​ $ 31,043 Lease liabilities arising from obtaining right-of-use assets: ​ ​ ​ Operating leases ​ $ 84,212 Finance leases ​ $ 22,902

General Information (Details)

General Information (Details) - USD ($)	3 Months Ended		9 Months Ended		36 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021
Property, Plant and Equipment [Line Items]
Impairment of long-lived assets	$ 0	$ 0	$ 0	$ 0
Payor contracts
Property, Plant and Equipment [Line Items]
Finite-Lived Intangible Asset, Useful Life			10 years
Contractual rental agreements
Property, Plant and Equipment [Line Items]
Finite-Lived Intangible Asset, Useful Life			2 years
Developed technology
Property, Plant and Equipment [Line Items]
Finite-Lived Intangible Asset, Useful Life			5 years
Minimum
Property, Plant and Equipment [Line Items]
Proceeds from Issuance of Debt					$ 1,000,000,000
Minimum | Tradenames [Member]
Property, Plant and Equipment [Line Items]
Finite-Lived Intangible Asset, Useful Life			5 years
Maximum | Tradenames [Member]
Property, Plant and Equipment [Line Items]
Finite-Lived Intangible Asset, Useful Life			10 years

General Information - Leases (D

General Information - Leases (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Recently Adopted Accounting Pronouncements
Operating Lease, Liability	$ 152,426
Operating Lease, Right-of-Use Asset	$ 148,891
Lease, Practical Expedients, Package [true false]	true
Cumulative Effect, Period of Adoption, Adjustment [Member]
Recently Adopted Accounting Pronouncements
Operating Lease, Liability		$ 91,500
Operating Lease, Right-of-Use Asset		$ 91,500

Revenue Recognition and Accou_3

Revenue Recognition and Accounts Receivable (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Apr. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Jul. 31, 2020
Revenue Recognition
Total net revenues		$ 653,293	$ 284,405	$ 1,752,429	$ 707,960
Recoupable Advance Payment, CARES Act	$ 45,800
CARES Act funding recouped		11,100		27,000
CARES Act deferred payments		22,500		22,500
Unbilled revenue		17,900		17,900		$ 20,200
Significant Acquisitions In 2021 [Member]
Revenue Recognition
CARES Act deferred payments							$ 3,700
Transferred at Point in Time [Member]
Revenue Recognition
Total net revenues		432,171	207,140	1,150,033	497,078
Transferred over Time [Member]
Revenue Recognition
Total net revenues		221,122	77,265	602,396	210,882
Sleep
Revenue Recognition
Total net revenues		236,114	99,626	642,571	298,254
Sleep | Transferred at Point in Time [Member]
Revenue Recognition
Total net revenues		173,359	74,655	465,372	227,970
Sleep | Transferred over Time [Member]
Revenue Recognition
Total net revenues		62,755	24,971	177,199	70,284
Diabetes [Member]
Revenue Recognition
Total net revenues		137,950	53,833	362,350	65,512
Diabetes [Member] | Transferred at Point in Time [Member]
Revenue Recognition
Total net revenues		134,228	52,887	352,559	64,566
Diabetes [Member] | Transferred over Time [Member]
Revenue Recognition
Total net revenues		3,722	946	9,791	946
Supplies to the home
Revenue Recognition
Total net revenues		42,441	44,579	126,479	100,479
Supplies to the home | Transferred at Point in Time [Member]
Revenue Recognition
Total net revenues		42,441	44,579	126,479	100,479
Respiratory
Revenue Recognition
Total net revenues		124,146	37,421	337,903	114,166
Respiratory | Transferred at Point in Time [Member]
Revenue Recognition
Total net revenues		6,228	5,152	25,003	26,034
Respiratory | Transferred over Time [Member]
Revenue Recognition
Total net revenues		117,918	32,269	312,900	88,132
HME
Revenue Recognition
Total net revenues		57,032	29,254	156,359	78,999
HME | Transferred at Point in Time [Member]
Revenue Recognition
Total net revenues		30,989	14,998	85,505	39,304
HME | Transferred over Time [Member]
Revenue Recognition
Total net revenues		26,043	14,256	70,854	39,695
Health Care, Other
Revenue Recognition
Total net revenues		55,610	19,692	126,767	50,550
Health Care, Other | Transferred at Point in Time [Member]
Revenue Recognition
Total net revenues		44,926	14,869	95,115	38,725
Health Care, Other | Transferred over Time [Member]
Revenue Recognition
Total net revenues		10,684	4,823	31,652	11,825
Insurance Payor [Member]
Revenue Recognition
Total net revenues		399,748	175,418	1,061,627	438,034
Government payor
Revenue Recognition
Total net revenues		180,511	81,967	491,564	193,725
Patient payor
Revenue Recognition
Total net revenues		$ 73,034	$ 27,020	$ 199,238	$ 76,201

Acquisitions (Details)

Acquisitions (Details) $ / shares in Units, $ in Thousands	Jul. 01, 2021USD ($)shares	Jun. 01, 2021USD ($)shares	Apr. 30, 2021USD ($)shares	Feb. 01, 2021USD ($)$ / sharesshares	Jul. 01, 2020USD ($)shares	Mar. 02, 2020USD ($)	Jan. 02, 2020USD ($)	Oct. 31, 2021USD ($)	Aug. 31, 2021USD ($)	Jul. 31, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)itemshares	Sep. 30, 2020USD ($)itemshares	Mar. 18, 2021shares	Dec. 31, 2020USD ($)shares	Oct. 31, 2020USD ($)	Aug. 04, 2020$ / shares	Nov. 08, 2019$ / shares
Business Acquisition
Gain on equity method investment												$ 1,922
Contingent consideration paid												1,135	$ (2,900)
Deferred purchase price in connection with acquisitions												$ 1,162	33
Preferred Stock, Shares Issued | shares												124,060			163,560
Exercise price | $ / shares																	$ 11.50	$ 11.50
Estimated fair values of net assets acquired
Goodwill												$ 3,362,268			$ 998,810
Additional consideration from adjustment												(657)
Series C Preferred Stock [Member]
Estimated fair values of net assets acquired
Preferred stock, liquidation preference (in dollars per share) | $ / shares				$ 0.0001
Shares of common stock received in conversion for each share of preferred stock | shares														100
Significant Acquisitions In 2021 [Member]
Business Acquisition
Cash payment												1,453,302
Estimated fair values of net assets acquired
Cash												34,699
Accounts receivable												119,168
Inventory												45,684
Prepaid and other current assets												6,394
Equipment and other fixed assets												215,350
Right-of-use assets												72,872
Other assets												1,194
Identifiable intangible assets												128,400
Goodwill												2,386,151
Accounts payable and accrued expenses												(107,410)
Contract liabilities												(14,619)
Net liabilities - working capital												(11,576)
Other long-term liabilities												(1,055)
Finance lease obligations												(6,867)
Operating lease obligations												(72,872)
Deferred tax liability												(67,849)
Net assets acquired												2,727,664
Total Merger Consideration												$ 2,717,664
AeroCare Holdings [Member]
Business Acquisition
Interest acquired, as a percent				100.00%
Cash payment				$ 1,100,000
Options issued in acquisition, in shares | shares				3,959,892
Exercise price | $ / shares				$ 6.24
Weighted average exercise period				7 years
Estimated fair values of net assets acquired
Cash				$ 27,700
Accounts receivable				75,900
Inventory				27,600
Equipment and other fixed assets				190,800
Right-of-use assets				55,100
Identifiable intangible assets				122,800
Goodwill				2,100
Accounts payable and accrued expenses				(82,700)
Net liabilities - working capital				(20,900)
Operating lease obligations				(55,100)
Deferred tax liability				(64,900)
Additional consideration from adjustment										$ 4,100
AeroCare Holdings [Member] | Contractual rental agreements
Estimated fair values of net assets acquired
Identifiable intangible assets				54,200
AeroCare Holdings [Member] | Tradenames [Member]
Estimated fair values of net assets acquired
Identifiable intangible assets				$ 68,600
AeroCare Holdings [Member] | Stock, common
Business Acquisition
Issuance of stock for acquisitions (in shares) | shares				13,992,615
AeroCare Holdings [Member] | Series C Preferred Stock [Member]
Business Acquisition
Preferred Stock, Shares Issued | shares				130,474.73
Spiro Health Services [Member]
Business Acquisition
Interest acquired, as a percent			100.00%
Cash payment			$ 66,100
Contingent consideration paid									$ 1,000
Issuance of stock for acquisitions (in shares) | shares			244,641
Estimated fair values of net assets acquired
Cash			$ 2,100
Accounts receivable			8,500
Inventory			4,900
Net assets - working capital			200
Equipment and other fixed assets			2,200
Right-of-use assets			2,700
Identifiable intangible assets			1,000
Goodwill			62,600
Accounts payable and accrued expenses			(5,100)
Finance lease obligations			(2,200)
Operating lease obligations			(2,700)
Maximum potential contingent consideration			$ 1,000
Healthy Living Medical Supply, L L C [Member]
Business Acquisition
Interest acquired, as a percent		100.00%
Cash payment		$ 47,000
Issuance of stock for acquisitions (in shares) | shares		196,779
Estimated fair values of net assets acquired
Cash		$ 600
Accounts receivable		7,500
Inventory		2,900
Net assets - working capital		200
Equipment and other fixed assets		1,200
Right-of-use assets		1,400
Identifiable intangible assets		1,300
Goodwill		42,000
Accounts payable and accrued expenses		(3,600)
Operating lease obligations		$ (1,400)
Home Medical Equipment Providers, Equity Interests And Assets Acquisitions [Member]
Business Acquisition
Interest acquired, as a percent												100.00%
Number of home medical equipment providers acquired | item												5
Number of entities acquired | item												6
Number of acquisitions including contingent consideration | item												1
Cash payment												$ 113,700
Issuance of stock for acquisitions (in shares) | shares												306,569
Estimated fair values of net assets acquired
Cash												$ 2,700
Accounts receivable												20,300
Inventory												5,800
Equipment and other fixed assets												12,000
Right-of-use assets												12,200
Goodwill												96,600
Accounts payable and accrued expenses												(13,600)
Net liabilities - working capital												(1,400)
Finance lease obligations												(4,700)
Operating lease obligations												(12,200)
Maximum potential contingent consideration												4,000
Additional consideration from adjustment												1,500
Home Medical Equipment Providers, Equity Interests And Assets Acquisitions [Member] | Tradenames [Member]
Estimated fair values of net assets acquired
Identifiable intangible assets												2,400
Agilis Med Holdings, LLC [Member]
Business Acquisition
Interest acquired, as a percent	100.00%
Investment carrying value																$ 8,100
Fair value of investment																$ 10,000
Gain on equity method investment												1,900
Cash payment	$ 30,800
Issuance of stock for acquisitions (in shares) | shares	538,079
Estimated fair values of net assets acquired
Cash	$ 1,200
Inventory	2,500
Right-of-use assets	500
Goodwill	52,900
Accounts payable and accrued expenses	(600)
Operating lease obligations	(500)
Maximum potential contingent consideration	1,000
Agilis Med Holdings, LLC [Member] | Tradenames [Member]
Estimated fair values of net assets acquired
Identifiable intangible assets	$ 500
WeCare Medical, LLC [Member]
Business Acquisition
Interest acquired, as a percent	100.00%
Cash payment	$ 34,800
Issuance of stock for acquisitions (in shares) | shares	231,866
Estimated fair values of net assets acquired
Cash	$ 500
Accounts receivable	6,300
Inventory	1,500
Equipment and other fixed assets	8,200
Right-of-use assets	1,000
Goodwill	29,100
Accounts payable and accrued expenses	(1,400)
Operating lease obligations	(1,000)
Deferred tax liability	(3,400)
WeCare Medical, LLC [Member] | Tradenames [Member]
Estimated fair values of net assets acquired
Identifiable intangible assets	$ 400
Other acquisitions
Business Acquisition
Cash payment												6,500
Deferred purchase price in connection with acquisitions												1,200
Estimated fair values of net assets acquired
Accounts receivable												600
Inventory												400
Equipment and other fixed assets												1,000
Goodwill												6,100
Accounts payable and accrued expenses												(300)
Net liabilities - working capital												(100)
Other acquisitions | Subsequent Event
Business Acquisition
Cash payment								$ 67,600
Significant Acquisitions In 2020 [Member]
Business Acquisition
Cash payment													623,107
Estimated fair values of net assets acquired
Cash											$ 17,798		17,798
Accounts receivable											49,464		49,464
Inventory											23,073		23,073
Prepaid and other current assets											4,254		4,254
Equipment and other fixed assets											42,852		42,852
Identifiable intangible assets											97,400		97,400
Goodwill											543,689		543,689
Accounts payable and accrued expenses											(47,759)		(47,759)
Contract liabilities											(3,675)		(3,675)
Other long-term liabilities											(1,186)		(1,186)
Unfavorable lease liability											(5,069)		(5,069)
Finance lease obligations											(1,708)		(1,708)
Net assets acquired											719,133		719,133
Total Merger Consideration													719,133
Additional consideration from adjustment												(700)
Patient Care Solutions (PCS) [Member]
Business Acquisition
Interest acquired, as a percent							100.00%
Cash payment							$ 15,000
Estimated fair values of net assets acquired
Accounts receivable											17,400		17,400
Equipment and other fixed assets											500		500
Goodwill											100		100
Accounts payable and accrued expenses											(3,600)		(3,600)
Net liabilities - working capital											(400)		(400)
Additional consideration from adjustment											1,000
Advanced Home Care Inc [Member]
Business Acquisition
Cash payment						$ 58,500
Estimated fair values of net assets acquired
Inventory											2,700		2,700
Net assets - working capital											1,600		1,600
Equipment and other fixed assets											21,000		21,000
Goodwill											35,800		35,800
Maximum potential contingent consideration											9,000	5,000	9,000		$ 5,000
Advanced Home Care Inc [Member] | Tradenames [Member]
Estimated fair values of net assets acquired
Identifiable intangible assets											$ 600		$ 600
Home Medical Equipment Provider Acquired In 2020 [Member]
Business Acquisition
Interest acquired, as a percent											100.00%		100.00%
Number of home medical equipment providers acquired | item													2
Number of acquisitions including contingent consideration | item													1
Cash payment													$ 88,100
Issuance of stock for acquisitions (in shares) | shares													824,693
Contingent consideration liability at fair value											$ 2,800		$ 2,800
Estimated fair values of net assets acquired
Cash											300		300
Accounts receivable											12,100		12,100
Inventory											4,100		4,100
Equipment and other fixed assets											14,700		14,700
Goodwill											91,200		91,200
Accounts payable and accrued expenses											(13,400)		(13,400)
Net liabilities - working capital											(1,300)		(1,300)
Finance lease obligations											(1,600)		(1,600)
Maximum potential contingent consideration											3,000		3,000
Home Medical Equipment Provider Acquired In 2020 [Member] | Tradenames [Member]
Estimated fair values of net assets acquired
Identifiable intangible assets											900		900
Solara Medical Supplies, LLC [Member]
Business Acquisition
Interest acquired, as a percent					100.00%
Cash payment					$ 380,700
Issuance of stock for acquisitions (in shares) | shares					3,906,250
Estimated fair values of net assets acquired
Cash					$ 12,100
Accounts receivable					15,100
Inventory					15,000
Equipment and other fixed assets					4,400
Identifiable intangible assets					85,700
Goodwill					347,100
Accounts payable and accrued expenses					(22,400)
Net liabilities - working capital					(3,000)
Additional consideration from adjustment												(700)
Solara Medical Supplies, LLC [Member] | Tradenames [Member]
Estimated fair values of net assets acquired
Identifiable intangible assets					25,700
Solara Medical Supplies, LLC [Member] | Payor contracts
Estimated fair values of net assets acquired
Identifiable intangible assets					$ 60,000
ActivStyle, Inc. [Member]
Business Acquisition
Interest acquired, as a percent					100.00%
Cash payment					$ 65,500
Estimated fair values of net assets acquired
Cash					5,000
Accounts receivable					4,100
Inventory					500
Net assets - working capital					900
Equipment and other fixed assets					1,000
Identifiable intangible assets					10,100
Goodwill					51,200
Accounts payable and accrued expenses					(7,300)
ActivStyle, Inc. [Member] | Tradenames [Member]
Estimated fair values of net assets acquired
Identifiable intangible assets					3,100
ActivStyle, Inc. [Member] | Developed technology
Estimated fair values of net assets acquired
Identifiable intangible assets					$ 7,000
Other acquisitions in 2020
Business Acquisition
Cash payment													16,300
Contingent consideration liability at fair value											3,700		3,700
Estimated fair values of net assets acquired
Cash											400		400
Accounts receivable											700		700
Inventory											700		700
Equipment and other fixed assets											1,300		1,300
Goodwill											18,300		18,300
Accounts payable and accrued expenses											(1,200)		(1,200)
Net liabilities - working capital											(300)		(300)
Maximum potential contingent consideration											5,000	4,400	5,000
Other acquisitions in 2020 | Other current liabilities
Estimated fair values of net assets acquired
Maximum potential contingent consideration												2,100
Other acquisitions in 2020 | Other long-term liabilities
Estimated fair values of net assets acquired
Maximum potential contingent consideration												$ 2,300
Other acquisitions in 2020 | Maximum
Business Acquisition
Deferred purchase price in connection with acquisitions													100
Other acquisitions in 2020 | Tradenames [Member]
Estimated fair values of net assets acquired
Identifiable intangible assets											$ 100		$ 100

Acquisitions - Consideration an

Acquisitions - Consideration and Allocation (Details) - USD ($) $ in Thousands	Feb. 01, 2021	Jul. 01, 2020	Mar. 02, 2020	Jan. 02, 2020	Jul. 31, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Equity consideration issued in connection with acquisitions							$ 1,261,200	$ 89,529
Deferred payments							1,162	33
Contingent consideration liability						$ 17,135	18,648	17,135	$ 33,540	$ 14,725
Estimated fair values of net assets acquired
Goodwill							3,362,268		998,810
Cash receipt from working capital adjustment							657
Payment of contingent consideration							1,000	1,000
Significant Acquisitions In 2021 [Member]
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Cash payment							1,453,302
Equity consideration issued in connection with acquisitions							1,261,200
Liability incurred							1,162
Consideration paid allocated to contingent consideration							2,000
Total consideration							2,717,664
Estimated fair values of net assets acquired
Cash							34,699
Accounts receivable							119,168
Inventory							45,684
Prepaid and other current assets							6,394
Equipment and other fixed assets							215,350
Right-of-use assets							72,872
Other assets							1,194
Identifiable intangible assets							128,400
Goodwill							2,386,151
Deferred tax liability							(67,849)
Accounts payable and accrued expenses							(107,410)
Contract liabilities							(14,619)
Net liabilities - working capital							(11,576)
Other long-term liabilities							(1,055)
Finance lease obligations							(6,867)
Operating lease obligations							(72,872)
Net assets acquired							2,727,664
AeroCare Holdings [Member]
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Cash payment	$ 1,100,000
Interest acquired, as a percent	100.00%
Estimated fair values of net assets acquired
Cash	$ 27,700
Accounts receivable	75,900
Inventory	27,600
Equipment and other fixed assets	190,800
Right-of-use assets	55,100
Identifiable intangible assets	122,800
Goodwill	2,100
Deferred tax liability	(64,900)
Accounts payable and accrued expenses	(82,700)
Net liabilities - working capital	(20,900)
Operating lease obligations	(55,100)
Cash receipt from working capital adjustment					$ (4,100)
AeroCare Holdings [Member] | Tradenames [Member]
Estimated fair values of net assets acquired
Identifiable intangible assets	$ 68,600
Series Of Individually Immaterial Business Acquisitions Member
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Cash payment							6,500
Deferred payments							1,200
Estimated fair values of net assets acquired
Accounts receivable							600
Inventory							400
Equipment and other fixed assets							1,000
Goodwill							6,100
Accounts payable and accrued expenses							(300)
Net liabilities - working capital							(100)
Significant Acquisitions In 2020 [Member]
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Cash payment								623,107
Equity consideration issued in connection with acquisitions								89,529
Liability incurred								33
Consideration paid allocated to contingent consideration								6,464
Total consideration								719,133
Estimated fair values of net assets acquired
Cash						17,798		17,798
Accounts receivable						49,464		49,464
Inventory						23,073		23,073
Prepaid and other current assets						4,254		4,254
Equipment and other fixed assets						42,852		42,852
Identifiable intangible assets						97,400		97,400
Goodwill						543,689		543,689
Accounts payable and accrued expenses						(47,759)		(47,759)
Contract liabilities						(3,675)		(3,675)
Other long-term liabilities						(1,186)		(1,186)
Unfavorable lease liability						(5,069)		(5,069)
Finance lease obligations						(1,708)		(1,708)
Net assets acquired						719,133		719,133
Cash receipt from working capital adjustment							700
Patient Care Solutions (PCS) [Member]
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Cash payment				$ 15,000
Interest acquired, as a percent				100.00%
Estimated fair values of net assets acquired
Accounts receivable						17,400		17,400
Equipment and other fixed assets						500		500
Goodwill						100		100
Accounts payable and accrued expenses						(3,600)		(3,600)
Net liabilities - working capital						(400)		(400)
Cash receipt from working capital adjustment						(1,000)
Advanced Home Care Inc [Member]
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Cash payment			$ 58,500
Maximum potential contingent consideration						9,000	5,000	9,000	$ 5,000
Estimated fair values of net assets acquired
Inventory						2,700		2,700
Net assets - working capital						1,600		1,600
Equipment and other fixed assets						21,000		21,000
Goodwill						35,800		35,800
Advanced Home Care Inc [Member] | Tradenames [Member]
Estimated fair values of net assets acquired
Identifiable intangible assets						$ 600		$ 600
Solara Medical Supplies, LLC [Member]
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Cash payment		$ 380,700
Interest acquired, as a percent		100.00%
Estimated fair values of net assets acquired
Cash		$ 12,100
Accounts receivable		15,100
Inventory		15,000
Equipment and other fixed assets		4,400
Identifiable intangible assets		85,700
Goodwill		347,100
Accounts payable and accrued expenses		(22,400)
Net liabilities - working capital		(3,000)
Cash receipt from working capital adjustment							$ 700
Solara Medical Supplies, LLC [Member] | Payor contracts
Estimated fair values of net assets acquired
Identifiable intangible assets		60,000
Solara Medical Supplies, LLC [Member] | Tradenames [Member]
Estimated fair values of net assets acquired
Identifiable intangible assets		25,700
ActivStyle, Inc. [Member]
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Cash payment		$ 65,500
Interest acquired, as a percent		100.00%
Estimated fair values of net assets acquired
Cash		$ 5,000
Accounts receivable		4,100
Inventory		500
Net assets - working capital		900
Equipment and other fixed assets		1,000
Identifiable intangible assets		10,100
Goodwill		51,200
Accounts payable and accrued expenses		(7,300)
ActivStyle, Inc. [Member] | Tradenames [Member]
Estimated fair values of net assets acquired
Identifiable intangible assets		3,100
ActivStyle, Inc. [Member] | Developed technology
Estimated fair values of net assets acquired
Identifiable intangible assets		$ 7,000

Acquisitions - Pro-forma Financ

Acquisitions - Pro-forma Financial Information and Results of Business Acquired (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Pro-forma financial information:
Pro-forma net revenue	$ 657,611	$ 600,794	$ 1,953,706	$ 1,770,675
Pro-forma operating income	77,046	58,973	181,039	167,279
Net revenue since acquisition date	289,604	115,077	680,460	208,803
Operating income (loss) since acquisition date	$ 37,454	$ 4,637	$ 95,143	$ (2,984)

Equipment and Other Fixed Ass_3

Equipment and Other Fixed Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Equipment and other fixed assets, gross	$ 517,434	$ 192,417
Less accumulated depreciation	(176,077)	(81,949)
Equipment and other fixed assets, net	341,357	110,468
Patient medical equipment
Property, Plant and Equipment [Line Items]
Equipment and other fixed assets, gross	436,725	158,108
Delivery vehicles
Property, Plant and Equipment [Line Items]
Equipment and other fixed assets, gross	27,012	8,211
Property, plant and equipment, other
Property, Plant and Equipment [Line Items]
Equipment and other fixed assets, gross	$ 53,697	$ 26,098

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill and post-closing adjustments (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Net carrying amount
Beginning balance			$ 998,810,000
Acquired goodwill during the period			2,386,151,000
Net cash receipts relating to prior acquisition			(657,000)
Increase (reduction)			(22,036,000)
Ending balance	$ 3,362,268,000		3,362,268,000
Goodwill, Impairment Loss	$ 0	$ 0	0	$ 0
Solara Medical Supplies, LLC [Member]
Net carrying amount
Net cash receipts relating to prior acquisition			(700,000)
Increase to accounts receivable			28,900,000
Increase to accounts payable			6,300,000
Decrease to goodwill from post-closing adjustment			$ 22,600,000

Goodwill and Identifiable Intan

Goodwill and Identifiable Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 10,100	$ 2,700	$ 34,351	$ 2,675
Finite-Lived Intangible Assets, Net, Amortization Expense, Rolling Maturity [Abstract]
2022	48,376		48,376
2023	28,993		28,993
2024	21,276		21,276
2025	20,828		20,828
2026	18,682		18,682
Thereafter	71,754		71,754
Finite-Lived Intangible Assets, Net, Total	209,909		209,909		$ 116,061
Impairment of Intangible Assets, Finite-lived	0	$ 0	0	$ 0
Tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	9,666		$ 9,666		$ 1,793
Finite-Lived Intangible Assets, Remaining Amortization Period			8 years 9 months 18 days		8 years 9 months 18 days
Finite-Lived Intangible Assets, Net, Amortization Expense, Rolling Maturity [Abstract]
Finite-Lived Intangible Assets, Net, Total	98,133		$ 98,133		$ 32,007
Payor contracts
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	9,766		$ 9,766		$ 3,616
Finite-Lived Intangible Assets, Remaining Amortization Period			8 years 9 months 18 days		9 years 7 months 6 days
Finite-Lived Intangible Assets, Net, Amortization Expense, Rolling Maturity [Abstract]
Finite-Lived Intangible Assets, Net, Total	72,234		$ 72,234		$ 78,384
Contractual rental agreements
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	19,383		$ 19,383
Finite-Lived Intangible Assets, Remaining Amortization Period			1 year 6 months
Finite-Lived Intangible Assets, Net, Amortization Expense, Rolling Maturity [Abstract]
Finite-Lived Intangible Assets, Net, Total	34,817		$ 34,817
Developed technology
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	1,575		$ 1,575		$ 630
Finite-Lived Intangible Assets, Remaining Amortization Period			3 years 9 months 18 days		4 years 6 months
Finite-Lived Intangible Assets, Net, Amortization Expense, Rolling Maturity [Abstract]
Finite-Lived Intangible Assets, Net, Total	$ 4,725		$ 4,725		$ 5,670

Fair Value of Assets and Liab_3

Fair Value of Assets and Liabilities - Valuation of Financial Assets and Liabilities (Details) - Recurring - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Level 1
Assets
Total assets measured at fair value	$ 200,059	$ 5,602
Level 1 | Money market accounts
Assets
Total assets measured at fair value	200,059	5,602
Level 2
Liabilities
Total liabilities measured at fair value	10,795	16,161
Level 2 | Interest Rate Swap Short-term [Member]
Liabilities
Total liabilities measured at fair value	5,957	5,941
Level 2 | Interest Rate Swap Long-term [Member]
Liabilities
Total liabilities measured at fair value	4,838	10,220
Level 3
Liabilities
Total liabilities measured at fair value	111,621	217,922
Level 3 | Acquisition-related contingent consideration obligations-short term
Liabilities
Total liabilities measured at fair value	15,398	23,941
Level 3 | Acquisition-related contingent consideration obligations-long term
Liabilities
Total liabilities measured at fair value	3,250	9,599
Level 3 | Contingent consideration common shares liability-short term
Liabilities
Total liabilities measured at fair value	21,402	36,846
Level 3 | Contingent consideration common shares liability-long term
Liabilities
Total liabilities measured at fair value	15,025	33,631
Level 3 | Warrant Liability Noncurrent [Member]
Liabilities
Total liabilities measured at fair value	$ 56,546	$ 113,905

Fair Value - Contingent Conside

Fair Value - Contingent Consideration Rollforward (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration liability at beginning of period	$ 33,540	$ 14,725
Additions	2,000	6,464
Payments	(18,200)	(1,200)
Gain	1,135	(2,900)
Other activity	173	46
Contingent consideration liability at end of period	18,648	$ 17,135
Level 3 | Other current liabilities
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration liability at beginning of period	23,900
Contingent consideration liability at end of period	15,400
Level 3 | Other long-term liabilities
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration liability at beginning of period	9,600
Contingent consideration liability at end of period	$ 3,300

Fair Value of Assets and Liab_4

Fair Value of Assets and Liabilities - Non-financial Assets Measured on Non-recurring Basis (Details) - Nonrecurring - Level 3 - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Goodwill (annual impairment assessment)	$ 3,362,268	$ 998,810
Finite-lived Intangible Assets, Fair Value Disclosure	$ 209,909	$ 116,061

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Financial instruments (Details) - Derivatives designated as hedging instruments - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Derivative financial instruments
Fair Value Liability	$ (10,795)	$ (16,161)
Interest rate swap agreements
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional amount	250,000	250,000
Interest rate swap agreements | Other current liabilities
Derivative financial instruments
Fair Value Liability	(5,957)	(5,941)
Interest rate swap agreements | Other long-term liabilities
Derivative financial instruments
Fair Value Liability	$ (4,838)	$ (10,220)

Derivative Instruments and He_4

Derivative Instruments and Hedging Activities - Effect on Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income	$ 0.8	$ 0.7	$ 2.2	$ 2.1
Derivatives in cash flow hedging relationships
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Recognized in OCI on Derivative	$ 1.4	$ 1.6	$ 5.4	$ (9.4)

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Accounts Payable and Accrued Expenses
Accounts payable	$ 211,373	$ 191,038
Employee related accruals	40,483	26,705
Accrued interest	11,178	11,062
Other	49,321	25,407
Accounts payable and accrued expenses	$ 312,355	$ 254,212

Debt (Details)

Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Aug. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Debt, Net	$ 2,207,373			$ 784,714
Current portion	(20,000)			(8,146)
Long-term portion	2,187,373			776,568
Term Loan 2021 [Member]
Debt Instrument [Line Items]
Debt, Gross	790,000
Revolving Credit Loans 2020
Debt Instrument [Line Items]
Debt, Gross				55,000
Term Loan 2020
Debt Instrument [Line Items]
Debt, Gross				248,438
Senior Unsecured Notes 4.625 Per Cent Due 2029 [Member]
Debt Instrument [Line Items]
Debt, Gross	$ 1,450,000
Senior Notes 6.125 Percent Due 2028 [Member]
Debt Instrument [Line Items]
Debt, Gross				350,000
New Promissory Note
Debt Instrument [Line Items]
Debt, Gross		$ 71,700	$ 71,800	143,500
Other
Debt Instrument [Line Items]
Debt, Gross				$ 333

Debt - Credit Facilities (Detai

Debt - Credit Facilities (Details) - USD ($) $ in Thousands

1 Months Ended

9 Months Ended

Aug. 31, 2021

Jun. 30, 2021

Jul. 31, 2020

Nov. 30, 2019

Sep. 30, 2021

Sep. 30, 2020

Aug. 19, 2021

Aug. 16, 2021

Apr. 30, 2021

Jan. 20, 2021

Jan. 04, 2021

Dec. 31, 2020

Nov. 08, 2019

Mar. 31, 2019

Debt Instrument [Line Items]

Write-off of deferred financing costs

$ 4,054

$ 46

Proceeds from Lines of Credit

1,165,000

536,275

Repayment of loan

822,271

$ 545,584

Credit Agreement 2021 [Member]

Debt Instrument [Line Items]

Payments of Debt Issuance Costs

7,600

Write-off of deferred financing costs

2,100

Letters of credit outstanding

$ 14,900

Credit Agreement 2021 [Member] | Minimum

Debt Instrument [Line Items]

Commitment fee (as a percent)

0.25%

Credit Agreement 2021 [Member] | Maximum

Debt Instrument [Line Items]

Commitment fee (as a percent)

0.50%

Credit Agreement 2021 [Member] | LIBOR | Minimum

Debt Instrument [Line Items]

Rate margin (as a percent)

1.50%

Credit Agreement 2021 [Member] | LIBOR | Maximum

Debt Instrument [Line Items]

Rate margin (as a percent)

3.25%

Revolving Credit Loans 2021 [Member]

Debt Instrument [Line Items]

Borrowing capacity

$ 450,000

Proceeds from Lines of Credit

$ 365,000

Revolver balance

0

Remaining maximum borrowings available

435,100

Letter Of Credit 2021 [Member]

Debt Instrument [Line Items]

Borrowing capacity

$ 55,000

Term Loan 2021 [Member]

Debt Instrument [Line Items]

Borrowing capacity

$ 800,000

Debt balance outstanding

$ 790,000

Credit facility Interest rate

2.63%

Term Loan 2021 [Member] | First Specified Repayment Period [Member]

Debt Instrument [Line Items]

Quarterly principal repayments

$ 5,000

Term Loan 2021 [Member] | Second Specified Repayment Period [Member]

Debt Instrument [Line Items]

Quarterly principal repayments

10,000

Revolving Credit Loans 2020

Debt Instrument [Line Items]

Borrowing capacity

$ 200,000

Debt balance outstanding

$ 55,000

Revolving Credit Loans 2020 | Minimum

Debt Instrument [Line Items]

Commitment fee (as a percent)

0.25%

Revolving Credit Loans 2020 | Maximum

Debt Instrument [Line Items]

Commitment fee (as a percent)

0.50%

Term Loan 2020

Debt Instrument [Line Items]

Borrowing capacity

$ 250,000

Debt balance outstanding

248,438

Term Loan 2020 | LIBOR | Minimum

Debt Instrument [Line Items]

Rate margin (as a percent)

2.50%

Term Loan 2020 | LIBOR | Maximum

Debt Instrument [Line Items]

Rate margin (as a percent)

3.75%

Senior Unsecured Notes 4.625 Per Cent Due 2029 [Member]

Debt Instrument [Line Items]

Face amount

$ 500,000

Debt balance outstanding

$ 1,450,000

Debt Interest rate

4.625%

Senior Unsecured Notes 5.125 Per Cent Due 2030 [Member]

Debt Instrument [Line Items]

Face amount

$ 600,000

Debt Interest rate

5.125%

5.125%

Senior Notes 6.125 Percent Due 2028 [Member]

Debt Instrument [Line Items]

Face amount

$ 350,000

Debt balance outstanding

350,000

Debt Interest rate

6.125%

New Promissory Note

Debt Instrument [Line Items]

Write-off of deferred financing costs

$ 600

$ 1,400

Debt balance outstanding

$ 71,700

$ 71,800

143,500

Promissory Note With Investor [Member]

Debt Instrument [Line Items]

Face amount

$ 100,000

$ 100,000

Promissory Note From Members Interest [Member]

Debt Instrument [Line Items]

Face amount

$ 43,500

Other

Debt Instrument [Line Items]

Debt balance outstanding

$ 333

2019 Credit Facility

Debt Instrument [Line Items]

Borrowing capacity

425,000

Proceeds from Lines of Credit

$ 216,300

Repayment of credit facility

$ 523,900

Initial/credit facility term loan

Debt Instrument [Line Items]

Borrowing capacity

300,000

Repayment of loan

$ 50,000

Delayed Draw Term Loan

Debt Instrument [Line Items]

Borrowing capacity

50,000

Revolving credit facility/revolver

Debt Instrument [Line Items]

Borrowing capacity

$ 75,000

Debt - Notes (Details)

Debt - Notes (Details) - USD ($) $ / shares in Units, $ in Thousands

Aug. 19, 2021

Jan. 04, 2021

Aug. 31, 2021

Jun. 30, 2021

Jul. 31, 2020

May 31, 2020

Sep. 30, 2021

Sep. 30, 2020

Jun. 30, 2020

Sep. 30, 2021

Sep. 30, 2020

Dec. 31, 2020

Aug. 16, 2021

Nov. 08, 2019

Mar. 31, 2019

Debt Instrument [Line Items]

Write-off of deferred financing costs

$ 4,054

$ 46

Proceeds from the issuance of senior unsecured notes

1,100,000

350,000

Deferred financing costs

$ 32,627

32,627

$ 12,557

Loss on extinguishment of debt from prepayment penalty

16,135

5,316

Repayments of Long-term Debt

822,271

545,584

Gain (loss) on extinguishment of debt

(16,135)

(5,316)

Number of shares in Consideration Unit

1

Number of shares under Put/Call Option and Consent Agreement

1,898,967

Minimum variable price, as percent of weighted average price

85.00%

Sales price (in dollars per share)

$ 15.76

Equity activity resulting from the Put/Call Agreement

$ (29,927)

(29,900)

Accumulated Deficit

Debt Instrument [Line Items]

Equity activity resulting from the Put/Call Agreement

$ 2,694

$ 2,700

Additional paid-in capital

Debt Instrument [Line Items]

Equity activity resulting from the Put/Call Agreement

$ (2,694)

$ (29,927)

Minimum

Debt Instrument [Line Items]

Minimum fixed purchase price (in dollars per share)

$ 14.50

New Promissory Note

Debt Instrument [Line Items]

Debt balance outstanding

$ 71,700

$ 71,800

$ 143,500

Write-off of deferred financing costs

600

1,400

Loss on extinguishment of debt from prepayment penalty

7,700

8,500

8,500

8,500

Gain (loss) on extinguishment of debt

$ (7,700)

$ (8,500)

(8,500)

(8,500)

Make-whole premium, as a percent

10.00%

10.00%

Promissory Note With Investor [Member]

Debt Instrument [Line Items]

Face amount

$ 100,000

$ 100,000

Promissory Note From Members Interest [Member]

Debt Instrument [Line Items]

Face amount

$ 43,500

Senior Unsecured Notes 4.625 Per Cent Due 2029 [Member]

Debt Instrument [Line Items]

Face amount

$ 500,000

Debt balance outstanding

$ 1,450,000

$ 1,450,000

Debt Interest rate

4.625%

Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed

40.00%

Debt Instrument Redemption Price Percentage, Proceeds From Equity Offerings

104.625%

Deferred financing costs

$ 10,400

Senior Unsecured Notes 4.625 Per Cent Due 2029 [Member] | Redemption Period One

Debt Instrument [Line Items]

Debt Instrument, Redemption Price, Percentage

100.00%

Senior Unsecured Notes 4.625 Per Cent Due 2029 [Member] | Redemption Period Two

Debt Instrument [Line Items]

Debt Instrument, Redemption Price, Percentage

102.313%

Senior Unsecured Notes 4.625 Per Cent Due 2029 [Member] | Redemption Period Three

Debt Instrument [Line Items]

Debt Instrument, Redemption Price, Percentage

101.156%

Senior Unsecured Notes 4.625 Per Cent Due 2029 [Member] | Redemption Period Four

Debt Instrument [Line Items]

Debt Instrument, Redemption Price, Percentage

100.00%

Senior Unsecured Notes 5.125 Per Cent Due 2030 [Member]

Debt Instrument [Line Items]

Face amount

$ 600,000

Debt Interest rate

5.125%

5.125%

Deferred financing costs

$ 11,100

Senior Unsecured Notes 5.125 Per Cent Due 2030 [Member] | Redemption Period One

Debt Instrument [Line Items]

Debt Instrument, Redemption Price, Percentage

100.00%

Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed

40.00%

Debt Instrument Redemption Price Percentage, Proceeds From Equity Offerings

105.125%

Senior Unsecured Notes 5.125 Per Cent Due 2030 [Member] | Redemption Period Two

Debt Instrument [Line Items]

Debt Instrument, Redemption Price, Percentage

102.563%

Senior Unsecured Notes 5.125 Per Cent Due 2030 [Member] | Redemption Period Three

Debt Instrument [Line Items]

Debt Instrument, Redemption Price, Percentage

101.281%

Senior Unsecured Notes 5.125 Per Cent Due 2030 [Member] | Redemption Period Four

Debt Instrument [Line Items]

Debt Instrument, Redemption Price, Percentage

100.00%

Senior Notes 6.125 Percent Due 2028 [Member]

Debt Instrument [Line Items]

Face amount

$ 350,000

Debt balance outstanding

350,000

Debt Interest rate

6.125%

Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed

40.00%

Debt Instrument Redemption Price Percentage, Proceeds From Equity Offerings

106.125%

Senior Notes 6.125 Percent Due 2028 [Member] | Redemption Period One

Debt Instrument [Line Items]

Debt Instrument, Redemption Price, Percentage

100.00%

Senior Notes 6.125 Percent Due 2028 [Member] | Redemption Period Two

Debt Instrument [Line Items]

Debt Instrument, Redemption Price, Percentage

103.063%

Senior Notes 6.125 Percent Due 2028 [Member] | Redemption Period Three

Debt Instrument [Line Items]

Debt Instrument, Redemption Price, Percentage

102.042%

Senior Notes 6.125 Percent Due 2028 [Member] | Redemption Period Four

Debt Instrument [Line Items]

Debt Instrument, Redemption Price, Percentage

101.021%

Senior Notes 6.125 Percent Due 2028 [Member] | Redemption Period Five and thereafter

Debt Instrument [Line Items]

Debt Instrument, Redemption Price, Percentage

100.00%

Other

Debt Instrument [Line Items]

Debt balance outstanding

$ 333

Stockholders' Equity - Activity

Stockholders' Equity - Activity (Details) $ / shares in Units, $ in Thousands	Mar. 18, 2021shares	Jan. 08, 2021USD ($)$ / sharesshares	Jan. 01, 2021shares	Nov. 08, 2019	Sep. 30, 2020shares	Jul. 31, 2020USD ($)$ / sharesshares	Jun. 30, 2020$ / sharesshares	Mar. 31, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)	Feb. 01, 2021$ / sharesshares	Dec. 31, 2020$ / sharesshares	Aug. 04, 2020$ / shares
Subsidiary or Equity Method Investee [Line Items]
Share Price | $ / shares														$ 18.7175
Net proceeds | $										$ 278,850	$ 142,600
Offering costs | $										13,832	11,197
Stock exchange ratio				1
Exchange of equity interests, in shares			13,218,758
Value of shares exchanged | $										$ 77,900
Preferred stock, par value (in dollars per share) | $ / shares										$ 0.0001			$ 0.0001
Debt repayment | $										$ 822,271	$ 545,584
Preferred stock, shares issued (in shares)										124,060			163,560
Adapt Health Holdings LLC
Subsidiary or Equity Method Investee [Line Items]
Percentage of economic and voting interests				49.00%
DFB Acquisitions Corp
Subsidiary or Equity Method Investee [Line Items]
Percentage of economic and voting interests				51.00%
Adapt Health Holdings LLC
Subsidiary or Equity Method Investee [Line Items]
Controlling interest, as a percent				56.00%
Adapt Health Holdings LLC | Shareholders of Adapt Health Holdings LLC
Subsidiary or Equity Method Investee [Line Items]
Noncontrolling interest, as a percent				44.00%
Stock, common
Subsidiary or Equity Method Investee [Line Items]
Conversion of Series A Preferred Stock to Class A Common Stock (in shares)					2,887,709
Exchange of Class A Common Stock for Series B-1 Preferred Stock (in shares)							15,810,547			3,950,000
Conversion Of Series C-1 Preferred Stock To Class A Common Stock, Shares	13,047,473
Series A Preferred Stock
Subsidiary or Equity Method Investee [Line Items]
Conversion of Series A Preferred Stock to Class A Common Stock (in shares)					39,706
Series B-1 Preferred Stock
Subsidiary or Equity Method Investee [Line Items]
Conversion of Series B-2 Preferred Stock to Series B-1 Preferred Stock (in shares)					25,454.55
Exchange of Class A Common Stock for Series B-1 Preferred Stock (in shares)							158,105.47			39,500
Preferred stock, par value (in dollars per share) | $ / shares							$ 0.0001
Preferred stock, liquidation preference (in dollars per share) | $ / shares							$ 0.0001
Shares of common stock received in conversion for each share of preferred stock							100
Preferred stock conversion, ceiling as a percent of outstanding common stock							4.9
Series B-2 Preferred Stock
Subsidiary or Equity Method Investee [Line Items]
Shares issued						35,000
Proceeds from sale of stock | $						$ 35,000
Conversion of Series B-2 Preferred Stock to Series B-1 Preferred Stock (in shares)					35,000
Series C Preferred Stock [Member]
Subsidiary or Equity Method Investee [Line Items]
Preferred stock, liquidation preference (in dollars per share) | $ / shares												$ 0.0001
Shares of common stock received in conversion for each share of preferred stock	100
Conversion Of Series C-1 Preferred Stock To Class A Common Stock, Shares	130,474.73
Series C Preferred Stock [Member] | AeroCare Holdings [Member]
Subsidiary or Equity Method Investee [Line Items]
Preferred stock, shares issued (in shares)												130,474.73
Private Placement [Member]
Subsidiary or Equity Method Investee [Line Items]
Proceeds from sale of stock | $						190,000			$ 223,361
Offering costs | $						$ 1,600			1,639
Private Placement [Member] | Stock, common
Subsidiary or Equity Method Investee [Line Items]
Shares issued						10,930,471
Private Placement [Member] | Series A Preferred Stock
Subsidiary or Equity Method Investee [Line Items]
Shares issued						39,706
Public Offering [Member]
Subsidiary or Equity Method Investee [Line Items]
Shares issued		8,450,000				9,200,000
Share Price | $ / shares		$ 33				$ 15.50
Proceeds from sale of stock | $		$ 278,900				$ 142,600		$ 265,018	133,042
Net proceeds | $		265,600
Offering costs | $		$ 13,800				$ 9,600		$ 13,832	$ 9,558

Stockholders' Equity - Warrants

Stockholders' Equity - Warrants (Details) $ / shares in Units, $ in Thousands	Aug. 04, 2020item$ / sharesshares	Sep. 30, 2021USD ($)shares	Sep. 30, 2020USD ($)shares	Sep. 30, 2021USD ($)shares	Sep. 30, 2020USD ($)shares	Nov. 08, 2019$ / sharesshares
Warrants and Rights Note Disclosure [Abstract]
Warrants outstanding		4,280,548		4,280,548		12,666,666
Common stock for each warrant exercised	0.3856					1
Warrant exercisable price | $ / shares	$ 11.50					$ 11.50
Warrants exercised in cashless transaction, number exercised				0	6,254,803
Shares issued in cashless exercise of warrants (in shares)					1,973,707
Shares issued in cash exercise of warrants (in shares)					2,131,315
Warrant liability, beginning | $				$ 113,905	$ 27,635
Change in fair value of warrant liability (note 10) | $		$ (16,737)	$ 36,912	(57,359)	72,358
Reclassification of warrant liability to equity for exercised warrants | $					(49,098)
Warrant liability, ending | $		$ 56,546	$ 50,895	$ 56,546	$ 50,895
Warrants exercised for cash, number exercised					2,131,315
Proceeds from the exercise of warrants | $					$ 24,495
Warrant Redemption Price | $ / shares	$ 0.01
Warrant Cashless Exercise, Share Equivalent Of Exercise Price	0.6144
Warrant Redemption, Stock Price Trigger | $ / shares	$ 18
Warrant Redemption, Threshold Consecutive Trading Days | item	30
Warrant Redemption, Threshold Trading Days | item	20
Share Price | $ / shares	$ 18.7175
Price period	10 days
Public warrants, number redeemed			2,285,410		2,285,410
Exercise of warrants (in shares)			881,239		881,239

Stockholders' Equity - Continge

Stockholders' Equity - Contingent consideration (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Class of Stock [Line Items]
Earn-out consideration, shares per annual installment					1
First stock price hurdle (in dollars per share)					$ 15
Second stock price hurdle (in dollars per share)					18
Third stock price hurdle (in dollars per share)					$ 22
Earn-out consideration, number of shares issued during the period					1
Change in amount of contingent common share liability
Contingent consideration common shares liability	$ 36,427	$ 51,166	$ 36,427	$ 51,166	$ 70,477	$ 9,316
Change in fair value of contingent consideration - common shares liability (note 10)	(10,006)	$ 25,525	(34,050)	$ 41,850
Current portion of contingent consideration common shares liability	21,402		21,402		36,846
Contingent Consideration Liability, Earn-Out, Current	21,402		21,402		36,846
Contingent consideration common shares liability, less current portion	$ 15,025		$ 15,025		$ 33,631
Minimum
Class of Stock [Line Items]
Actual average share price during the period					$ 15
Stock, common
Class of Stock [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.0001		$ 0.0001		0.0001
Class B Common Stock
Class of Stock [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.0001		$ 0.0001		$ 0.0001

Stockholders' Equity - Compensa

Stockholders' Equity - Compensation, options grants and assumptions (Details) - USD ($) $ / shares in Units, $ in Thousands	Apr. 13, 2021	Jan. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted		703,170
Options granted, grant date fair value		$ 6,900
Options forfeited	648,401		234,390		914,000
Exercise of stock options (in shares)					1,114,000
Exercise of stock options			$ 9,840	$ 2,300	$ 12,100
Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Exercise period		5 years
Accelerated vesting, number of shares	184,932
Accelerated vesting cost			$ 1,900		$ 1,900
Expected volatility					44.50%
Risk-free interest rate					0.18%
Expected term					4 years
2019 Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance			10,000,000		10,000,000
Stock available for issuance			3,418,548		3,418,548
Options granted					703,000
Options granted, exercise price					$ 48.72
Options forfeited					914,000
Exercise of stock options (in shares)					1,034,000

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Option activity (Details) - $ / shares	Apr. 13, 2021	Jan. 31, 2021	Sep. 30, 2021	Sep. 30, 2021
Number of Options
Outstanding at beginning of period (in shares)		3,464,000		3,464,000
Granted (in shares)		703,170
Exercised (in shares)				(1,114,000)
Forfeited (in shares)	(648,401)		(234,390)	(914,000)
Outstanding at end of period (in shares)			6,099,000	6,099,000
Weighted-Average Grant Date Fair Value per Share
Outstanding at end of period (in dollars per share)			$ 11.03	$ 11.03
Weighted-Average Exercise Price per Share
Outstanding at beginning of period (in dollars per share)		$ 11.56		11.56
Exercised (in dollars per share)				11.13
Forfeited (in dollars per share)				$ 11.66
Weighted Average Remaining Contractual Term
Weighted average remaining contractual term (in years)				6 years 8 months 12 days
Number of shares issued for options exercised on a cash basis			897,984	1,097,984
AeroCare Holdings [Member]
Number of Options
Granted (in shares)				3,960,000
Weighted-Average Exercise Price per Share
Granted (in dollars per share)				$ 6.24
2019 Incentive Plan
Number of Options
Outstanding at beginning of period (in shares)		3,464,000		3,464,000
Granted (in shares)				703,000
Exercised (in shares)				(1,034,000)
Forfeited (in shares)				(914,000)
Outstanding at end of period (in shares)			2,219,000	2,219,000
Weighted-Average Grant Date Fair Value per Share
Outstanding at beginning of period (in dollars per share)		$ 2.18		$ 2.18
Granted (in dollars per share)				9.81
Exercised (in dollars per share)				2.19
Forfeited (in dollars per share)				2.27
Outstanding at end of period (in dollars per share)			$ 3.75	3.75
Weighted-Average Exercise Price per Share
Outstanding at beginning of period (in dollars per share)		$ 11.56		11.56
Granted (in dollars per share)				48.72
Exercised (in dollars per share)				11.57
Forfeited (in dollars per share)				11.66
Outstanding at end of period (in dollars per share)			$ 19.36	$ 19.36
Weighted Average Remaining Contractual Term
Weighted average remaining contractual term (in years)				7 years 3 months 18 days

Stockholders' Equity - Restrict

Stockholders' Equity - Restricted stock (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	May 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation expense		$ 5.4	$ 5.5	$ 21.4	$ 11
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, shares				1,015,000
Vesting accelerated, shares		22,192
Vested fair value		$ 0.5		$ 0.5
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested balance at beginning of period				2,248,000
Granted, shares				1,015,000
Vested, shares				(335,000)
Forfeited, shares		(77,808)		(616,000)
Non-vested balance at end of period		2,312,000		2,312,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Non-vested, grant date fair value at beginning of period				$ 15.60
Granted, grant date fair value				30.62
Vested, grant date fair value				17.39
Forfeited, grant date fair value				16.77
Non-vested, grant date fair value at end of period		$ 21.32		$ 21.32
Restricted Stock | Various Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, shares				969,152
Grant date fair value				$ 30
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Granted, shares				969,152
Restricted Stock | Non-employee Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, shares				45,938
Vesting period				1 year
Grant date fair value				$ 1.1
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Granted, shares				45,938
Restricted Stock | Minimum | Various Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period				3 years
Restricted Stock | Maximum | Various Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period				4 years
Vesting based on service (continued employment)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						4 years
Vesting percentage	25.00%					50.00%
Vesting based on performance
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						1 year
Vesting percentage						50.00%

Stockholders' Equity - Incentiv

Stockholders' Equity - Incentive units (Details) - USD ($) $ in Millions	1 Months Ended	9 Months Ended	12 Months Ended
	May 31, 2020	Sep. 30, 2021	Dec. 31, 2019	Dec. 31, 2018
Vesting based on service (continued employment)
Equitybased Compensation
Vesting percentage	25.00%		50.00%
Vesting period			4 years
Accelerated vesting cost		$ 1.5
Vesting based on performance
Equitybased Compensation
Vesting percentage			50.00%
Vesting period			1 year
2019 Incentive Plan
Equitybased Compensation
Grant date fair value			$ 4.5
2018 Incentive Plan
Equitybased Compensation
Grant date fair value				$ 5.3

Stockholders' Equity - Other ac

Stockholders' Equity - Other activity (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation expense	$ 5.4	$ 5.5	$ 21.4	$ 11
Awards To Newly Hired Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, shares			63,249
Equity-based compensation expense			$ 2.3

Stockholders' Equity - Equity-b

Stockholders' Equity - Equity-based compensation (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation expense	$ 5.4	$ 5.5	$ 21.4	$ 11
Unrecognized compensation expense	38.3		$ 38.3
Recognition period			2 years 8 months 12 days
General and administrative expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation expense	3.4	3.7	$ 14.5	7
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation expense	$ 2	$ 1.8	$ 6.9	$ 4
2019 Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock available for issuance	3,418,548		3,418,548

Earning Per Share (Details)

Earning Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Net Income (Loss) Attributable to Parent [Abstract]
Net Income (Loss) Attributable to Parent	$ 58,092	$ (51,035)	$ 133,233	$ (81,116)
Earnings allocated to participating securities	5,002		12,572
Net income (loss) basic	53,090	(51,035)	120,661	(81,116)
Change in fair value of contingent consideration - common shares liability, net of tax	(8,145)		(27,718)
Change in fair value of warrant liability	16,737	(36,912)	57,359	(72,358)
Net Income (Loss) Available to Common Stockholders, Diluted	$ 28,208	$ (51,035)	$ 35,584	$ (81,116)
Denominator:
Weighted Average Number of Shares Outstanding, Basic	131,684	57,372	124,228	47,986
Add: Contingent Consideration Shares	2,000		2,000
Add: Warrants	2,245		2,598
Diluted weighted average common shares outstanding	140,322	57,372	133,638	47,986
Earnings Per Share, Basic	$ 0.40	$ (0.89)	$ 0.97	$ (1.69)
Earnings Per Share, Diluted	$ 0.20	$ (0.89)	$ 0.27	$ (1.69)
Anti-dilutive securities excluded (in shares)	12,406	22,941	12,944	10,592
Preferred Stock
Denominator:
Anti-dilutive securities excluded (in shares)	12,406	18,356	12,944	6,567
Options
Denominator:
Add: Stock options	3,794		4,112
Anti-dilutive securities excluded (in shares)		1,566		1,163
Restricted Stock
Denominator:
Add: Unvested restricted stock	599		700
Anti-dilutive securities excluded (in shares)		383		724
Warrant [Member]
Denominator:
Anti-dilutive securities excluded (in shares)		1,936		1,438
Contingent Consideration Common Shares [Member]
Denominator:
Anti-dilutive securities excluded (in shares)		700		700

Leases - Balance Sheet (Details

Leases - Balance Sheet (Details) $ in Thousands	Sep. 30, 2021USD ($)
Leases [Abstract]
Operating Lease, Right-of-Use Asset	$ 148,891
Finance Lease, Right-of-Use Asset, after Accumulated Amortization	25,803
Right of use assets, total	174,694
Operating Lease, Liability, Current	31,015
Operating Lease, Liability, Noncurrent	121,411
Operating Lease, Liability, Total	152,426
Finance Lease, Liability, Current	21,672
Finance Lease, Liability, Noncurrent	203
Finance lease liability, total	$ 21,875
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other Liabilities, Noncurrent

Leases - Cost (Details)

Leases - Cost (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Leases [Abstract]
Operating Lease, Cost	$ 9,837	$ 27,695
Finance Lease, Right-of-Use Asset, Amortization	8,487	27,549
Short-term Lease, Cost	4,093	19,905
Variable Lease, Cost	3,784	10,061
Sublease Income	$ 405	$ 911

Leases - Operating Lease Maturi

Leases - Operating Lease Maturity (Details) $ in Thousands	Sep. 30, 2021USD ($)
Leases [Abstract]
2021	$ 9,540
2022	34,352
2023	29,396
2024	24,451
2025	20,435
Thereafter	56,793
Operating leases, total payments	174,967
Less: amount representing interest	(22,541)
Operating Lease, Liability	$ 152,426

Leases - Finance Lease Maturity

Leases - Finance Lease Maturity (Details) $ in Thousands	Sep. 30, 2021USD ($)
Leases [Abstract]
2021	$ 10,788
2022	11,034
2023	149
Finance leases, total payments	21,971
Less: amount representing interest	(96)
Finance lease liability, total	$ 21,875

Lease - Operating preadoption (

Lease - Operating preadoption (Details) $ in Thousands	Dec. 31, 2020USD ($)
Minimum annual lease commitments under noncancelable leases
2021	$ 18,403
2022	14,893
2023	11,788
2024	9,055
2025	5,960
Thereafter	15,646
Lease commitments	75,745
Minimum sublease rentals	$ 1,900

Leases - Wtd Average and Cashfl

Leases - Wtd Average and Cashflow info (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Leases [Abstract]
Operating Lease, Weighted Average Remaining Lease Term	6 years 9 months 18 days
Finance Lease, Weighted Average Remaining Lease Term	7 months 6 days
Operating Lease, Weighted Average Discount Rate, Percent	3.70%
Operating Lease, Payments	$ 27,154
Finance Lease, Principal Payments	31,043
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	84,212
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability	$ 22,902

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Income Taxes
Income Tax Expense (Benefit)	$ 12,147	$ (4,921)	$ 22,782	$ (4,736)
Unrecognized tax benefits	$ 1,900		1,900		$ 1,900
Increase in liability due to additional exchanges			146,500
Increase in deferred tax asset			163,300
Liability related to TRA			$ 300,100		$ 152,000

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	1 Months Ended
	May 31, 2018item	Sep. 30, 2021USD ($)
Commitments and Contingencies.
Accrual related to lawsuits, claims, investigations and proceedings | $		$ 5.1
Number of subsidiaries | item	1
Agreement Term	5 years

Related Party Transactions (Det

Related Party Transactions (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)item	Sep. 30, 2020USD ($)
Related Party Transaction [Line Items]
Gain (loss) on extinguishment of debt			$ (16,135)	$ (5,316)
Vendor two
Related Party Transaction [Line Items]
Number of executives | item			1
Ownership interest, as a percent	1.00%		1.00%
Expense for related party	$ 1,200	$ 600	$ 3,400	$ 1,700

Subsequent Events (Details)

Subsequent Events (Details) - Series Of Individually Immaterial Business Acquisitions Member - USD ($) $ in Millions	1 Months Ended	9 Months Ended
	Oct. 31, 2021	Sep. 30, 2021
Subsequent Event
Cash payment		$ 6.5
Subsequent Event
Subsequent Event
Cash payment	$ 67.6